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1. Introduction
1.1 Epidemiology & Etiology
The urinary bladder together with the pyelum, ureters and urethra form the urinary tract 
system (figure 1.1); the system that is responsible for the excretion and collection of urine. 
With approximately 357,000 new cases per year worldwide, tumours of the urinary tract 
system contribute significantly to the overall human cancer burden1. Urothelial cancer of the 
bladder is the fifth most common malignancy in the western world and accounts for 5% of all 
diagnosed cancers2. In Japan a much lower incidence is seen (Figure 1.2a). In the Netherlands, 
approximately 4,550 new cases present each year (Figure 1.2b), one of the highest incidence 
rates in the European Union.
The walls of the urinary tract are covered by a specialized epithelial lining, called urothelium. 
Approximately 90-95% of all tumours in the bladder are urothelial carcinoma (UC), previ-
ously known as transitional cell carcinomas3, 4. Other histological subtypes of bladder cancer 
are squamous cell carcinomas (< 5%), adenocarcinomas (1-2%) often originating from an 
embryologic remnant at the dome of the urinary bladder, i.e. the urachus, neuroendocrine 
tumours and soft tissue tumours (<1%), which are very rare I. In this thesis the general term 
bladder cancer will sometimes be used to refer to urothelial carcinoma (UC) although this 
terminology is not entirely correct. 
The male-to-female ratio of UC is in most western counties approximately 3:1. Bladder cancer 
represents in males the fourth most common cancer, in women the eighth, both if incidence 
and disease specific mortality rate are considered1. Some studies on gender differences 
showed that female patients are more frequently diagnosed with higher stages of bladder 
cancer and upper urinary tract tumours at first presentation5.
The origin of bladder cancer is multifactorial. In most countries cigarette smoking is by far 
the most important risk factor. The risk of bladder cancer in smokers is two to six fold that of 
non-smokers, and smoking accounts for 30-50% of all bladder cancers6-9. It is estimated that 
the risk of bladder cancer attributed to tobacco smoking is 66% in men and 30% in woman 
implying that women are somewhat protected against the carcinogenic effects of smoking II. 
The smoking behaviour largely explains the gender difference in incidence of bladder cancer. 
Other etiological factors include analgesic abuse and occupational exposure to aromatic 
amines. Until 1970 aniline dye in paint caused an increased frequency of bladder tumours in 
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I  Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2003). Cancer incidence in Five continents. IARC Scientific Publications No155. IARC 
Press: Lyon
II          IARC (2004), IARC monographs on the evaluation of carcinogenic risks to humans: Tobacco smoke and involuntary smoking, IARC Press 
Lyon.
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professional painters. In Egypt and other countries in Africa and the Middle East the endemic 
spread of schistosomiasis (Schistosoma haematobium) is a frequent cause of chronic Schis-
tosoma cystitis, provoked by deposition of eggs in the tissue underlying the urothelium. As 
a consequence the majority of the patients with bladder cancer in Egypt are diagnosed with 
squamous cell carcinoma, an uncommon type of bladder cancer in the western countries 
where squamous cell carcinoma of the bladder has an incidence rate of less than 5%10, 11. 
In 95% of the cases UC develops primarily in the bladder, the other 5% develops in the pel-
vicalyceal system, ureter or urethra. Tumours of the ureter and renal pelvis account for 8% 
of all urinary tract neoplasms and of these more than 90% are urothelial carcinomas12. The 
Figure 1.1
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Figure 1.1 
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Urinary tract system: urothelial cancer originates from the urothelial lining of the pyelo-caliceal system (pyelum), ureters, the bladder and 
urethra. 1 papillary tumours in the pyelo calyceal system; 2 papillary tumours in ureter; 3 papillary tumours in the bladder.
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Figure 1.2a
4
Figure 1.2a
Age-standardized (world) incidence rates for bladder cancer, by sex and world regions, (estimates over 2002). Source: Cancer Research UK, 
bladder cancer (www.cancerresearchuk.org).
Figure 1.2b
5
Figure 1.2b
Age-standardized (European) incidence rates for bladder cancer, by sex and EU countries, (estimates over 2002). Source: Cancer Research UK, 
bladder cancer (www.cancerresearchuk.org).
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incidence of these tumours had increased slightly in the past 30 years. Compared to UC of 
the bladder, there is a different male to female ratio of 1.7 to 1 with an increasing incidence 
in females13. 
The renal pelvis is together with the ureter, bladder and urethra, part of the lower urinary 
tract. Nevertheless clinicians generally refer to the UC of the renal pelvis and ureter as upper 
urinary tract tumours. Malignant tumours of the renal pelvis are twice as common as those of 
the ureter14 and they are frequently associated with additional UC in the urinary bladder and 
contralateral pelvis and ureter15. In 80% of the cases the malignant tumours that arise in the 
pyelum or ureter follow an earlier diagnosis of urinary bladder UC16 and in 65% of the cases 
urothelial tumours develop at multiple sites in the urinary tract17.
The following paragraphs will first discuss the symptoms of patients with UC, the pathologi-
cal diagnosis with corresponding clinical management and the biological characteristics and 
subsequently we will focus on the surveillance and prognosis of urothelial carcinoma.
2. Clinical Diagnosis
2.1 Symptoms
Bladder cancer is accompanied by a few symptoms that may alert patients that something 
is wrong. The most important and often first symptom patients present with is painless 
haematuria. In 85% of the patients the haematuria will only be microscopically visible, the 
other 15% of the patients will present with red coloured urine. In approximately 25% of the 
patients irritative bladder symptoms are the first symptom; e.g. dysuria (painful and difficult 
voiding), stranguria (burning sensation during voiding), pollakisuria (frequent voiding), 
painful bladder contractions after voiding, infections or symptoms of urethral obstruction. 
In case the tumour process obstructs the ureter, the accumulation of urine will compress the 
renal parenchyma (hydronephrosis) and cause pain in the kidney region. Patients with a flat 
cancerous lesion of the bladder mucosa (carcinoma in situ (CIS)) may present with dysuria 
but are often asymptomatic. The diagnosis of bladder cancer may be delayed if the patient 
misinterprets the complaints of intermittent bleeding to urinary tract infection, kidney or 
bladder stones or menstrual bleeding (patient delay). Physicians may also misinterpret the 
symptoms as cystitis or other lower urinary tract problems (doctors delay).
2.2 Diagnostics
Once the patient presents at the outpatient clinic the urologist will take a history of the 
patient, his or her urine will be examined by cytology and, if available, a urine test will be 
performed in order to further evaluate the possibility of a bladder cancer. Bladder cancers 
will usually present as polypoid masses protruding in the lumen of the bladder. This makes 
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them easily visible by endoscopic inspection (cystoscopy). Thus, if clinical suspicion is high 
enough a cystoscopy will be performed. This technique however may not easily detect the 
less frequent flat bladder cancers like carcinoma in situ. To determine whether UC is present 
in the pyelo-caliceal system or ureter, the patient will undergo radiological imaging exami-
nations as ultrasound, intravenous urography (IVU) or retrograde pyelogram (RPG), and CT 
(computed tomography)-urography (currently proposed as the standard in patients older 
than 50 years with macroscopic haematuria). 
Urinary cytology is performed on the sediment of freshly voided urine samples. Both normal 
urothelial cells and tumour cells are exfoliated into the urine and these cells shed in the urine 
are microscopically examined. For this purpose, voided urine is centrifuged; the sediment 
is spread on a glass slide and stained with the Papanicolaou technique. Cytology is highly 
specific (86%), especially for high-grade UC and CIS (see pathology), but has a low sensitivity 
for low-grade UC (58%). As a consequence, when urinary cytology is positive a high-grade 
UC is very likely. A positive urinary cytology may indicate the presence of a UC anywhere 
in the urinary tract, including the renal pelvis, the ureters, the urinary bladder or urethra. 
A negative cytology result occurs in approximately half of the patients with bladder cancer 
and does not exclude the presence of a low-grade bladder cancer. Many studies evaluated 
the use of urinary markers for the diagnosis of UC in patients under clinical suspicion for UC 
in the urinary tract. Tests for bladder tumour antigen (BTA), nuclear matrix protein 22 (NMP 
22), fibrin-degradation products, Quanticyt, Immunocyt and multi-targeted fluorescence in 
situ hybridisation (FISH) in voided urine have been introduced in the clinical setting. However 
none of these tests are implemented in routine clinical practice, partly due to their lack of 
accuracy. Although most of these diagnostic tests have a better sensitivity than cytology 
their specificity is lower. 
Cystoscopy is an endoscopically based technique that uses the entrance via the urethra to 
examine the bladder and therefore this procedure is also refered to as urethro-cystoscopic 
surveillance (UCS) (Figure 1.3). During the procedure patients are in lithotomy position so op-
timal manual examination of the pelvic area is also possible. Looking inside the hollow organs 
and body cavities of human beings is a concept advocated in 1806 by Philipp Bozzini. Already 
in 1877 Maximilian Carl-Friedrich Nitze (1848-1906) used the first cystoscope in Vienna. A 
growing interest in kidney and bladder diseases made him realize that a successful treatment 
depends on an accurate diagnosis18. Since then cystoscopy has become the mainstay in the 
diagnosis of urinary bladder disease with a high sensitivity and specificity for the detection 
of the most common polypoid or papillary lesions19-21. Flat lesions are more difficult to detect 
and recent studies have aimed to improve their visibility by cystoscopy (note: sensitivity of 
cystoscopy) by using photodynamic diagnosis (PDD). Photosensitizers proved their use in 
enhancing the visual demarcation between normal and neoplastic tissue22. Fluorescence or 
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photodynamic cystoscopy is performed using blue light and a porphyrin-based photosensi-
tizer, (Hexi)-aminolaevulinic acid (HAL or ALA). Because HAL has higher bioavailability than 
ALA and is distributed throughout all urothelial layers, HAL is preferred. It has now been 
demonstrated that HAL is better able to detect papillary tumours, dysplasia and CIS22. How-
ever promising, this investigational method has not yet been implemented on a regular basis 
in daily practice. This is partly due to the extended time that patients need to be prepared 
at outpatient clinic and the costs related to the specially needed instrumentation. Current 
practice is to instill a photosensitizer in the bladder during 1 hour and subsequently perform 
the cystoscopic examination within 1 hour after emptying the bladder. Several clinical stud-
ies analysed the accuracy of classical white light cystoscopy (until now the gold standard) by 
comparing with photodynamic diagnosis (PDD). In these studies the sensitivity of white light 
Figure 1.3a
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Figure 1.3a-d 
 
 
 
 
 
 
 
 
a b 
c d 
Lithotomy position allows optimal examination of the bladder and pelvic floor by (a) rigid (c) and flexible (b) cystoscope in females (c) and 
males (b). Endoscopic view of a papillary lesion of the urothelium in the bladder (d). 
Rigid and flexible scope (lithotomy position)
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cystoscopy for detection of any bladder cancers, including flat lesions, was demonstrated to 
range between 68-86%23-30. In this thesis we will also critically assess the sensitivity of white 
light cystoscopy, in the light of our surprising findings in a randomized trial conducted on a 
large number of patients with low risk bladder cancer. 
3. Pathological Diagnosis 
3.1 Classification of bladder cancer
The aim of classifying tumours is to delineate subsets of tumours, which are similar in clinical 
behaviour and treatment response. Clinical and histopathological criteria are generally the 
basis of such a tumour classification system. Owing to the progression in molecular pathology 
research 1) more and more genetic and biologic differences between tumours are identified 
and 2) the current clinical and histological classifications may in the future be supplemented 
Table 1.1 TNM Classification of urinary bladder cancer, UICC 2002
T – Primary Tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ: “flat tumour”
T1 Tumour invades subepithelial connective tissue
T2 Tumour invades muscle (m detrusor)
T2a Tumour invades superficial muscle (inner half )
T2b Tumour invades deep muscle (outer half )
T3 Tumour invades perivesical tissue
T3a Microscopically
T3b Macroscopically (extravesical mass)
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall
T4a Tumour invades prostate, uterus or vagina
T4b Tumour invades pelvic wall or abdominal wall
N – Regional Lymph Nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node 2cm or less in greatest dimension
N2
Metastasis in a single lymph node more than 2cm but not more than 5cm in greatest dimension, or multiple lymph 
nodes, one more than 5cm in greatest dimension
N3 Metastasis in a lymph node more than 5cm in greatest dimension
M – Distant Metastasis
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
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by molecular genetic parameters. Current treatment is still mainly based on the following two 
histopathological parameters: 1) tumour extension (staging) according to the most recent 
TNM classification of 2002 (Table 1.1 and 1.2) and 2) the differentiation grade of the tumour, 
determined by a process called tumour grading (according to the WHO-ISUP classification 
most recently adjusted in 2004, Table 1.3). Specifically tumour grading is an important task 
of the pathologist.
3.2 TNM classification of bladder cancer
The TNM classification defines the extension of invasion of the primary tumour (T), the meta-
static spread into local or regional lymph nodes (N) and the presence of metastases in organs 
at distance (M). The Union International Contre le Cancer (UICC) approved the current clas-
sification in 2002 (Figure 1.4). If the clinical staging performed by clinician and radiodiagnost 
(cTNM) has been further confirmed by histopathological examination of tissues surgically 
removed from the patient the suffix “p” is added to the stage (pTNM). 
Table 1.2 Stage grouping according to TNM Classification of urinary bladder cancer, UICC 2002
TNM Classification 
Stage
T N M
  0a Ta N0 M0
  0is Tis N0 M0
  I T1 N0 M0
  II T2a,b N0 M0
  III T3a,b N0 M0
T4a N0 M0
  IV T4b N0 M0
Any T N1, N2, N3 M0
Any T Any N M1
Table 1.3 WHO grading 1973 and 2004
1973 WHO grading
ە Urothelial papilloma
ە Grade 1: well differentiated
ە Grade 2: moderately differentiated
ە Grade 3: poorly differentiated
2004 WHO grading
ە Urothelial papilloma
ە Papillary urothelial neoplasm of low malignant potential (PUNLMP)
ە Low-grade papillary urothelial carcinoma
ە High-grade papillary urothelial carcinoma
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T category
To define the extension of invasion of a bladder tumour, cystoscopic examination provides 
a limited role18, 31, 32. Transurethral resection of all visible lesions down to the deepest parts 
of the lesions is required for an accurate histopathological assessment of depth of tumour 
invasion. A complete and correct TUR is essential to determine the prognosis of the patient.
A non-invasive papillary UC that is histologically classified as pTa is limited to the bladder 
mucosa, whereas a tumour, which invades the subepithelial connective tissue, but not the 
deep muscle, is classified as pT1. The distinction between pTa and pT1 UC can only be made 
by histopathological examination of the resected bladder tumour fragments. An accurate 
pathologic staging of the tumour is very important since the treatment of a pTa/T1 high-
grade and a pT2 tumour is completely different. It should be kept in mind that there is a 10% 
risk of pathological understaging of the tumour33.
The (non-invasive) pTa and superficially invasive (pT1) or non muscle invasive (NMI) UC 
have been collectively termed by clinicians as “superficial bladder cancer”. For the subset of 
Figure 1.4
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Figure 1.4 
 
Stage classification of bladder cancer according to TNM classification of 2002, but also including the most commonly applied subdivision of 
pT1 bladder cancers (i.e. pT1a, pT1b and pT1c); CIS (high grade intra-urothelial neoplasia), pTa (non-invasive papillary urothelial carcinoma), 
pT1 (invasion of urothelial carcinoma into the lamina propria). pT1a: invasion above  MM and VP, pT1b: invasion into MM and/or VP and pT1c: 
invasion beyond VP, pT2: invasion into the muscular detrusor). MM: muscular mucosae, VP: vascular plexus, LP: lamina Propria, CIS: Carcinoma 
in situ.
Background 23
papillary pT1 UC and CIS, the clinical management is not standardized. This is a consequence 
of the elusive biologic behaviour of individual cases34, 35. Clinicians are inclined to monitor 
and treat pT1-tumours, in particular the ones with high-grade in combination with carcinoma 
in situ (CIS), more aggressively, because their much higher risk of progression to muscle inva-
sive UC36, 37. Clinically muscle invasive tumours (≥T2) can be distinguished from non-muscle 
invasive UC (Ta, T1) by bimanual examination (vaginal or rectal) which can also reveal large 
muscle infiltrating tumours (≥T2). In cystectomy specimens, but not in transurethral resec-
tions of bladder tumours the pathologist can determine if and to what extent the tumour 
cells have invaded the muscularis propria: superficial (pT2a) or deep (pT2b). Stage T3 tumours 
extend either microscopically (pT3a) or macroscopically (pT3b) in the perivesical fat. Stage 
T4 tumours extend into contiguous organs, like colon, prostate, uterus or pelvic wall. The 
accuracy of imaging techniques (CT, MRI, PET) for determining the T-category is limited38-40.
N category
The N-stage is determined by the assessment of regional lymph nodes for the presence of 
lymph-borne metastatic disease. Numerous studies investigated the impact of CT and MRI 
for the detection of regional lymph node metastases, but their sensitivity remains limited 
(33%)41-43. Nevertheless, lymph node enlargement (> 1 cm) on CT or MRI is highly predictive 
of metastatic disease44. 
M category
The presence of blood borne distant metastasis of bladder carcinomas (M-stage) can be 
determined by an X-ray of the lungs and imaging of the liver (ultrasound, CT, MRI). Skeletal 
scintigraphy for the detection of bone metastases should be performed in symptomatic 
patients. About 50% of patients with muscle-invasive bladder cancer already have occult 
distant metastases at the time of diagnosis, which limits the efficacy of local therapy. 
The 5-year survival with surgery (radical cystectomy) alone is about 45% in patients with 
pT2N0M0 and approximately 35% in patients with pT3N0M0 bladder cancer. Patients with 
advanced disease, that is with positive lymph nodes (N+) and or distant metastases (M+) 
have a 5-year survival rate of only 10%. 
3.3 Non-muscle invasive bladder cancers 
(“Superficial” bladder cancers)
Fortunately, 80% of the patients first presenting with symptoms of bladder cancer is diag-
nosed with primary NMI UC. Until recently these NMI UC were grouped under the heading 
“superficial bladder cancer” because of their similar therapeutic approach; both can be 
radically removed by transurethral resection. However, clinical experience has demonstrated 
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the highly unpredictable behaviour of pT1 lesions and from a molecular biological perspec-
tive they often share genetic alterations with the unfavourable muscle invasive UC (pT2). 
For this reason the term “superficial bladder cancer” is currently considered obsolete. The 
clinical course of both pTa and pT1 papillary urothelial carcinoma (UC), now also commonly 
described as non-muscle invasive UC, is characterized by a high tendency to recur (up to 
70%) and a propensity to progress in grade (10-30%) or stage (10-15%)2. The follow-up policy 
and treatment of these patients is predominantly dictated by conventional parameters like 
grade and the associated presence of flat lesions like carcinoma in situ (CIS)45, 46. Urothelial 
carcinoma in situ (CIS) is a non-invasive, flat lesion (lacking papillary formations) in which the 
surface epithelial lining contains cells that are cytologically malignant. The intra-urothelial CIS 
accounts in the solitary form for less than 1-3% of urothelial neoplasms. However (secondary) 
CIS is present in 7-15% of papillary neoplasms and concomitant with muscle invasive UC in 
45-65%47-51.  Given the highly variable behaviour of pT1 UC an attempt was made to stratify 
pT1 UC on the basis of the depth of invasion of the lamina propria by a micrometer34, or by the 
assessment of invasion relative to the muscularis mucosa and venous plexus52, 53. Although 
this substaging of pT1 UC was reported to have prognostic significance, the recognition of 
the depth of invasion by morphological criteria may be problematic because of tangential 
sectioning, thermal and mechanical injury or inverted (pushing) growth34, 52, 54, 55. 
3.4 WHO classification of bladder tumours
Histopathological criteria are essential to differentiate benign and malignant urothelial 
neoplasms. These histopathological criteria comprise architectural patterns and features of 
urothelial differentiation. The differentiation of urothelial cells refers to the extent to which 
they resemble the healthy urothelium, both morphologically and functionally. Well-differen-
tiated cells resemble very closely their normal counterparts. The more malignant neoplasms 
are characterised by an increasing lack of differentiation; loss in uniformity of individual cells 
and loss of architectural orientation, pleomorphism (marked variation of cells in shape and 
size), hyperchromatic and large nucleoli, increased nuclear-cytoplasmic ratio and presence 
of (atypical) mitoses. 
In 1973 the WHO made a first attempt to develop a worldwide applicable bladder tumour 
classification. The aim was to offer a standard of histopathological criteria to distinguish 
subsets of bladder cancers and to promote a uniform bladder tumour terminology. Most 
importantly, the classification system needed to be sufficiently reproducible and compre-
hensive to be applied by all pathologists and urologists. The grading system of the WHO 1973 
bladder tumour classification recognized three different degrees: G1 (well differentiated), G2 
(moderately differentiated) and G3 (poorly differentiated). Grade 3 carcinoma is related to a 
worse prognosis than grade 1 or grade 2 carcinoma, which is supported by several studies56. 
Grade 3 UC is strongly associated with genetic instability, concomitant carcinoma in situ 
(CIS), and muscle-invasive UC. However, two issues regarding the WHO 1973 classification 
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system prompted its revision: 1) the terminology of “carcinoma” for the subset of non-invasive 
papillary UC with indolent behaviour, 2) the lack of well-defined criteria for each of the three 
grades, resulting into a high inter-observer variation and into disproportionally large number 
of grade 2 cancers. In the WHO 1973 bladder tumour classification the grade 2 cancers were 
Figure 1.5
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Figure 1.5
PapillomaPapilloma
WHO 1973 WHO 2004
G I
G II
G III
Low Grade
High Grade
PUN LMP
Comparison of the World Health Organization (WHO) Classification Systems 1973 and 2004. The vertical column represents the continuum of 
grades of urothelial neoplasms from the lowest (at the top) to the highest grade (at the bottom). The transverse lines at the left side of the bar 
illustrate the cut-offs as indicated by the WHO 1973 grading system and the transverse lines at the right side of the bar the cut-offs along the 
same spectrum for the WHO 2004 classification. The photomicrographs (x40) illustrate from top to bottom (from order to disorder and increase 
in variation); PUN LMP-Grade 1 (papillary urothelial neoplasm of low malignant potential), low-grade-Grade 1 (LG GI), low-grade-Grade II (LG 
GII), high-grade-Grade II (HG GII) and high-grade-Grade III (HG GIII).
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mainly defined as cancers, which did neither fulfil the criteria of grade 1 nor those of grade 3 
carcinomas (“garbage-bin” function of grade 2). 
The WHO 2004 classification system of bladder neoplasms distinguishes flat lesions, non-
invasive and invasive papillary lesions. Flat lesions include hyperplasia, dysplasia and car-
cinoma in situ, while non-invasive papillary lesions may range from the benign urothelial 
papilloma, to borderline malignant papillary urothelial neoplasm of unknown malignant 
potential (PUN-LMP) and low and high-grade non-invasive (pTa) urothelial carcinomas (Figure 
1.5a and 1.5b). PUNLMP is a papillary urothelial tumour that resembles the benign papilloma 
with regard to its cytonuclear features (lacking atypia) but shows an increased number of all 
layers of the urothelium. Its prognosis is excellent, progression to invasive carcinoma is rare, 
but recurrences may occur in 25-35% of patients. 
Non-invasive papillary (pTa) low-grade UC shows contrary to PUNLMP variations in nuclear 
features such as size, shape and chromatin pattern. Low-grade UC shows an orderly appear-
ance of papillary stalks with increased mitotic activity, but high-grade non-invasive papillary 
UC conversely shows a predominant pattern of disorder with large variations in nuclear fea-
tures, prominent nucleoli and frequent mitoses. Low-grade non-invasive (pTa) UC progresses 
to invasive disease in less than 5% of cases, but recurrences are common, i.e. 48-71% in the 
first year after diagnosis57-59. High-grade UC is associated with poorer prognosis, as most 
pT1 and muscle invasive UC are high-grade. In the WHO 2004 terminology, carcinoma in 
Situ (CIS), a non-papillary flat lesion hiding within the surface epithelium, is also labelled 
high-grade intra-urothelial neoplasia. (Primary or isolated) CIS accounts for less than 1-3% of 
urothelial neoplasm, but (secondary) CIS is concomitantly seen in 45-65% of infiltrating UC 
and in 7-15% of papillary neoplasms. Data suggest that de novo (primary) CIS is less likely to 
progress to invasive disease than secondary CIS60-63. 
4. Treatment of bladder cancer
4.1 Treatment of non-muscle invasive bladder cancer
Primary complete transurethral resection (TUR) is the recommended treatment of both pTa 
and pT1 UC. A second resection, re-TUR, should be performed in high-grade tumours or 
if the initial resection has been incomplete. The presence of residual tumour at the site of 
initial resection is frequently observed during control cystoscopy at three months after TUR. 
The high recurrence rate at 3 months after TUR indicates that TUR is incomplete or provokes 
recurrences in a considerable percentage of patients46. It is therefore necessary to give every 
patient adjuvant therapy, which is intravesical chemotherapy within 24 hours after TUR, de-
creasing the relative risk of recurrence by 40%. Mitomycine C, epirubicine and doxirubicine 
have all shown to provide an equally beneficial effect. A meta-analysis demonstrated that one 
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post-operative instillation would prevent on average 12 TURs in every 100 patients, which is 
highly cost-effective64. 
The need for further intravesical therapy during follow-up in the year after TUR depends 
on the patient’s risk of recurrence and/or progression. Patients with multiple tumours, large 
tumours (≥3 cm) and highly recurrent tumours (>1 recurrence/year) are at the highest risk 
of recurrence while patients with stage pT1 tumours, high-grade tumours and CIS have the 
highest risk of progression. The choice between intravesical chemotherapy (Mitomycine C, 
epirubicine, doxirubicine) and intravesical immunotherapy (BCG; bacillus Calmette-Guerin) 
largely depends on the risk that needs to be reduced: recurrence or progression. Adjuvant 
chemotherapy administered locally by bladder instillation is effective in preventing recur-
rence in low-grade UC and is associated with minor side effects. For high-grade UC and for 
CIS, BCG immunotherapy, consisting of induction and maintenance regimens, has proven to 
be superior to intravesical chemotherapy65, 66. BCG is a very effective treatment, but due to 
its substantial risk of toxic side effects only the high-risk tumours (multiple pT1 low-grade, 
pTa-T1 high-grade with or without concomitant CIS, CIS alone) should be treated with BCG. 
Nonetheless, in more than 10-15% of the patients with high-risk tumours the tumour will 
progress in spite of the intravesical therapy. Cystectomy may be indicated for high-risk non-
muscle invasive (pT1 high-grade and BCG-resistant CIS) and for extensive papillary disease 
that cannot be controlled with conservative measures. In all patients with pT1 UC who fail 
intravesical therapy cystectomy is considered a good option. Delay in cystectomy increases 
the risk of progression and cancer-specific death. 
4.2 Treatment of muscle invasive bladder cancer 
Cystectomy is the preferred curative treatment for localised bladder neoplasm; T2-T4a, N0-Nx, 
M0 and high-risk non-muscle invasive UC. Radical cystectomy includes removal of the blad-
der, together with prostate and vesiculae seminales (in male) and together with uterus, both 
adnex and part of the ventral site of the vagina (in females), and removal of regional lymph 
nodes of which the extent of dissection has not been sufficiently defined67-69. According to 
some authors pelvic lymph node dissection up to the aortic bifurcation represents the state-
of-art procedure, a potential therapeutic impact has been attributed to this procedure69-71. 
The urethra will be radically removed if there is evidence of CIS and/or UC in the bladder 
neck or prostatic urethra. Before cystectomy, the patient should be counselled adequately 
regarding all possible alternatives in urinary diversion techniques and post-operative care. 
Three different techniques for a urinary diversion are available. Most commonly is the 
uretero-ileocutaneostomy according to Bricker, which is an incontinent stoma demanding 
a permanent reservoir for the collection of urine. The second possible diversion procedure 
is a continent stoma called ‘Indiana pouch’ surgically shaped from the ileo-coecal corner, 
which needs to be emptied by self-catheterisation through a passage in the belly button 
or abdomen. A third form of diversion is an orthotopic bladder substitution or neobladder. 
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In this latter type an isolated part of the ileum forms a reservoir that is directly connected 
to the urethra. Contraindications for orthotopic bladder substitution are UC and/or CIS of 
the prostatic urethra or bladder neck (females), high-dose preoperative irradiation, complex 
urethral stricture and pre-existing incontinence. The terminal ileum and colon are the intes-
tinal segments of choice for urinary diversion. The type of urinary diversion does not affect 
oncological outcome72-74. Mortality as a consequence of the cystectomy in combination with 
a urinary diversion is less than 2%. 
Preoperative radiotherapy does not show any survival benefit75. Neoadjuvant cisplatin-
containing combination chemotherapy improves overall survival by 5-7% at 5-years, irre-
spective of the type of definitive treatment76. 
5. Biology of Bladder Cancer
5.1 Genetic alterations in human cancer
Cancer is a disease of the genome with accumulation of DNA alterations in premalignant 
tissue, leading to evolution of cell clones with increasing genomic instability and finally to 
the development of cells with invasive and metastatic capabilities77. Most mutations found in 
human malignancy are somatic and found only in the patient’s tumour tissue. It is generally 
accepted that some of these alterations are causally involved in the transition of a normal cell 
into a tumour cell78. Additionally, epigenetic alterations (e.g. methylation of DNA sequences 
resulting in gene silencing) can play a role in the cellular transformation. The development of 
cancer is a multistep process of genetic and epigenetic alterations. These alterations lead to 
dysregulation of proliferation, apoptosis, and may cause an epithelial-mesenchymal transi-
tion underlying invasion and ultimately metastasis. 
Most tumours are characterised by increasing genomic instability further facilitating the 
accumulation of mutations79. The variations caused by chromosome abnormalities include 
numerical and structural changes. Numerical changes of the genome result in a deviation 
of the normal set of 46 chromosomes. Aberrations in chromosome structure are caused by 
breakage and reunion of chromosome segments during mitosis and by environmental influ-
ence of agents like radiation, chemicals or viruses. Genetic instability exists at two levels80; 
microsatellite instability and chromosomal instability (CIN). Microsatellite instability is defined 
as alterations in the length of stretches of di, tri or tetra nucleotide repeats, and is generally 
the consequence of defects in the mismatch DNA repair system. Chromosomal instability 
reflects the alterations at the chromosomal level, as manifested by losses of smaller or larger 
chromosomal regions or even entire chromosomes. The targets of the genomic instability, at 
the nucleotide or at the chromosomal level, comprise 2 classes of genes81: proto-oncogenes 
and tumour suppressor genes. The activation of proto-oncogenes and inactivation of tumour 
suppressor genes as the result of genetic instability form the key contributions to tumour de-
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velopment. Excessive cell growth can result from either oncogene activation or inactivation 
of a tumour suppressor gene. To date no proto-oncogenes or tumour suppressor genes have 
been found that are indiscriminately activated or inactivated in all cancers. Even comparable 
cancers from the same organ and cell type never completely share alterations in the same 
genes. However comparable tumours might probably have alterations in the same molecular 
pathways but with different components affected82-84.
5.2 Genetic instability in bladder cancer
Microsatellite instability is found in a very small subset of bladder cancers, and these tumours 
are predominantly diploid. In most bladder cancers instability is observed at the chromosomal 
level (CIN), resulting in losses and gains of partial or even entire chromosomes (aneuploidy)85. 
The contribution of CIN is mostly minor in NMI UC compared to muscle invasive UC were CIN 
is frequently displayed. 
5.2.1 Hereditary bladder cancer
Genes mutated in the germ cells can cause hereditary cancer syndromes such as the BRCA1, 
BRCA2, CHEK2 and TP53 gene mutations associated with breast cancer, APC gene mutations 
associated with colonic cancer and mutations in mismatch repair genes associated with 
hereditary non-polyposis colon cancer. In the latter families an increased frequency of upper 
urinary tract UC (renal pelvis, ureter) and bladder is observed86-91. Extended families with 
bladder cancer are very rare. A recent study with high-resolution array based CGH (Com-
parative Genomic Hybridization) in 10 high-risk UC families in The Netherlands showed no 
evidence of candidate regions for a gene that may predispose to the development of bladder 
cancer92.  However, very recently it was demonstrated that germ line mutations in the CHEK2 
kinase gene are associated with a slightly (OR 1.9) increased risk of bladder cancer93. 
5.3 Molecular alterations in non-muscle invasive bladder cancer
Many studies have assessed the status of known oncogenes and tumour suppressor genes 
and have searched for common chromosomal alterations to identify novel genomic events 
in bladder cancer94-97. 
Non-muscle invasive UC displays few molecular alterations. Comparative genomic Hy-
bridisation (CGH) has identified different copy number changes including gain of 1q, 17 and 
20q, amplifications of 11q and loss of 10q but none of these are as frequent as the deletions 
involving chromosome 9. Loss of heterozygosity analysis (LOH) has revealed frequent loss 
of 9q (60% concerning all UC), 4p (22% all UC), 8p (23% in high-grade, high stage UC), 11p 
(40% correlated with tumour grade), and 17p (p53 loci, associated with muscle invasive UC). 
Next to the genetic alterations involving chromosome 9 are the mutations of the Fibroblast 
Growth Factor receptor 3 (FGFR3) representing the most frequently found molecular altera-
tion in non-muscle invasive UC.
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5.3.1 The Fibroblast Growth Factor Receptor 3 gene  
One of the most exciting recent discoveries in bladder cancer molecular genetics is the 
frequent observation of gain of function mutations in the Fibroblast Growth Factor Receptor 3 
(FGFR3) gene98-104 (Figure 1.6). The FGFR3 gene is located on chromosome region 4p16.3105. 
Abnormal activation of FGFR3 can be caused by translocation of the gene region to chro-
mosome 14 leading to overexpression or by activating point mutations in the FGFR3 gene. 
Activating mutations of FGFR3 are found in the germline in several autosomal dominant 
human skeletal syndromes associated with dwarfism, like achondroplasia, hypochondropla-
sia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), 
thanatophoric dysplasia types I and II (TD) and Crouzon Syndrome. In the germline, activating 
mutations have profound effects on the growth of the long bones where premature differen-
tiation of chondrocytes in the growth plates is induced, causing shortness of stature (Figure 
1.7). Besides the inhibitory role of FGFR3 mutations in skeletal disorders, an oncogenic role 
for FGFR3 in human cancer has emerged. In somatic cells translocations of the FGFR3 gene 
region are found in Multiple Myeloma (MM). Overexpression leads to myeloma cell prolifera-
tion and prevents apoptosis106. Activating mutations in somatic cells were frequently found 
in urothelial cell carcinomas (urinary tract), and sporadically in adenocarcinomas (colon), 
squamous cell carcinomas (cervix, nasopharynx, mouth) and multiple myeloma107, 108. It 
was in 1999 that the group of François Radvanyi reported for the first time the presence 
of FGFR3 mutations in bladder cancer109. All identified mutations were identical to the ger-
mline mutations that cause TD I and II (R248C, S249C, Y375C, K652E). TDI and TDII are lethal 
forms of dwarfism, suggesting that these mutations represent highly activated forms of the 
receptor. Several studies since have identified 11 different mutations of the FGFR3 gene 
Figure 1.6
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Schematic picture of the FGFR3 protein consisting of an extracellular domain: SP (NH2-terminal hydrophobic Signal Peptide), an Ig (three 
immunoglobulin-like domains (Ig I, II and III)), an AB (acid box); a transmembrane domain (TM) and an intracellular domain TK 
(tyrosine kinase domain). Mutations may occur in all three domains, the arrows point to the location of the eleven FGFR3 mutations found in 
bladder cancer.
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region. FGFR3 mutations in bladder cancer are strongly associated with low tumour grade 
and stage110-112 and genomically stable tumours107, 113, 114. Furthermore frequent mutations 
have been detected in benign skin lesions (seborrhoeic keratoses and epidermal nevi). These 
findings in skin lesions, and the preponderance of mutations in PUN-LMP or NMI UC together 
with the apparent lack of mutations in other malignancies, indicates an association of FGFR3 
mutations with low risk cancers and benign epithelial overgrowths107, 115-120. The lack of an 
association of FGFR3 mutations in bladder cancer with LOH at 4p16, the location of the FGFR3 
gene, corresponds best with its putative role as an oncogene. It is therefore unlikely that 
FGFR3 functions as a tumour suppressor gene117. 
5.3.2 Chromosome 9 and loss of heterozygosity
Loss of heterozygosity (LOH) of chromosome 9 is found in more than 50% of all bladder 
cancer tumours regardless of grade and stage121-124 (Figure 1.8a and 1.8b). Because chromo-
some 9 alterations 1) may be present in morphologically normal urothelium of patients with 
bladder cancer and 2) may represent the most frequent genetic event in bladder cancer, 
alterations in chromosome 9 are considered an initiating or otherwise a very early event in 
early bladder tumourigenesis125, 126. Many UC demonstrate LOH of the entire chromosome, 
suggesting loss of function of tumour suppressor genes on both chromosome arms. Thus, 
identification of these genes is considered vital to aid understanding of disease pathogenesis 
and to provide useful clinical markers and targets. Somewhat disturbing, however, to date no 
definite tumour suppressor gene on chromosome 9 has been identified.
5.4 Theories concerning bladder carcinogenesis
Simultaneous or metachronous development of multifocal tumours with identical or variable 
histology in the urothelial tract of one patient is a well-known characteristic of UC47, 49, 53. 
Similar observations of multifocal premalignant or malignant lesions have been reported 
Figure 1.7
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Achondroplasia caused by activated FGFR3 mutations 
in germline. These mutations have profound 
effects on the growth of the long bones. Premature 
differentiation of chondrocytes is induced in the 
growth plates causing dwarfism. (This picture 
is credited to UPI/Bettman, source: website Prof 
Dr Steven Carr, department of biology, Memorial 
University of Newfoundland, St. John’s Canada; 
www.mun.ca/biology/scarr/Research)
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Figure 1.8b
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Schematic overview of Loss Of Heterozygosity analysis (LOH); the m(aternal) and p(aternal) copy of chromosome 9 of normal tissue (left) and 
abnormal tumour tissue (right) are shown. Alterations (i.e. loss of parts) of chromosome 9 are frequent events in bladder cancer. The CA repeats 
(depicted as dark bars in the p-arm of the chromosomes) often differ in length in the maternal (m, CA(20)) and paternal (p, CA(15)) copy of 
the chromosome, a phenomenon known as heterozygosity. Loss of heterozygosity (LOH) means that the chromosome lost one of the parts of 
the short (p-arm) or long (q-arm) of the chromosome containing such a particular CA repeat. The CA repeats of both normal and tumour tissue 
can be amplified by PCR (Polymerase Chain Reaction), subsequently are the specific CA-repeat parts labeled by radioactive (A) or fluorescent 
(B) labels. Because the pat and mat fragments containing the CA repeats differ in length, their presence and quantity can be identified in 
tumour and normal tissue (A) on a gel and quantified by the intensity of the radioactive labels in the gel or (B) by the height of the peaks in the 
fluorescence detection using a Genetic Analyzer. 
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A karyotype of a tumour with a 
deletion (LOH) of a part of the long arm 
(9q) of one of the chromosomes 9.
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Hypothetical model for bladder cancer progression showing the molecular pathways of tumorigenesis, partly adapted from Th van der Kwast 
(Scand J of Urology and Nephrol, 2008) with permission. The thickness of the arrow represents the likeliness of frequency of occurrence. A, B, 
C, D and E represent morphological transitions characterized by  specific genetic and epigenetic alterations. A: activation of RAS, PIK3CA 
mutation; B: loss of RASSF1A, deletion of the INK4a locus; C: loss of RASSF1A; D: activation of RAS, deletion of the INK4a locus, loss 
of RB expression; E: activation of RAS, loss of chromosome 8p, expression of extracellular matrix remodelling genes. It is further assumed that 
FGFR3 mutation in tumours will provide an advantage in early proliferation, while in tumours with a wild type FGFR3 gene, activating RAS 
genes and homozygous deletion of the INK4a locus (depending on the region in which p53 is mutated) will cause a growth-inducing signal. 
FGFR3 (Fibroblast Growth Factor Receptor 3 gene mutation; wild type or mutant), UC (Urothelial Carcinoma), PUN-LMP (Papillary 
Urothelial Neoplasm of Low Malignant Potential), p53 (p53 gene muations). 
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in the oral cavity, respiratory epithelium, and Barrett’s esophagus. Macroscopic “normal” 
urothelium shows in many cases areas of microscopic dysplasia50. 
The frequent multifocality and multiple recurrences of bladder cancer raised the question of the 
clonal nature of the spatially and temporally distinct UC. Two main theories have been put forward 
to explain this phenomenon: the field cancerization theory and the monoclonality hypothesis. 
The “field cancerization” theory defends the hypothesis that the entire urothelium is unstable and 
many different clones of altered cells are present that give rise to unrelated polyclonal tumours. 
Many of the observed associations between bladder cancer and various external factors (i.e. 
tobacco use, aniline dyes) can be subsumed in this genetic theory of carcinogenesis. Carcinogens 
affect the urothelium at multiple sites, leading to numerous mutations and independent growth 
of multifocal nonrelated tumours127. 
The other theory describes tumours developing from descendants of a single transformed cell, 
the monoclonality hypothesis. Most molecular genetic studies confirmed this second hypothesis 
as they demonstrated monoclonality of multiple tumours within the same patient. The pres-
ence of multiple shared genetic changes in all tumours resected from one individual patient 
suggests that these lesions are related and have most likely evolved from a single altered cell 
clone. Furthermore, precursor lesions like dysplasia and carcinoma in situ (CIS) generally display 
the same genetic alterations as the accompanying UC128-130. Divergence between the genetic 
changes found among multiple lesions has been used to determine the timing of the events in 
tumourigenesis. The assumption is that cancers develop increased numbers of additional genetic 
changes when they are distantly related as compared to closely related cancers. In this way, a 
chronological pedigree of multiple recurrences within the same patient could be generated131. 
Strikingly, these pedigrees demonstrate that the earliest clinically manifest bladder cancer in a 
patient may not necessarily represent the ¨genetically youngest¨ cancer (Figure 1.9). 
The group of Hartmann reported that in some patients oligoclonality might explain the 
presence of multifocal UC in a single patient, an observation in line with the field cancerization 
hypothesis132. However, in a later paper the same group concluded that multiple metachronous 
tumours shared a monoclonal origin based on their genetic relations133. 
In some cases an upper urinary tract UC may develop after the clinical detection of a tumour 
in the urinary bladder, and this may seem to contradict the hypothesis of intraluminal seeding. It 
should be noted here, that the time of diagnosis may not necessarily correlate with the time of tu-
mour development, as explained above. Recently, Hoglund combined the field cancerization and 
monoclonal hypotheses into one model. He hypothesises that the tumour process is initiated by 
genetically altered but histologically normal cells producing fields of altered cells by intraepithelial 
displacement. Accumulation of further genetic alterations generates fields of altered urothelium 
that may reach a state of criticality, and which locally may produce frank tumours134. 
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5.4.1 Molecular pathways of bladder carcinogenesis
Non-invasive UC can have two distinct morphologies: the papillary, low-grade, multifocal, 
highly recurrent, rarely progressive pTa tumours and those with a flat morphology (dysplasia, 
CIS) frequently progressive to invasive carcinomas. Molecular studies have identified distinct 
genetic and epigenetic changes in these groups, which led to the identification of at least two 
major molecular pathways of bladder cancer. TP53 mutations are often present in CIS lesions 
and deep muscle invasive (pT2 bladder cancers, but generally not in pTa cancers135. FGFR3 
mutations were found to be commonly present in tumours of low stage and grade and were 
generally absent in tumours with TP53 mutations, in line with a mutually exclusive two pathway 
model of carcinogenesis136. This concept is confirmed by studies relating histological and mo-
lecular characteristics of UC with proliferative activity of the cancers, as measured by the Ki-67 
labeling index. Tsuji et al showed that a high Ki-67 labeling index correlates with p53 nuclear 
accumulation in UC137. Van Rhijn et al showed that the favorable FGFR3 mutation was strongly 
related to a low Ki-67 proliferation index and he reported that a molecular grading system, 
based on a combination of FGFR3 mutation analysis and Ki-67 labeling index was superior to 
other parameters considering disease free survival138. Barbisan et al recently reported that 
a strong immuno-histochemical expression of FGFR3, a superficial staining pattern of CK20, 
which is indicative of adequate terminal differentiation by the carcinoma cells, and a low prolif-
erative activity define those papillary urothelial neoplasms of low malignant potential that do 
not recur139. A further description of the Ki-67 labeling index and CK20 staining as biomarkers 
for bladder cancer will be given in paragraph 7.2.3. Further corroborating the concept of a dual 
bladder carcinogenesis was the observation by Lindgren et al that FGFR3 mutant and wild 
type bladder cancers were highly distinct with regard to their gene expression signatures as 
assessed by cDNA expression profiling studies124. FGFR3 mutations in NMI UC probably provide 
a growth advantage in early tumour development. In low-grade papillary tumours without this 
mutation, activation of other genes, like e.g. the ras oncogene may cause activation of a specific 
signaling pathway related to growth. Mutant ras proteins can also be trapped in an activated 
form (just like the gain of function mutant FGFR3 gene products), which triggers the cell to 
activate specific signaling pathways resulting in a persistent signal to proliferate. For tumour 
progression, that is the development of more aggressive tumour behaviour, other genetic 
events are needed. 
Several attempts have been made to apply the molecular and histopathological observa-
tions to one comprehensive carcinogenesis model to reflect the possible genetic pathways of 
UC development. Figure 1.10 shows such a model for bladder carcinogenesis. Most probably 
this model is not yet complete, but it may provide a useful anchor for further molecular and 
clinical studiesIII. 
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III        Th.H. van der Kwast; How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions, 
Scandinavian journal of Urology and Nephrology, 2008; 42, 175-184.  
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Our understanding of bladder carcinogenesis still has to deal with a couple of mind-boggling 
questions. The first concerns the interpretation of CIS. CIS is according to the WHO 2004 a 
non-invasive intra-urothelial neoplasm, which is considered to represent a premalignant 
lesion with a very high risk of progression to invasive disease. As a consequence a diagnosis 
of CIS often leads to an aggressive therapeutic approach by urologists. One study showed a 
significant difference in genetic alterations between isolated CIS (primary CIS) and secondary 
CIS, that is CIS associated with a papillary UC. Isolated CIS did not show LOH of chromosome 
9, in contrast to most secondary CIS140. This may suggest the existence of two distinct forms 
of CIS associated with different developmental pathways. It is conceivable that CIS found in 
association with high-grade UC with LOH of chromosome 9 could represent a precursor of 
the associated papillary tumour. A second important question concerns the enigmatic origin 
and biological behaviour of pT1 UC. Are these tumours caught in their journey towards the 
muscle or does this group actually represent the intertwining of the two pathways of bladder 
carcinogenesis? One author even suggested that pT1 UC may represent a third pathway of 
Figure 1.10
 14 
Figure 1.10 
 
 
Follow-up scheme of the randomized clinical trial “Cost-effectiveness of follow-up of patients with non-muscle invasive bladder cancer (CEFUB-
trial).”
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bladder carcinogenesis, since in this subset of cancers FGFR3 mutations and TP53 mutations 
are not mutually exclusive as they may coexist141. Indeed, pT1 UC is a clinically very heteroge-
neous disease, and it is difficult to distinguish the aggressive forms from the less aggressive 
ones. About 15% of pT1 UC are thought to have metastasized already at the time of their 
diagnosis. Some clinicians tend to treat pT1 UC by radical treatment early on, and others have 
a more conservative approach, by lack of robust parameters, which may distinguish low and 
high-risk pT1 UC.
6. Surveillance in non-muscle invasive bladder cancer
6.1 (Urethro-) Cystoscopic Surveillance
At the time of first diagnosis approximately 70-80% of the patients with bladder cancer 
presents with non-invasive papillary U (pTa) or with early (non muscle) invasive UC (pT1). As a 
consequence the fast majority of patients with newly detected UC will undergo local, bladder 
preserving therapy like transurethral resection (TUR) and intravesical immuno/chemotherapy. 
The likelihood that these tumours recur is 70% in 5 years with its peak incidence in the first 
year after initial treatment. Up to about 30% of these recurrent tumours will present with 
a higher histologic grade and about 5-10% will progress to muscle-infiltrating (pT2) UC142. 
Muscle infiltrating (pT2) UC are life-threatening cancers with a 50% risk of metastatic disease 
in 5 years. Therefore, patients are recommended to adhere to regular (urethra)-cystoscopic 
surveillance (UCS) to detect recurrent tumour at early stage. The effectiveness of UCS to 
improve UC survival has been shown unequivocally19, 21, 143. The European Association of 
Urology (EAU edition 2008) now recommends 2 cystoscopies in the first year after diagnosis 
of NMI UC followed by annual cystoscopies for up to five years in patients with pTa low-grade 
NMI UC (low-risk). Patients with pT1 UC and/or CIS, or with high-grade pTa tumours (15% of 
all patients), who are all at high risk for recurrence and progression, are recommended to be 
monitored by cystoscopy every 3 months in the first 2 years, every 4 months in the third year, 
every sixth months until 5 years of follow-up, and yearly thereafter. In addition, for this subset 
of patients, a yearly urography of the upper urinary tract (Intravenous Urogram or Computed 
Tomography) is advised. Patients with an intermediate risk have an in-between follow-up 
scheme, adapted according to personal and subjective factors. These recommendations are 
based on retrospective studies, while prospective studies are lacking. As a result considerable 
practice variation is observed144. 
Given the high prevalence of NMI UC this disease is costly to manage, particularly since 
cystoscopy is a labour intensive method21, 143, 145, 146. Besides cystoscopy is an endoscopic 
(invasive) procedure. Worldwide many research groups continue to search for alternative 
methods (urine tests) that are at least as accurate and robust as cystoscopy in the detection 
of UC recurrence. The aim of these research endeavours is to develop a urine test that can 
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compete with cystoscopy, the current gold standard for the detection of UC recurrences in 
patients with NMI UC. Such a test needs to be easy to perform, cost-effective and accurate. This 
thesis will address the important issue of cost-effectiveness of surveillance of patients with 
NMI UC using the data from a prospective multicenter trial studying the cost-effectiveness of 
an alternative surveillance strategy. 
6.2 Urinary Markers
Since Papanicolaou introduced the cytological investigation of urine sediment it is clear 
that a voided urine sample represents an easy source of exfoliated tumour cells and tumour 
related products like proteins, DNA and RNA that may in theory serve as a marker for the 
presence of UC. Unfortunately, urine cytology is of limited value for the surveillance of low-
grade UC, mainly because of its low sensitivity and also because of a considerable operator 
dependency147. Apparently, urine cytology cannot serve as an alternative to cystoscopy 
for surveillance of low-grade NMI UC. Many studies have focused on evaluating molecular 
urinary markers and several new urine-based tests for UC have been developed. The United 
States Food and Drug Administration (FDA) approved ImmunoCyt and FISH (UroVysion, 
2001)147-149. Van Rhijn et al reported in a review of the literature on the performance of these 
urinary markers for surveillance of patients with NMI UC150, 151. The markers generally have a 
higher sensitivity but a lower specificity than conventional cytology. Further, it is clear that 
for high-grade cancers these urinary markers display an increased sensitivity. In the author’s 
view Cytokeratin (CK) based assays (CYFRA21-1 for fragments of cytokeratin 19), the NMP22 
assay, immunocytology (ImmunoCyt, LewisX; cytokeratin 20) and the detection of genetic 
alterations based on the genetic instability of malignancies (Microsatellite Analysis (MA) and 
Fluorescence in situ Hybridisation (FISH UroVysion)) in voided urine samples are the most 
promising urine markers for surveillance. The highest median sensitivities were reported 
for CYFRA21-1 (85%), cytokeratin20 (85%) and Microsatellite Analysis (82%). The highest 
specificities were reported for cytology (94%), the BTA test (92%) and Microsatellite Analysis 
(89%)150, 151. No prospective (randomized) trials have been reported to date to demonstrate 
the efficacy of any of these urine tests. The main problem remains to determine what level of 
sensitivity and specificity of a potential urine marker is required and accepted by urologist 
and patient. The accuracy needed for a test will principally depend on the purpose of its 
use; whether it is solely used for screening an asymptomatic population, or for diagnostic 
reasons in symptomatic patients or whether it is used as an ancillary test for the surveillance 
of patients with a previous diagnosis of UC.
6.2.1 Statistic analysis of diagnostic tests
Diagnosis is an essential part of clinical practice, and much medical research is carried out to 
try to improve methods of detection. In the surveillance of bladder cancer the early detection 
of recurrent tumours is an important item. The paramount question of surveillance is whether 
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we improve the prognosis of patients by detecting recurrences earlier when compared to 
the current methods; therefore we want to know how accurate is an urine test in the early 
detection of bladder cancer recurrences and how does the urine test relate to the so-called 
‘gold standard’ method cystoscopy in diagnosing the true patient status (diseased or healthy; 
recurrence or no recurrence). 
Table 1.4 shows possible approaches to calculate the quality of the test. Sensitivity (a/a+c) 
and specificity (d/b+d) percentages show the proportions of patients with normal and 
abnormal test outcome in relationship to presence and absence of disease as measured by 
a gold standard. Sensitivity is the proportion of patients with recurrent disease that were 
correctly identified by the test. Specificity is the proportion of patients without recurrent 
disease that are correctly identified by the test. At first sight these simple calculations ap-
pear to have answered the question, but we have to keep in mind that we related the test 
outcome only to the gold standard test outcome, which is in this case cystoscopy, the point 
of reference. In other words we assume that the cystoscopy results reflect the patient’s true 
status of disease. Currently, there are some reasons to doubt the use of cystoscopy as ¨gold 
standard¨: If one uses photodynamic blue light cystoscopy instead of the standard white light 
cystoscopy more bladder cancer recurrences are detected22. In this thesis we also will provide 
data to show that cystoscopy may not represent a true gold standard for detection of UC 
recurrences.
Another approach to determine the accuracy of the test is by its positive and negative pre-
dictive value. How accurate is the test in predicting abnormality. A positive predictive value 
(a/a+b) is the proportion of patients with a positive test result who are correctly diagnosed 
with a recurrent disease and the negative predictive value (d/c+d) is the proportion of pa-
tients with a negative test result who could not be diagnosed with a recurrent tumour. These 
two values give a direct assessment of the usefulness of the test in practice. Unfortunately 
the lower the risk for recurrence, the more certain we can be that a negative test indicates 
no recurrence, on the other hand the less certain that a positive test result really indicates a 
tumour. 
Table 1.4
Tumour + Tumour not proven
Test +
A
Absolute number of true 
positive (TP)
B
Absolute number of 
False positive (FP)
A+B
(A/A+B)
Positive predictive value 
(PPV)
Test -
C
Absolute number of 
false negative (FN)
D
Absolute number of true 
negative (TN)
C+D
(D/C+D)
Negative predictive 
value (NPV)
A+C B+D N
(A/A+C)
Sensitivity
(D/B+D)
Specificity
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The main difficulty in the analysis of a diagnostic test is the need to decide how accurate 
the test should be in order to be clinically relevant. In the surveillance of low-grade non-
muscle invasive bladder cancer (pTaT1, G1 G2) we are actually screening an ostensibly ‘cured’ 
population with a probability of recurrence of 38% (and risk of progression <5%) in the first 
year and a probability of recurrence of 62% (and risk of progression 10%) within 5 years152. 
Within the 3-monthly surveillance scheme of patients with bladder cancer the risk of finding 
a recurrence at a follow-up moment is much lower. In the surveillance of patients with NMI UC 
we particularly want to avoid false negative results (low sensitivity that is missing cancers), 
but we are willing to accept a moderate number of false positives results. A concern with false 
positive test outcomes during surveillance of NMI UC patients is the increased burden for the 
patient as they lead to unnecessary cystoscopies, imaging and bladder biopsies. 
The clinical value of the currently available urine tests remains uncertain as data from large 
prospective multicenter trials considering both the costs and diagnostic accuracy are lacking. 
6.2.2 Microsatellite Analysis (MA)
The now most commonly used genetic test on urine, the UroVysion test, is based on the 
detection of genetically altered cells shed in urine by fluorescence in situ hybridization (FISH), 
a test approved by the FDA in 2001. This test detects chromosomal abnormalities (i.e. aneu-
ploidy for chromosome 3, 7, 17 and loss of 9p21) in tumour cells exfoliated in the urine of 
patients with bladder cancer by microscopic visualization of individual cells. Since this FISH 
test may detect chromosomal alterations in both low-grade and high-grade bladder cancers, 
this test could in theory be suitable for both the first diagnosis of bladder cancers but also for 
surveillance strategies (low-risk and high-risk adapted schemes). Nonetheless this test is not 
implemented in routine clinical practice. A cost-effectiveness study has recently indicated 
that this FISH test on voided urine samples is not cost-effective153. 
Several authors provided evidence that the use of microsatellite analysis (MA) for detection 
of cells with loss of heterozygosity (LOH) in voided urine samples may represent a promising 
tool in diagnosing recurrent UC of the urinary bladder as well as upper urinary tract UC154-158. 
Microsatellites are non-coding, highly polymorphic, short repetitive DNA sequences that 
are repeated frequently throughout the genome. Because changes in length of microsatel-
lites are frequent in the population it is possible to distinguish between the two copies of 
a chromosome by using the polymerase chain reaction (PCR) to amplify the repeat region 
from genomic DNA (i.e. heterozygosity is detected). Loss of one of the chromosomal regions 
then results in an absent or lower peak of the microsatellite from this chromosome (i.e. loss-
of-heterozygosity or LOH). UC is characterised by LOH often displayed at the chromosomal 
locations: 9q, 9p, 17p (p53 locus), 4p, 8p and 11p. These features of allelic imbalance can 
be detected by microsatellite analysis (Figure 1.8b). In this technique DNA is extracted from 
(voided) urine sediments and analysed for the presence of LOH of up to 20 polymorphic 
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markers from chromosomal regions known to show a high percentage of LOH. Several 
studies have demonstrated the value of MA in the detection of recurrent UC. A phase II trial 
performed in our laboratory on patients with NMI UC (‘superficial’ bladder cancer) reported 
a sensitivity of MA on voided urine samples of 75% and a specificity of 82%154-158. A prospec-
tive trial is the obvious next step to demonstrate that MA on voided urine samples of patients 
with NMI UC is sufficiently accurate and cost-effective for implementation as a routine test. 
The main focus of this thesis is the evaluation of MA as a surveillance tool in patients with NMI 
UC and the cost-effectiveness of the test, which we studied in a prospective multicenter trial 
(CEFUB-trial) conducted from 2002 to 2006.  
6.2.3 Outline of a randomized clinical trial 
The main idea of a clinical trial is to compare groups of patients who differ only with respect 
to their surveillance method. Two arms of patients monitored by two different surveillance 
schemes can be compared; one arm testing a new method, the urinary test, and another 
control arm where patients are monitored by the ‘gold standard,’ cystoscopy. In order to 
avoid bias, both groups may only differ in their surveillance scheme. Patients are randomly 
assigned to their surveillance group, consequently independent of the characteristics of the 
tumour and the patient; every patient has the same chance of receiving either surveillance 
method. The FGFR3 gene mutation status, histological stage and grade of the tumour are 
strong prognostic factors in UC, by incorporating these variables in a stratified randomisation 
scheme these variables can be controlled at the start of the trial. 
This thesis reports on a randomized clinical trial, in order to evaluate cost-effectiveness of the 
follow-up of patients with low-grade (WHO 1973 grade 1 or 2) NMI UC by either a conven-
tional regimen (control arm) or a follow-up scheme in which the cystoscopies at 6, 9, 15, 18 
and 21 months of follow-up after the last recurrence were replaced by microsatellite analysis 
(MA) on DNA extracted from voided urine samples (test arm). Primary outcome measure is 
the number of tumour recurrences in the patients randomized to the test arm and the control 
arm. In addition, the proportion of patients with tumour progression has been determined. 
Detection in the test arm of significantly more pT2 tumours would imply that MA detects 
tumour recurrences at a time that a recurrence had progressed too far. If significantly more 
low stage tumour recurrences were found in the test arm this might imply that the MA test is 
more sensitive than cystoscopy. Secondary outcome measures are 1) the quality of life during 
follow-up of the patients, including physical complaints as a consequence of the diagnostic 
intervention and 2) comparison of the cost-effectiveness of the two arms of the trial; using the 
direct and indirect costs involved with the diagnostic interventions and 3) the identification 
of clinico-pathologic and molecular parameters that may identify low-risk UC patients which 
may require less frequent follow-up, either by cystoscopy and/or by MA. Patients needed to 
undersign the informed consent to participate in the trial that they agreed to be randomized. 
Ch
ap
te
r 1
42
After randomisation patients were stratified for FGFR3 gene status, histological grade and 
stage of the last tumour and hospital. The flow chart in figure 1.11 provides a scheme depict-
ing the interventions in the control and the test arm of the randomized CEFUB trial.
7. The prediction of the disease course in NMI UC
As mentioned before a more individual-tailored follow-up scheme for patients with NMI 
UC dependent on their risk profile would be of help to reduce patient burden and costs of 
surveillance. A more accurate prediction of risk of recurrence and particularly of progression 
in the individual patient would enable such a person-adjusted follow-up scheme. Lutzeyer 
and Heney demonstrated in 1982 the clinical value of a number of conventional clinico-
pathological prognostic factors, including multifocality, location, site of tumour, pathological 
grade and stage159, 160. Many studies have been conducted since to identify and quantify 
prognostic factors for the risk of recurrence35, 46, 56, 142, 160-166, risk of progression46, 56, 160, 167 
and mortality risk46, 168-170 in patients with NMI bladder cancer171, 172. A first step towards 
individualizing the follow up policy of NMI bladder cancer is the search for prognostic fac-
tors to classify patients into different risk groups. Millan-Rodriguez was able to categorize 
patients into three risk groups, low-risk (50%), intermediate risk (35%) and high risk (15%), 
by using clinico-pathological prognostic factors56. These three risk groups however do not 
differentiate between risk of recurrence and progression. Oosterlinck et al evaluated the same 
conventional clinico-pathological factors to classify NMI UC into low, intermediate and high-
risk groups for recurrence and progression separately to enable the appropriate choice of 
adjuvant therapy173. However the need to predict more accurately the short-term and long-
term risks of both recurrence and progression in individual patients remained. Therefore the 
European Organization of Research and Treatment of Cancer (EORTC) developed a scoring 
system using risk tables based on the six most significant clinical and pathological factors; 
number of tumours, tumour size, prior recurrence rate, stage, presence of CIS and grade152 
(Figure 1.12). Although these tables are currently in clinical use, the search continues for better 
prognostic factors of progression and particularly of recurrence. Besides, continuous efforts 
are undertaken to improve the accuracy of prediction of progression and recurrence. Most 
of these studies focus on the identification of molecular tissue biomarkers as tools to predict 
the clinical course. Currently proven molecular and genetic predictors for UC recurrence are 
being weighed for their additional value in risk-profiling (such as FGFR3 gene mutations, TP53 
gene mutations, deletions of chromosome 9, immuno-histochemical staining of CK20, Ki-67 
labeling index, p27-index, etc)98, 100, 103, 104, 112, 136, 174-180. 
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EORTC risk score table allowing the calculation of the risk of recurrence and progression in individual patients using six conventional clinico-
pathologic parameters (reprinted with permission of RJ Sylvester; www.eortc.be)
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7.1 What is a clinically relevant independent prognostic factor?
In NMI UC a prognostic factor is defined as a characteristic associated with prognosis and 
outcome (recurrence and progression). A prognostic factor, a prognosticator, is clinically 
relevant if it describes the relation with an unknown variable (recurrent disease, progression) 
independent from other factors (grade, stage, biological markers) and thus is able to improve 
significantly the prediction of the clinical course of a patient with bladder cancer. Due to 
the availability of modern high-throughput technology many research groups tend to be 
more focused on the discovery of candidate markers rather than on their clinical utility. A 
prognosticator needs to be reproducible, easy to handle (feasible) in clinical practice and 
applicable in a broad spectrum of clinical settings. As pointed out in a review by Birkhahn et 
al a combined analysis of a panel of markers spanning different pathways may become the 
most promising approach to develop a powerful prognostic tool181. 
7.2 Prognostic Factors
7.2.1 Clinical Characteristics
Clinical features as age and comorbidity are not considered as prognosticators for recurrences or 
progression in NMI UC, in contrary to gender and smoking behaviour, both of which have been 
studied for their potential impact on the prognosis of NMI UC6, 8, 9. Studies have consistently 
shown that smokers have on an increased risk for bladder cancer compared to non-smokers. 
Moreover women who smoke comparable amounts of cigarettes may have a higher risk of 
bladder cancer than man9. The proportion of bladder cancer cases attributable to ever smoking 
was 0.66 (0.61-0.70) for all men and 0.73 (0.66-0.79) for men younger than 607.
Irritative bladder symptoms can be indicative for tumours localised in the trigone or CIS or 
for a large tumour volume reducing the bladder capacity. The latter two are associated with 
increased risk of progression. Large tumours (>5 cm), multifocality and tumours with diffuse 
appearance have a higher risk of recurrence182. In case of a history of recurrent tumours, 
the probability of future recurrences increases to approximately 80%. Short disease free 
interval is also indicative for future recurrences. The risk of recurrence decreases with each 
normal cystoscopy and is less than 10% at 5 years and extremely low at 10 years if all interval 
cystoscopies had been normal. Patients with multifocal tumours in the bladder or tumours 
involving other sites of the urothelial tract (i.e. renal pelvis, ureter, urethra) are at increased 
risk for recurrence, progression or death due to disease35, 152, 159, 167. 
7.2.2 Pathological Characteristics
Histological grade is a powerful prognosticator for progression in NMI UC, but of limited and 
disputable value for recurrence183-185. PUNLMP has a moderate risk for recurrence (35%) and 
a very low risk for progression in stage58, 59, 185, 186. Patients with PUNLMP have essentially a 
normal age-related life expectancy. Low-grade NMI UC recur frequently (up to 70%) but they 
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progress in stage only in up to 12% of the patients57-59. The prognosis of high-grade NMI UC 
is strikingly different. Tumours frequently progress in stage and the mortality due to disease 
can be as high as 65%187, 188. Presence of dysplasia and concomitant CIS are associated with a 
much-increased risk for progression in stage and death due to disease60, 189, 190.
Stage is a strong prognosticator for recurrence and progression in NMI UC. The prognosis 
of patients with pTa tumours is mainly defined by the grade of differentiation. Patients with 
a single, small, low-grade pTa tumour without CIS are at low risk for both recurrence and 
progression. Patients with high-grade pTa tumours are at high risk of progression. Most pTa 
tumours are however well differentiated. Most pT2 and higher staged tumours are high-
grade, and the prognostic significance of grade as a risk factor for metastatic disease an 
disease specific survival is limited. Muscle invasive (pT2) UC have a 50% risk of metastatic 
disease. In pT1 UC the UC tumour cells invade the lamina propria but they do not invade into 
the muscularis detrusor. Their biological behaviour is highly variable and unpredictable with 
the current grading. Stage pT1 tumours frequently are high-grade and they show a recur-
rence rate of 80%, a progression rate of 60% and a 10-year survival rate of 35%. In efforts 
to stratify pT1 tumours further, substaging systems have been proposed based on the level 
of invasion into the lamina propria. Tumours that infiltrate beyond the muscularis mucosae 
have a higher progression rate37, 45, 47, 191. An alternative is to stratify patients according to 
the level of invasion into the lamina propria measured by a micrometer attached to the 
microscope192-194. A major problem with these substaging systems is their poor reproduc-
ibility among pathologists. Further, the lack of orientation of transurethrally resected tissue 
samples often precludes the possibility to substage according to the level of invasion relative 
to the vascular plexus an the muscularis mucosae. For this reason we developed in this thesis 
a more simplified substaging system, which we tested on a series of primary pT1 UC. 
Lymphatic and/or vascular invasion is associated with decreased survival in pT1 tumours 
(44% 5-year survival). However vascular invasion is frequently over-diagnosed195. Neverthe-
less, pathologists report this parameter if identified.
7.2.3 Molecular Characteristics
The encountered limitations of the conventional characteristics have challenged many research 
groups to discover molecular markers, which can classify bladder cancer in more detail in order 
help in the selection of the optimal treatment. More specifically, the identification of molecular 
markers predictive of recurrence and progression is now considered of utmost importance 
to enable accurate risk stratification for a given patient. Below we describe the scientific and 
clinical evidence for the potential use of a limited number of biomarkers used in this thesis. 
7.2.3.1 FGFR3 gene mutations
One of the most promising prognosticators of NMI UC is the mutation status of the fibroblast 
growth factor receptor 3 (FGFR3)99, 100, 103, 104, 107-109, 111, 112, 136, 191.  Ostensibly, mutant FGFR3 
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represents an oncogene, as the mutations activate the FGFR3 signaling pathway.  However 
in UC this mutation is associated with genetically stable bladder cancer and with low-grade, 
low stage disease99, 102, 104, 110, 113, 178, 196. The presence of an FGFR3 mutation is an indicator 
for favourable prognosis as the risk to progress in disease is much lower in the presence of 
this mutation107, 113, 114. The potential of FGFR3 mutation status as a prognosticator for recur-
rences used to be somewhat controversial, but most studies now agree that the presence of a 
FGFR3 mutation is not strongly associated with an altered frequency of recurrences. In a large 
Spanish study a series of 772 UC was analysed for FGFR3 gene mutation and only the subset 
of patients with mutant pTaG1 UC showed a slightly higher risk of recurrence102. 
7.2.3.2 TP53 tumour suppressor gene
By definition, a tumour suppressor gene provides a growth advantage to the affected cells 
in case of its reduced expression or its inactivation. Alterations in the cell cycle regulation 
pathway are thought to underlie the development of UC. The gene has been mapped to 
chromosome 17p13 and encodes for a 53kDa protein. This protein plays a protective role 
in several pivotal cellular processes including regulation of the cell cycle, response to DNA 
damage, cell death and stimulation of neovascularization197. In response to DNA damage, 
the wild type TP53 stops the cell cycle in order to offer the cell time to repair its DNA or to 
induce apoptosis in case the repair mechanism fails (cell death). Therefore the gene has been 
referred to as the ‘guardian of the genome’198. This protective mechanism does not work 
anymore if the TP53 gene is mutated or both alleles are eliminated by deletion (homozygous 
loss): DNA damage goes unrepaired, mutations become fixed in dividing cells, and the cell 
turns onto a one-way street that leads to progressive genetic instability. 
TP53 alterations are the most common genetic defects found in human cancer. Missense 
mutations in the TP53 tumour suppressor gene result in the incorporation of non-cognate 
amino acids. These changes result in a change in the 3D structure of the TP53 protein. The 
half-life of the altered protein increases because its degradation is inhibited; this leads to 
nuclear accumulation of the protein. All human cells express TP53 but, in non-cancerous 
cells, the short half-life (6-30 minutes) prevents the TP53 protein from accumulating in the 
nucleus. Often TP53 mutations can be detected by immunohistochemistry because of this 
abnormal nuclear accumulation. Numerous studies highlight the frequent nuclear TP53 ac-
cumulation in less differentiated and more advanced UC199, 200. Lamy et al found inactivating 
TP53 mutations in 10% of pTa, 42% of pT1 and 58% of pT2 tumours141. Nevertheless, sofar 
its prognostic impact additional to conventional clinico-pathological markers is limited, and 
staining for TP53 is not a standard procedure in pathology diagnostics of bladder cancer. The 
main reason is the highly variable immunostaining outcome, hampering the interpretation 
of staining results in a given tumour. 
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7.2.3.3 Ki-67 
Proliferative activity has frequently been studied as a potential prognosticator in urothelial 
carcinomas201, 202. The Ki-67 protein is a cellular marker for proliferation, which is strictly as-
sociated with cell proliferation. The protein is present during all active phases of the cell cycle 
(G1, S, G2, and mitosis), but is absent in resting cells (G0). The monoclonal antibody anti-Ki-67 
reacts exclusively with the nuclei of the proliferating cells203, 204. Ki-67 is an excellent marker 
to determine the growth fraction of a given cell population. The fraction of Ki-67-positive 
tumour cells (the Ki-67 labelling index) has been shown to be associated with the clinical 
course of several cancers, including bladder cancer.  
One of the monoclonal antibodies most commonly used in clinical applications to deter-
mine the Ki-67 labelling index is MIB-1205. Increased proliferative activity reflected by MIB-1 
immuno-histochemical staining increases with tumour stage and grade and is a prognostic 
factor in disease progression and recurrence206. Tsuji et al showed that high Ki-67 index cor-
relates with p53 nuclear accumulation in urothelial bladder carcinoma137. Asakura et al found 
Ki-67 as a prognostic factor for recurrence and progression in non-muscle invasive bladder 
carcinoma207. In pTa/T1 tumours, Ki-67 labeling index and expression of cyclins D1 and D3, 
which are upstream regulators of the cell cycle, might be relevant predictors of survival208. 
Nevertheless, in pTa G2 tumours, Holmang et al did not observe any correlation between 
high progression rate and high labeling index58. In spite of these contradictory results this 
biological marker continues to be a potential prognosticator that might be implemented 
in the pathological routine of bladder cancer diagnostics. Importantly, Van Rhijn et al of 
our laboratory successfully incorporated the Ki-67 labeling index in their molecular grading 
system of bladder cancers98.  
7.2.3.4 CK20 protein expression
Cytokeratins are intermediate filament proteins present in normal epithelia and their expres-
sion is maintained during malignant transformation. CK-antibodies are exploit to identify the 
primary site of epithelial tumours. CK20 is one of 20 cytokeratin subtypes that is expressed 
in mature enterocytes and goblet cells of intestinal mucosa, and Merkel cells of the skin. 
In addition, specifically umbrella cells of the normal urothelial lining, but not basal or in-
termediate urothelial cells express CK20. Therefore CK20 expression is related to a normal 
differentiation and maturation. In UC CK20 expression may be aberrant, which becomes 
manifest by its complete absence of staining or by involvement of multiple cell layers with 
> 10% of the cells stained. When CK20 expression in non invasive UC is limited to the most 
superficial (umbrella) cells, a normal expression pattern, it is associated with a mild disease 
course, whereas expression in >10% of the cells of the entire urothelial thickness is associated 
with higher tumour grade and an increased risk of recurrence and progression100, 209-211. Its 
independent prognostic role continues to be a controversial issue. 
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8. Patients’ Opinion 
Quality of life
Quality of life is the degree of well-being felt by an individual or a group of people (Wikipedia). 
Quality of life is not a concrete topic in science, and cannot be measured directly. Two components 
of quality of life must be considered; the physical component (pain, morbidity, possibilities to 
protect against disease etc) and the emotional component (stress, fear,pleasure etc). Although it 
is difficult to quantify quality of life issues, one can assume that the higher average level of physi-
cal and emotional experiences a person has, the better overall quality of life is experienced.
Today quality of life issues play a pivotal role in todays health care. A growing field 
of research is dedicated to the development, evaluation and application of quality of life 
measures within health related research (e.g. within randomized controlled trials). Many of 
these research efforts focus on the quantitative measurement of health related quality of life 
(HRQoL). They also focus on measuring HRQoL from the perspective of the patient and thus 
take the form of self completed questionnaires. 
The role of HRQoL is increasing. Patient satisfaction and preferences together with utility 
assessment are particularly important when it comes to the selection of new diagnostic and/
or therapeutic regimens. Not much is known regarding the burden imposed by bladder can-
cer upon patient HRQoL. We all assume that the HRQoL related to the diagnosis of bladder 
cancer depends a) on the extent (stage) of the carcinoma and corresponding therapies and 
b) on the intensity of the surveillance and the surveillance method in case of NMI UC. Several 
studies have quantified the differences in quality of life in patients with the diagnosis MI 
UC regarding bladder sparing surgery, cystectomy and urinary diversions212-216, but only few 
studies have focused on the influence of the bladder cancer surveillance on the well-being of 
patients. In this thesis we made an attempt to fill this gap. 
Patients diagnosed with NMI UC are recommended to adhere to an intensive surveillance 
scheme by cystoscopic examinations in order to detect UC recurrences. Cystoscopy is an 
invasive method which is assumed to be experienced as painfull, burdensome and to have a 
major impact on patients’ general functioning. The introduction of the flexible scope improved 
patients’ perspective on the endoscopic experience217, 218, but the experience obviously 
continues to be of invasive nature and potentially distressful for the patient. A few studies in-
vestigated the opinion of patients regarding flexible cystoscopic examination and confirmed 
the assumption that it is painful; when the tip passess the external sphincter219, irrespective 
of the analgesic method220, irrespective of delayed or immediate cystoscopic examination 
after lidocaine injection221. We assume that patients consider an invasive method as less at-
tractive compared to a less invasive method like urinary tests. Further, Stav et al reported a 
transient impairment of sexual performance until two weeks after cystoscopy222. Vriesema et 
all investigated patients’ opinion about the required validity of non-invasive diagnostic tools 
and concluded that 89% of the patients prefer flexible cystoscopy if sensitivity of a urinary 
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test is lower than 90%223. Yossepowitch et al asked seven years later a similar question and 
concluded that from a patient perspective a urinary biomarker would likely require a 95% or 
greater diagnostic accuracy224. Hence; what we know so far is that, although patients experi-
ence a cystoscopy as painful (of course) they prefer a solid, well-established and accurate 
method above a non-invasive method in an experiment of thoughts. 
Although we still assume that the burden and the impact on general functioning of a 
cystoscopic examination is so large that we need to offer patients a non-invasive test, we still 
do not know if the impact on quality of life in bladder cancer patients is due to the diagnosis 
and the fear of recurrence or due to the prospect of an intensive surveillance scheme. This 
thesis tries to evaluate to what extent the burden of cystoscopy is outweighed by its better 
diagnostic properties as compared to non-invasive urine tests.  
9. Health Care System
Botteman et al. calculated (based on values in the year 2001) that bladder cancer was the fifth 
most expensive cancer in overall costs, but the most expensive cancer per patient19, 143, caused 
by the long-term survival and life-long monitoring and treatment of individual patients. They 
concluded that current diagnostic processes, follow-up schedules and treatment are very 
expensive, especially for NMI UC, which can be considered a chronic disease. Avritscher et 
al confirmed these findings, and thereby demonstrated in a single-institution cohort that 
approximately 60% of the costs were related to surveillance and treatment of recurrences 
and 30% to complications. Transurethral resections of (recurrent) bladder cancers proved to 
be the strongest contributor to the costs of surveillance of patients with a bladder cancer. For 
this reason, alternatives are being explored, such as in office fulguration of small cancers and 
expectant management of low-grade low stage cancers. The lifetime cost of bladder cancer 
was lower for a worst-case scenario (99,270 dollars) than for a best-case scenario (120,684 
dollars)225, 226. It can be hypothesized that a lowering of the frequency of recurrences, the 
reduction of the incidence of progression and the disappearance of the number of complica-
tions will decrease the lifetime costs of bladder cancer. Further, it may be considered to lower 
the costs of surveillance by introducing cheaper methods and/or an alternative scheme of 
surveillance, based, e.g. on an improved patient stratification. In this thesis we will address 
the question, how much an alternative method or surveillance scheme may cost in order to 
replace cystoscopy in a cost-effective way.  
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10. Abbreviations
ALA Aminolaevulinic Acid
BCG Bacillus Calmette-Guerin
BTA Bladder Tumour Antigen
CEFUB-trial Trial to evaluate the Cost-
Effectiveness of Follow-up of 
Patients with Bladder cancer
CGH Comparitive Genomic 
Hybridization
CI  Confidence Interval
CIN  Chromosomal Instability
CIS  Carcinoma in Situ
CK20 Cytokeratin 20
CRF Case Report Form
CT  Computed Tomography
CYFRA21-1 Fragment of Cytokeratin 21
DNA Deoxyribonucleic acid 
EAU European Association of 
Urology
EORTC European Organization of 
Research and Treatment of 
Cancer
FDA  Food and Drug Administration
FGFR3 Fibroblast Growth Factor 
Receptor 3
FISH Fluorescence in situ Hybridisa-
tion
FN  False Negative
FP  False Positive
HAL Hexi-aminolaevulinic Acid
HE  haematoxyline-eosine
hpf  high power field
HR   Hazard Rate
HRQoL Health Related Quality of Life
IVU  Intravenous Pyelogram
LOH Loss of Heterozygosity
MA  Microsatellite Analysis
MI  Muscle Invasive
MM Multipele Myeloma
MRI Magnetic Resonance Imaging
MSI  Microsatellite Instability
NMI UC Non-muscle invasive Urothelial 
Carcinoma
NMP 22 Nuclear Matrix Protein 22
NPV Negative Predictive Value
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PDD Photo Dynamic Diagnosis
PET  Positron Emission Tomography
PPV Positive Predictive Value
PUN-LMP Papillary Urothelial Neoplasm 
of Low Malignant Potential
RR  Relative Risk
SADDAN Severe Achondroplasia with 
Developmental Delay and 
Acanthosis Nigricans
TD  Thanatophoric Dysplasia
TNM Tumour-Node-Metastases at 
distance
TUR Trans Urethral Resection
UC  Urothelial Carcinoma
UCS Urethro-Cystoscopic Surveil-
lance
UICC Union International Contre le 
Cancer
UUT Upper Urinary Tract
VAS  Visual Analog Scale
WHO World Health Organisation
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Outline of the thesis
In an ideal health care scenario the four aspects of bladder cancer patient care (that is 
diagnosis and risk stratification of patients, surveillance, optimal quality of life and societal 
impact of the management of bladder cancer) would be integrated in such a way that an 
optimal management can be offered to patients with NMI UC. This thesis on surveillance of 
patients with non-muscle invasive bladder cancer attempts to analyse these four aspects as 
reflected in the contents of its parts: Part I General introduction provides a background on 
epidemiology, diagnosis, treatment and biology of bladder cancer, Part II is reporting our 
studies on the clinical relevance of conventional and novel prognostic factors for bladder 
cancer behaviour, Part III is devoted to the analysis of an alternative surveillance scheme 
in patients with non-muscle invasive bladder cancers, Part IV is reporting on the impact of 
surveillance on quality of life, Part V analyses the economic impact of bladder cancer surveil-
lance with an alternative urine test and Part VI discusses the results of the studies of this 
thesis. Parts III-V report specifically the outcomes of a randomized multicenter prospective 
trial on the cost-effectiveness of the follow-up of patients with non-muscle invasive bladder 
cancer (CEFUB-trial) conducted in the region surrounding Rotterdam. 
In more detail, Part I, chapter 1 of the thesis gives the necessary background of this thesis, 
describing the molecular biology and cancer genetics of bladder cancer underlying the 
diagnosis and prognosis in bladder cancer. 
Part II aims to answer the question how to predict bladder cancer behaviour by tissue 
biomarkers in order to achieve optimal risk stratification. Knowledge of the biologic 
behaviour of newly diagnosed cancer might enable the identification of subgroups of pa-
tients to offer a tailor-made surveillance scheme. Chapters 3–5 comprise part II of the 
thesis, analyzing conventional and novel prognosticators for NMI UC. A meta-analysis of 
5021 patients with bladder cancer described in chapter 3 analyses the prognostic value of 
conventional clinical and pathological parameters. To individualize surveillance strategies it 
is necessary to distinguish in a meaningful way between high and low risk patients in the 
group of non-muscle invasive bladder cancer patients (NMI UC). By the introduction of the 
WHO 2004 classification system of bladder cancers a change in grading of bladder cancers 
has been introduced, but some controversy remained with regard to the clinical impact of 
this new grading system as compared the older WHO 1973 system. Further, there is evidence 
that novel prognostic factors like FGFR3 gene mutation status and immuno-histochemical 
staining for a number of biomarkers (e.g. Ki-67 labeling index, cytokeratin 20 staining pat-
tern) may be of additional value to improve patient stratification. In Chapter 4 we describe in 
a prospective study involving multiple contributing hospitals the prognostic impact of two 
grading systems (WHO 1973 and 2004) together with the biomarkers FGFR3 mutation status, 
CK-20 expression pattern and Ki-67 labeling index. The possibility to subdivide the subset of 
NMI UC that invades into the sub-epithelial connective tissue (pT1) at first presentation is of 
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great clinical interest. The behaviour of these pT1 UC is very unpredictable and they seem 
to display a considerable biological and molecular heterogeneity. In chapter 5 we propose 
a simplified pathological substaging system for pT1 UC, we related this novel substaging 
method to FGFR3 mutation status and tumour grade and we investigated whether we were 
able to improve the risk stratification of pT1 UC by any of these markers. Surveillance (Part 
III) of patients with NMI UC after diagnosis is currently done by an intensive scheme of 
cystoscopic examinations. Because cystoscopy is generally considered a burdensome and 
costly method new preferably non-invasive methods have been developed. Can we improve 
surveillance of bladder cancer? Several studies suggested that microsatellite analysis (MA) 
of voided urine samples for detection of cells with loss of heterozygosity (LOH) might offer a 
reliable substitute for cystoscopy. Further, MA may also be able to detect upper urinary tract 
UC. For a new method to compete with cystoscopy it needs to be feasible in routine clinical 
practice: highly reproducible, accurate and at acceptable costs. For this reason we engaged 
on a prospective randomized multicenter trial on patients with low-grade (WHO 1973 grade 
1 and 2), low stage (pTa, pT1) bladder cancer, comparing a conventional follow-up scheme by 
cystoscopy alone to a follow-up scheme in which part of the cystoscopies was replaced by 
MA (chapter 6). The findings of this randomized trial prompted us to further scrutinize the 
view that cystoscopy represents the gold standard for detection of UC recurrences in patients 
with NMI UC (chapter 7). 
How does surveillance affect patients with NMI UC? The influence of surveillance of blad-
der cancer on their quality of life is the topic of chapters 8 and 9 of Part IV. We aimed to 
quantify the experienced burden of patients at one week after cystoscopy in order to verify 
the generally assumed heavy impact of cystoscopy on the patients’ perceived quality of life 
(chapter 8). In a small side study we also examined to what extent sexual dysfunction occurs 
in patients with NMI UC (chapter 9). 
What are the effects versus the costs in surveillance if cystoscopy is partly replaced by 
the MA urinary test? To implement a new method in a routine clinical practice, patients, clini-
cians as well as public health care providers must be convinced that the new scheme is more 
cost-effective than the traditional surveillance scheme. Cost-effectiveness includes economic 
costs, quality of life and effects of the method on the health status of the patient. Chapter 
10 of part V reports on an analysis of cost-effectiveness of the surveillance of patients with 
NMI UC in which cystoscopy is partly replaced by MA. This analysis tries to determine how 
high the costs of an alternative urine test may be in relationship to its accuracy and effects on 
health status in order to be implemented successfully. 
The final part VI comprises chapter 11 and 12. In the former chapter the results of our 
study are discussed and an outline of future studies aimed at the improvement of surveil-
lance for patients with NMI UC is provided. The latter chapter summarizes the content of the 
studies described in this thesis.
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Abstract
We aimed to quantify the importance of clinical and pathological prognostic factors in the 
outcome of non-muscle invasive bladder cancer (NMI UC) based on current literature. We 
identified 14 publications published between 1980 and 2004 that reported on the association 
between clinical and pathological prognostic factors for tumour recurrence, tumour progres-
sion and overall mortality after transurethral resection of a NMI UC tumour. Relative risks (RR) 
were estimated using meta-analytic techniques to combine results of separate studies. In 
total, 2536 of 5021 patients had a tumour recurrence, 317 of 3313 had tumour progression 
and 531 of 1548 died. The strongest prognostic factor for tumour recurrence was the result 
of the first 3-monthly cystoscopy (RR, 2.2; 95% CI, 1.8-2.7). The strongest prognostic factor for 
tumour progression was grade 3 compared to grade 1 (RR, 6.7; 95% CI 4.7-9.5). The presence 
of CIS had a strong effect on tumour progression (RR, 4.4; 95% CI 3.4-5.5) and on the overall 
mortality (RR, 4.0; 95% CI 2.4-6.5). Tumour shape, grade 3 and patient age also had strong 
effects on survival. Clinical and pathological prognostic factors could not predict tumour re-
currence, but showed strong associations with tumour progression and overall mortality. To 
individualize surveillance strategies emphasis should be on the search for novel prognostic 
factors that can reliably predict recurrence.
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Introduction
Bladder cancer is the fourth most common malignancy in men and the eight most common 
in women1. The majority of the urinary bladder cancers are non-muscle invasive urothelial 
carcinomas (NMI UC)1. The muscle- invasive UC have a significantly worse prognosis2. A major 
problem of NMI UC is that it recurs in up to 70% of the cases after a transurethral resection 
(TUR)3. Approximately 10-30% of these recurrences will progress to a more malignant form4-7, 
with a 5-year survival rate after cystectomy of 45%2. Therefore it is necessary for the patients 
to be monitored at regular intervals. Follow up consists worldwide of schemes of cystoscopy, 
the gold standard, and cytology. 
Because of the high costs related to surveillance of patients with a NMI UC, the benefit 
of maintaining a fixed follow up scheme for all patients, irrespective of their individual risk, 
is questionable8, 9. A first step towards individualizing the follow up policy of NMI UC is the 
search for prognostic factors to classify patients into different risk groups. Much research has 
been conducted to identify and quantify prognostic factors for the risk of recurrence5, 8, 10-18, 
risk of progression5, 14, 16, 18 and mortality risk16, 19-21 in NMI UC patients. In addition several 
reviews have qualitatively summarized studies on prognostic factors22, 23. These reviews how-
ever were not carried out systematically, and did not include formal statistical techniques to 
appropriately combine results from individual studies.
We therefore aimed to perform a systematic review to quantify the strength of prognostic 
factors more accurately. More objective prognostic effects can be obtained by analyzing all 
available studies, including those reporting no significant effects. Also, by consideration of 
larger numbers of patients, effects can be estimated more precisely. Systematic reviews have 
therefore been promoted as at the core of evidence-based medicine24.
Patients and Materials
Study Identification
We searched the MEDLINE database from 1980 to 2004 to identify English-language studies 
on clinical and pathological prognostic factors for tumour recurrence, tumour progression 
and mortality in NMI UC (transitional) of the urinary bladder. Search words were “prognostic 
factors” and “Superficial bladder cancer” and “non-muscle invasive bladder cancer”. Relevant 
references in articles were also considered.
Studies were included if the association between any of the three above mentioned end-
points and the clinical and pathological characteristics were quantified, or if it was possible to 
calculate relative risks from the reported data. In order to limit publication bias, studies were 
excluded if it was not possible to calculate the relative risks of non-significant prognostic 
factors from the reported data. Publication bias might arise when a positive or statistically 
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significant association is more likely to be reported than a negative or statistically non-signif-
icant association. When two studies included patients from the same center with overlapping 
time periods, we included the study with the largest population or with the longest follow up 
period. Studies had to have patients with primary and/or recurrent NMI bladder cancer to be 
included for analysis. We defined NMI UC as tumour extension limited to the mucosa (stage 
Ta) or limited to the lamina propria (stage T1). Primary carcinoma in situ (CIS) without other 
disease was not considered to be a NMI tumour. Studies on patients with NMI UC tumours 
located in the upper urinary tract were excluded. We also excluded studies with patients 
likely to have a worse prognosis, so who had received chemotherapy, radiotherapy or had 
undergone a cystectomy prior to the start of the study.
Clinical and Pathological Characteristics 
We studied the following clinical and pathological characteristics: patient gender, patient 
age, stage of the tumour, grade of the tumour, multiplicity of tumours, presence of dysplasia, 
presence of CIS, tumour size, location of the tumour, the shape of the tumour, disease status, 
result of cystoscopy at 3 months after TUR. These prognostic factors were chosen since they 
were considered in more than one study.
The stage of the tumour was considered when it was determined according to the tumour-
node-metastasis system classification of ’7825: Stage pT1 was compared to pTa. All of the 
studies classified the grade of the tumour according to the WHO classification system of ’7326. 
One study used both a local and reference pathologist to stage and grade the tumours12. 
Only the data from the reference pathologist was analyzed. Multiplicity was defined as the 
presence of multiple tumours at diagnosis. Multiple tumours were compared to solitary tu-
mours. Results from a study that compared patients with 6 or less tumours with patients with 
7 or more tumours were therefore not analyzed16. The presence of dysplasia was compared to 
normal urothelium. One study compared normal urothelium to mild/moderate dysplasia and 
to severe dysplasia5. Mild, moderate and severe dysplasia were all considered as the presence 
of dysplasia. Different cutoff values were chosen for the size of the tumour. One study used 
a cutoff value of 5 cm11, two studies used a cutoff value of 2 cm15, 17, while the other studies 
used a cut-off of 3 cm8, 10, 16, 18 and 2.5 cm12. We assessed two cutoff values, namely 2 cm for 
the two studies that used a cutoff value of 2 cm and 3 cm for the other studies that used a 
cutoff value of 2.5-3 cm. Cutoff values of 60 and 65 years were considered for patient age14, 
1615, 17 . We assessed the involvement of two locations of the bladder wall in tumour growth, 
the posterior wall and the trigone, since only these tumour locations were studied in more 
than one study. For the disease status a recurrent tumour was compared to a primary tumour. 
The first 3-monthly cystoscopy after diagnosis was either positive or negative. A positive 
result was defined as the presence of a recurrence and/or a progression of the tumour. For 
the shape of the tumour, papillary tumours were compared to tumours of other shape.
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Endpoints
Three endpoints were analyzed, namely: tumour recurrence, tumour progression and overall 
mortality. For the risk of first tumour recurrence, most studies4, 5, 11, 12, 14-17 used time to 
first tumour recurrence or the disease free interval as a measure. Three other studies8, 10, 13 
reported the recurrence rate. Tumour progression was defined as a shift to stage T2 or worse 
and/or the development of regional and/or distant metastases. Four studies5, 14, 16, 18 were 
included for the analysis of tumour progression. Time to tumour progression or disease free 
interval was used as a measure for tumour progression. Survival curves were used in all stud-
ies16, 19-21 to assess the mortality risk.
Statistical Analysis
For each prognostic factor we required relative risks and standard errors. These were some-
times directly available in the reports. Alternatively, when Kaplan-Meier curves had been 
reported, we scanned and enlarged published curves in a graphical computer package. We 
measured the heights of these curves and calculated corresponding probabilities of the 
events, from which relative risks were derived. The standard error of each study was esti-
mated based on the number of patients with an endpoint. Weights were obtained by taking 
the inverse of the square of the standard error. These weights were used to calculate pooled 
relative risks (RR) for the prognostic factors, using standard meta-analytical methods27. 
Heterogeneity between studies was assessed graphically and judged satisfactory. We also 
report on the fraction of patients with a prognostic characteristic, since this also determines 
its clinical relevance. If a characteristic, for example, has a strong effect (i.e. high relative risk) 
a low occurrence may make it of rather limited relevance.
Results
We included fourteen studies (Table 3.1), with eleven studies reporting on tumour recur-
rence5, 8, 10-18, four studies on tumour progression5, 14, 16, 18 and four studies on the overall 
mortality16, 19-21. The total numbers of patients were respectively 5021, 3313 and 1548 for 
recurrence, progression and overall mortality. The reported median follow up periods ranged 
from 27 to 48 months for recurrence and 39 to 48 months for progression. The maximum 
follow up period for overall mortality ranged from 5 to 20 years (median follow up periods 
were not reported).  A total of 2536 of 5021 patients had a recurrence, 317 of 3313 patients 
had progression and 531 of 1548 patients died. The follow up policy varied between the 
different studies (Table 3.2). Most started with 3 monthly intervals during the first years, but 
the frequency differed especially during later years.
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Tumour recurrence
Multiplicity was considered in all eleven studies5, 8, 10-18 and was found statistically significant 
in eight5, 8, 10, 12-15, 18. Tumour stage, tumour grade and tumour size were considered eleven5, 8, 
10-18, eleven5, 8, 10-18 and nine times5, 8, 10-12, 15-18, respectively, and were found significant four5, 
8, 13, 14, four5, 8, 13, 16 and six times5, 8, 10, 16-18, respectively (Table 3.1).
The strongest prognostic factor for tumour recurrence was the result of cystoscopy after 
3 months (pooled RR, 2.2; 95% CI, 1.8-2.7, Table 3.3a). Smaller effects were found for disease 
status (RR 1.5; 95% CI, 1.3-1.8), trigone involvement (RR 1.5; 95% CI, 1.2-1.8), multiplicity (RR 
1.4; 95% CI 1.3-1.6), tumour size (3 cm cutoff value, RR 1.4; 95% CI 1.2-1.7) and grade of disease 
(grade 3 compared to grade 1, RR 1.4; 95% CI 1.2-1.6). Patient age and patient gender did not 
have a prognostic value for tumour recurrence.
Table 3.1
Table 1.   Characteristics of 14 studies included in the systematic review of clinical and pathological prognostic factors for the   
                  risk of recurrence, progression and mortality in superficial bladder cancer
Recurrence
Study Acrual  Patients with Considered Significant 
First author (ref) Year N  type period   recurrence  prognostic factors  prognostic factors
Dalesio (10) 1983 308 rct 1975-1978 202 ag, gr, mu, re, si, tr, ts mu, re, si, tr*
Heney (5) 1983 243 rct 1974-1977 133 gr, mb, mu, si, st, ur gr, mb, mu, si, st, ur
Smith (11) 1983 112 cohort 1978-1981 59 gr, mb, mu, si, st mb
Parmar (12) 1989 305 rct 1981-1986 143 cy, gr, lo, mu, si, st cy, mu*
Shinka (13) 1990 198 cohort 1986-1988** 60 gr, mb, mu, pp, st gr, mu, st
Kiemeney (14) 1994 1001 cohort 1983-1989 513 ag, ge, gr, mb, mu, nlo, st mb, mu, nlo, st*
Mulders (15) 1994 371 rct 1987-1990 138  ag, ge, gr, lo, mu, si, st, ts lo, mu*
Kurth (16) 1995 576 rct 1979-1987** 311  ag, ge, cy, gr, lo, mu, re, si, st, td, ts gr, lo, re, si*
Allard (8) 1998 333 cohort 1990-1995** 230  ag, ge, gr, lo, mb, mu, si, sm, st gr, mu, si, st*
Kondo (17) 1999 45 cohort 1989-1997 13 ag, ge, gr, mb, mu, sh, si, st ag, sh, si*
Millan-Rodriguez (18) 2000 1529 cohort 1968-1996 734  gr, mb, mu, si, st, tr mb, mu, si, tr*
Total 1983-2000 5021 2536
Progression
Study Acrual  Patients with Considered Significant 
First author (ref) Year N  type period   progression  prognostic factors  prognostic factors
Heney (5) 1983 207 rct 1974-1977 25 gr, mb, si, st gr, mb, si, st
Kiemeney (14) 1994 1001 cohort 1983-1989 102 ag, ge, gr, mb, mu, nlo, st ag, gr, mb, mu*
Kurth (16) 1995 576 rct 1979-1987** 75  ag, ge, cy, gr, lo, mu, re, si, st, td, ts cy, ge, gr, lo, re, si*
Millan-Rodriguez (18) 2000 1529 cohort 1968-1996 115  gr, mb, mu, si, st, tr gr, mb, mu, si, tr*
Total 1983-2000 3313 317
Mortality
Study Acrual  Patients  Considered Significant 
First author (ref) Year N  type period died  prognostic factors  prognostic factors
Flamm (19) 1990 345 cohort 1971-1982 40 ag, ge, gr, lo, mb, mu, rw, st, tai gr, mb, tai*
Lipponen (20) 1993 272 cohort 1965-1991 83 ag, ge, gr, sh, st ag, gr*
Kurth (16) 1995 576 rct 1979-1987** 127  ag, ge, cy, gr, lo, mu, re, si, st, td ag, ge, re, si*
Zieger (21) 1998 355 cohort 1976-1984 281 gr, mb, mu, sh, si, st gr, si, st*
Total 1990-1998 1548 531
*prognostic factors found significant after multivariable analysis
**study period estimated from the reported longest follow up period 
Abbreviations: ag, age; cy, 3 month cystoscopy result; ge, gender; gr, tumor grade; lo, tumor location; mb, mucosal biopsy; mu, multiplicity;
    nlo, number of tumor locations; pp, purified protein derivative; rct, randomized clinical trial; re, prior recurrence rate; rw, resection weight;
    sh, tumor shape; si, tumor size; sm, smoking status; st, tumor stage; tai, tumor associated inflammation; td, time from diagnosis; tr, treatment; 
    ts, tumor status; ur, urinary cytology
*prognostic factors found significant after multivariable analysis
**study period estimated from the reported longest follow-up peri d
Abbreviations: ag, age; cy, 3 months cystoscopy result; ge, gender; gr, tumour grade; lo, tumour location; mb, mucosal biopsy; mu, multiplicity; 
nlo, nu ber of tumour locations; pp, purified protein derivative; rct, randomized clinical trial; re, prior recurrence rate; rw, resection weight; 
sh, tumour shape; si, tumour size; sm, smoking status; st, tumour stage; tai, tumour associated inflammation; td, time from diagnosis; tr, 
treatment; ts, tumour status; ur, urinary cytology.
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Table 3.2Table 2.    Follow up policies for the 14 included studies
Study references Follow up policy
8,17,19-20 3 monthly first two years, 6 monthly thereafter
10,16 3 monthly first year, 4 monthly second year, 6 monthly thereafter
12,14 3 monthly first year, 6 monthly second year, yearly thereafter
13,15 3 monthly for two to three years
18 4 monthly for first two years, 6 monthly thereafter
21 4 monthly for five years
Surveillance management regarding cystoscopic examination in the 14 reviewed studies
Table 3.3aTable 3a.   Pooled univariable relative risks for tumor recurrence 
Study Total Patients with 
Prognostic factor  references  patients  characteristic (%) RR 95 % CI
Stage
T1 v Ta 5,8,11-18 4693 2029 (43) 1.2 1.1-1.3
Grade
2 v 1 5,8,11-14,16-18 3507 2143 (61) 1.2 1.1-1.4
3 v 1 5,8,11-14,16-18 2155 791 (37) 1.4 1.2-1.6
2-3 v 1 5,8,10-14,16-18 4298 2937 (68) 1.3 1.2-1.4
3 v 1/2 5,11-18 4336 823 (19) 1.1 1.0-1.2
Multiplicity
multiple v solitary 5,8,10,12-15,17-18 3981 1487 (37) 1.4 1.3-1.6
Dysplasia presence
dysplasia v normal 5,8,11,14 497 135 (27) 1.3 1.0-1.8
CIS presence
CIS v without CIS 8,11,13-14,18 1332 95 (7) 1.2 0.9-1.6
Size (cm)
>3 v <3  8,10,12,16,18 1369 480 (35) 1.4 1.2-1.7
>2 v <2  15,17 389 225 (58) 1.2 0.9-1.7
Gender
female v male 8,14-17 2531 502 (20) 1.0 0.9-1.1
Posterior wall involvement
yes v no 8,12,15-16 1446 822 (57) 1.3 1.1-1.5
Trigone involvement
yes v no 8,15-16 1141 490 (43) 1.5 1.2-1.8
Age
>60 v <60  14,16 1577 1155 (73) 1.0 0.8-1.1
>65 v <65 15,17 416 205 (49) 0.9 0.6-1.2
Disease status
recurrent v primary 10,15-16 1253 557 (44) 1.5 1.3-1.8
Cystoscopy at 3 months
positive v negative 12,16 881 143 (16) 2.2 1.8-2.7
Abbreviations: RR, relative risk; 95 %CI, 95 % confidence intervalPooled univariable relative risks for tumour recurrence
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Table 3.3bTable 3b.   Pooled univariable relative risks for tumor progression 
Study Total Patients with 
Prognostic factor  references  patients characteristic (%) RR 95 % CI
Stage
T1 v Ta 5,14,16,18 3311 1624 (49) 2.2 1.7-2.7
Grade
2 v 1 5,14,16,18 2608 1724 (66) 2.2 1.5-3.1
3 v 1 5,14,16,18 1545 661 (43) 5.7 4.0-8.1
2-3 v 1 5,14,16,18 3269 2385 (73) 3.1 2.3-4.3
3 v 1/2 5,14,16,18 3269 661 (20) 3.6 2.9-4.4
Multiplicity
multiple v solitary 14,18 2488 787 (32) 2.0 1.6-2.5
CIS presence
CIS v without CIS 14,18 2393 355 (15) 4.4 3.4-5.5
Size (cm)
>3 v <3  16,18 1622 294 (18) 1.7 1.3-2.3
Age
>60 v <60  14,16 1577 1155 (73) 1.8 1.2-2.6
Gender
female v male 14,16 1577 281 (18) 1.1 0.7-1.6
Abbreviations: RR, relative risk; 95 %CI, 95 % confidence intervalPooled univariable relative risks for tumour progression
Table 3.3cTable 3c.   Pooled univariable relative risks for overall mortality 
Study Total Patients 
Prognostic factor  References  patients characteristic (%) RR 95 % CI
Stage
T1 v Ta 16,19-21 1547 775 (50) 1.0 0.8-1.2
Grade
2 v 1 16,19,20 1013 443 (44) 2.0 1.4-2.7
3 v 1 16,19,20 711 141 (20) 3.3 2.2-4.9
2-3 v 1 16,19,20 1154 584 (51) 2.2 1.7-3.0
3 v 1/2 16,19-21 1500 214 (14) 2.5 1.9-3.3
CIS presence
CIS v without CIS 19,21 707 37 (5) 4.0 2.4-6.5
Size (cm)
>3 v <3  16,21 928 179 (19) 1.7 1.2-2.3
Age
>60 v <60  16,20 845 610 (72) 3.5 2.2-5.5
Multiplicity
multiple v solitary 19,21 699 218 (31) 1.7 1.2-2.5
Shape
other v papillary 20-21 375 40 (11) 3.9 2.4-6.1
Abbreviations: RR, relative risk; 95 %CI, 95 % confidence intervalPooled univariable relative risks for overall mortality
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Tumour progression
Table 3.1 shows the prognostic factors considered by the four studies. Tumour grade and 
stage were considered in four studies5, 14, 16, 18 and were found significant in four5, 14, 16, 18 and 
one5, respectively. The size of the tumour5, 14, 16, 18 and the presence of carcinoma in situ (CIS)5, 
14, 16, 18 were studied in three studies and were found significant in all three.
Pooling showed that grade of disease (grade 3 compared to grade 1, RR 6.7; 95% CI 4.7-9.5) 
and the presence of CIS (RR 4.4; 95% CI 3.4-5.5, Table 3.3b) were the strongest prognostic 
factors for tumour progression. Grade 3 disease was present in 43% of the patients and CIS 
was present in 15% of the patients. Prognostic factors that had an intermediate effect were 
tumour stage (RR 2.2; 95% CI 1.7-2.7), multiplicity (RR, 2.0; 95% CI 1.6-2.5), age of first diag-
nosis (with 60 years cutoff, RR 1.8; 95% CI 1.2-2.6) and tumour size (with 3 cm cutoff, RR 1.7; 
95% CI 1.3-2.3). Note that the prognostic factors for tumour progression were each stronger 
compared to the prognostic factors for tumour recurrence.
Mortality
In all four studies16, 19-21 tumour grade and tumour stage were considered as prognostic  fac-
tors for overall mortality and found significant in three19-21 and one21 respectively. Tumour 
size was considered in two studies significant in both16, 21 (Table 3.1).
The strongest prognostic factors were the presence of CIS (pooled RR 4.0; 95% CI 2.4-6.5, 
Table 3.3c), a non-papillary shape of the tumour (RR 3.9; 95% CI 2.4-6.1), the age of the patient 
(with a cutoff of 60 years, RR 3.5; 95% CI 2.2-5.5) and grade 3 compared to grade 1 disease 
(RR 3.3; 95% CI 2.2-4.9). However only 5% of the studied patients had CIS and only 11% had a 
non-papillary tumour. Prognostic factors with an intermediate effect were tumour size (with 
3 cm cutoff, RR 1.7; 95% CI 1.2-2.3) and multiplicity (RR 1.7; 95% CI 1.2-2.5). Tumour stage (RR 
1.0; 95% CI 0.8-1.2) did not have a prognostic value for overall mortality.
Discussion
In this study we evaluated conventional clinical and pathological prognostic factors in blad-
der cancer for the endpoints recurrence, progression and overall mortality. We systemati-
cally combined evidence on classical clinical and pathological characteristics in NMI bladder 
cancer. The strongest factor to predict tumour recurrence was the result of the first 3-monthly 
cystoscopy after transurethral resection. For both progression and overall mortality we found 
that the differentiation grade of the tumour and the presence of CIS had the strongest ef-
fects.
Prediction of recurrence or the time to first recurrence is essential to determine the optimal 
interval for clinical follow up in the surveillance of urothelial cell carcinoma (UC). The result of 
the first 3-monthly cystoscopy had the strongest prognostic effect on recurrence (RR 2.2), yet 
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it has been considered in only a few studies12, 16. In contrast, multiplicity has been studied by 
many5, 10, 12, 28, 29, nonetheless its pooled effect was rather modest (RR 1.4). Other prognostic 
factors, such as disease status and location of tumour, had stronger prognostic effects than 
multiplicity. Considering all prognostic factors for tumour recurrence, we only found weak 
to intermediate effects. We conclude that it is not possible to reliably predict time to recur-
rence with the current characteristics, let alone discriminate different patient groups at risk 
for recurrence. 
Prediction of tumour progression may influence the policy on follow-up and treatment. 
High-grade tumours5, 11, 28 and the presence of CIS14, 18 were confirmed to be very strong 
prognostic factors. Moreover, except for patient gender, all the pooled prognostic factors 
showed intermediate to strong effects. So we confirm that we can predict which patients 
are at higher risk for tumour progression with clinical and pathological characteristics. This 
implies that the prognostic factors for progression can divide the UC population into differ-
ent risk-groups, independent from the recurrence rate per year. As risk for progression is the 
major drive for intense surveillance it may even be conceivable that patients at low risk for 
progression would require less frequent follow-up irrespective of the predicted recurrence 
rate. 
We also found relatively strong prognostic factors for overall mortality in NMI bladder can-
cer patients. The strongest prognostic factor was the presence of CIS. The strong prognostic 
effect of patient age16, 20 and grade of tumour for overall mortality19, 21, 30 were both confirmed 
in our meta-analysis. The shape of the tumour was also an important prognostic factor. How-
ever, the total numbers of patients studied for tumour shape were relatively small. Although 
stage is considered to be an important characteristic in survival studies for patients with NMI 
UC bladder cancer5, 28, 30-32, we could not confirm this for the overall mortality risk (pT1 vs pTa: 
RR 1.0). Surprisingly, the mortality risk is precisely equal for patients with pTa or pT1 tumours. 
This may be explained in part by the heterogeneity of pT1 UC as is apparent from molecular 
and histopathological data. Recognition of this heterogeneity led pathologists to attempt 
substaging of pT1 UC in those with a NMI UC and with more invasive pattern33.
Our meta-analysis has several strong points. First of all, a relatively large numbers of 
patients were assessed. This increased the power of the study as reflected in confidence 
intervals that are much smaller than in each of the studies. Second, the analysis included 
data of studies that showed no clear prognostic effect, thereby increasing the objectiveness 
of our findings. This is in contrast to classical reviewing, where the selection of studies may be 
biased. Furthermore three different endpoints were assessed for the most important clinical 
and pathological prognostic factors. Thus, the overall prognostic value of the various factors 
could be assessed more clearly.
However, like most meta-analyses, our study also has several limitations. Because of strict 
inclusion criteria we were only able to include eleven studies for tumour recurrence, four 
studies for tumour progression, and four studies for overall mortality. This reflects that the 
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latter two endpoints have not been studied as extensively in the literature. Another prob-
lem was that several definitions were used for the prognostic factors. Therefore, not all the 
available data could be analyzed. Other limitations were the differences in study designs, 
study population follow up policies, and the mixture of primary and/or recurrent tumours in 
patients. Finally, the treatment among the studied patients varied, which may have affected 
the effect of a prognostic factor, as in any prognostic study.
Kiemeney et al found that predictability in individual patients is highly inaccurate, but that 
the available prognostic factors in NMI bladder cancer may be useful to identify high and 
low risk subgroups34. Therefore, they concluded that more relevant prognostic factors are 
needed to decrease current over-treatment and under-treatment rates. Similarly, Witjes et23 
al concluded in a qualitative review that no single prognostic factor is able to predict prog-
nosis in an individual patient with NMI UC bladder cancer. Thus a combination of multiple 
prognostic factors is needed to optimize current follow up policies. 
This combination could consist of some of the clinical and pathological prognostic fac-
tors that are studied in the present meta-analysis together with prognostic factors based on 
molecular characteristics. Considerable information is already available regarding molecular 
pathogenesis and genetic prognostic factors of bladder cancer and is still evolving. Many 
oncogenes, gene products and tumour suppressor genes are identified (i.e. FGFR3, p53, p16, 
Rb). Especially the p53 and Rb genes are associated with progressive disease. Recently it has 
been demonstrated that FGFR3 mutations are especially prevalent in the NMI UC pTa group. 
In a retrospective study we showed that these mutations are associated with a low risk for 
progression. We also showed that molecular grading of bladder tumours using a combina-
tion of FGFR3 mutation status and high or low staining of the proliferation marker MIB-1 
was superior in predicting progression than a combination of clinicopathological variables35. 
Moreover, it has been demonstrated that two mutually exclusive molecular pathways of 
bladder carcinogenesis can be identified, which correspond to UC with either a favourable 
or an aggressive clinical behavior36. Recent research shows that FGFR3 mutations are associ-
ated with the favourable pathway, whilst p53 mutations are found in the tumours with an 
unfavourable prognosis37, 38. Further research, preferably in a prospective setting, into the 
prognostic value of these markers and combinations of markers and factors is important to 
bring the ideal of individualized follow-up closer.
In conclusion, clinical and pathological prognostic factors had at most intermediate effects 
for tumour recurrence. There were a few strong prognostic factors for tumour progression 
and overall mortality. To enable individualization of surveillance strategies, current (clinical 
and pathological) prognostic factors need to be combined with markers found by research-
ers in the molecular field.  
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Table 3.4
Appendix: Estimation of relative risks (RR) and standard errors (SE) for tumor recurrence (rec), progression (pro) and overall mortality (mor). Not 
available (na).
Tumor stage (T1 v Ta)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Heney (5) 1.4 0.18 7.2 0.47 na na
Smith (11) 1.0 0.35 na na na na
Parmar (12) 1.3 0.23 na na na na
Shinka (13) 1.4 0.26 na na na na
Kiemeney (14) 1.4 0.09 2.4 0.20 na na
Mulders (15) 1.3 0.17 na na na na
Kurth (16) 1.0 0.11 2.0 0.24 1.1 0.18
Allard (8) 2.0 0.17 na na na na
Kondo (17) 2.3 0.65 na na na na
Millan-Rodriguez (18) 1.0 0.06 1.8 0.16 na na
Flamm (19) na na na na 1.5 0.32
Lipponen (20) na na na na 2.0 0.41
Zieger (21) na na na na 0.8 0.12
Tumor shape (other v papilary)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Lipponen (20) na na na na 6.0 0.31
Zieger (21) na na na na 2.2 0.35
Multiplicity (multiple v solitary)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Dalesio (10) 2.1 0.14 na na na na
Heney (5) 1.3 0.18 na na na na
Parmar (12) 1.9 0.21 na na na na
Shinka (13) 1.8 0.28 na na na na
Kiemeney (14) 1.3 0.09 2.4 0.20 na na
Mulders (15) 1.7 0.17 na na na na
Allard (8) 2.1 0.14 na na na na
Kondo (17) 2.7 0.61 na na na na
Millan-Rodriguez (18) 1.3 0.06 1.9 0.14 na na
Flamm (19) na na na na 2.2 0.32
Zieger (21) na na na na 1.5 0.24
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Tumor grade (2 v 1)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Heney (5) 1.2 0.19 5.2 0.78 na na
Smith (11) 1.2 0.37 na na na na
Parmar (12) 1.1 0.21 na na na na
Shinka (13) 1.3 0.29 na na na na
Kiemeney (14) 1.2 0.10 2.2 0.30 na na
Kurth (16) 1.3 0.13 2.9 0.31 1.6 0.21
Allard (8) 1.8 0.17 1.3 0.32 na na
Kondo (17) 1.4 1.08 na na na na
Millan-Rodriguez (18) 1.2 0.10 na na na na
Flamm (19) na na na na 3.1 0.41
Lipponen (20) na na na na 2.5 0.33
Tumor grade (3 v 1/2)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Heney (5) 1.6 0.22 7.0 0.40 na na
Smith (11) 1.1 0.40 na na na na
Parmar (12) 1.9 0.26 na na na na
Shinka (13) 1.4 0.31 na na na na
Kiemeney (14) 1.1 0.11 3.8 0.20 na na
Mulders (15) 1.1 0.20 na na na na
Kurth (16) 1.1 0.18 2.6 0.28 1.2 0.29
Kondo (17) 2.6 0.63 na na na na
Millan-Rodriguez (18) 1.0 0.07 3.4 0.15 na na
Flamm (19) na na na na 2.6 0.33
Lipponen (20) na na na na 4.2 0.29
Zieger (21) na na na na 2.8 0.20
Tumor grade (2/3 v 1)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Dalesio (10) 1.4 0.16 9.6 0.74 na na
Heney (5) 1.3 0.18 na na na na
Smith (11) 1.2 0.33 na na na na
Parmar (12) 1.3 0.18 na na na na
Shinka (13) 1.4 0.26 na na na na
Kiemeney (14) 1.2 0.09 3.4 0.28 na na
Kurth (16) 1.3 0.12 3.3 0.30 1.6 0.20
Allard (8) 1.9 0.16 na na na na
Kondo (17) 1.8 1.05 na na na na
Millan-Rodriguez (18) 1.2 0.10 2.2 0.31 na na
Flamm (19) na na na na 3.6 0.38
Lipponen (20) na na na na 3.4 0.30
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Tumor grade (3 v 1)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Heney (5) 1.7 0.23 20.8 0.76 na na
Smith (11) 1.2 0.43 na na na na
Parmar (12) 1.9 0.27 na na na na
Shinka (13) 1.5 0.34 na na na na
Kiemeney (14) 1.2 0.13 6.4 0.30 na na
Kurth (16) 1.3 0.20 5.1 0.36 1.6 0.31
Allard (8) 2.6 0.23 na na na na
Kondo (17) 3.5 1.12 na na na na
Millan-Rodriguez (18) 1.2 0.11 4.4 0.32 na na
Flamm (19) na na na na 4.7 0.43
Lipponen (20) na na na na 6.5 0.35
Gender (female v male)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Kiemeney (14) 0.9 0.12 1.3 0.24 na na
Mulders (15) 1.3 0.20 na na na na
Kurth (16) 1.0 0.15 0.7 0.36 na na
Allard (8) 1.0 0.16 na na na na
Kondo (17) 0.9 0.78 na na na na
Age (>60 v <60)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Kiemeney (14) 1.0 0.10 2.0 0.27 na na
Kurth (16) 0.9 0.13 1.6 0.30 3.5 0.30
Lipponen (20) na na na na 3.5 0.35
Age (>65 v <65)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Mulders (15) 0.8 0.17 na na na na
Kondo (17) 1.6 0.61 na na na na
Cystoscopy at 3 months (positive v negative)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Parmar (12) 2.1 0.20 na na na na
Kurth (16) 2.3 0.12 na na na na
Disease status (recurrent v primary)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Dalesio (10) 1.9 0.14 na na na na
Mulders (15) 1.2 0.19 na na na na
Kurth (16) 1.4 0.12 na na na na
Prognostic factors: a meta-analysis 83
Posterior wall involvement (yes v no)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Parmar (12) 1.4 0.20 na na na na
Mulders (15) 2.0 0.20 na na na na
Kurth (16) 1.3 0.11 na na na na
Allard (8) 1.0 0.15 na na na na
Trigone involvement (yes v no)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Mulders (15) 2.0 0.20 na na na na
Kurth (16) 1.3 0.15 na na na na
Allard (8) 1.2 0.29 na na na na
CIS presence (yes v no)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Smith (11) 2.9 0.75 na na na na
Shinka (13) 1.2 0.43 na na na na
Kiemeney (14) 1.1 0.16 4.4 0.25 na na
Allard (8) 1.6 0.59 na na na na
Millan-Rodriguez (18) 1.0 0.08 4.3 0.14 na na
Flamm (19) na na na na 8.6 0.32
Zieger (21) na na na na 1.1 0.41
Dysplasia presence (yes v no)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Heney (5) 1.3 0.21 na na na na
Smith (11) 2.2 0.34 na na na na
Allard (8) 0.8 0.37 na na na na
Kiemeney (14) 1.1 0.12 na na na na
Tumor size (>3 cm v <3 cm)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Dalesio (10) 1.2 0.15 na na na na
Parmar (12) 1.8 0.19 na na na na
Kurth (16) 1.0 0.15 1.9 0.26 1.4 0.22
Allard (8) 1.9 0.14 na na na na
Millan-Rodriguez (18) 1.1 0.09 1.6 0.18 na na
Zieger (21) na na na na 2.0 0.23
Tumor size (>2 cm v <2 cm)
First author (ref) RR rec SE rec RR pro SE pro RR mor SE mor
Mulders (15) 1.2 0.18 na na na na
Kondo (17) 2.7 0.61 na na na na
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Abstract
The clinical management of non-muscle invasive urothelial cell carcinoma of the bladder 
(UC) is challenging, as it has a marked tendency to recur and to progress. Aim of the study 
was to investigate the prognostic value of the WHO 1973 and 2004 grading systems and 
biomarkers FGFR3, CK20 and Ki-67. In a prospective study, tumours from 221 patients were 
studied for the expression of CK20 and Ki-67 by immunohistochemistry and FGFR3 status by 
SNaPshot mutation detection. Staging and grading were performed according to the WHO 
classification systems of 1973 and 2004. Median follow-up was 35 months. Recurrence oc-
curred in 72/221 patients. None of the parameters was able to predict disease recurrence. 
CK20, Ki-67, FGFR3 mutation, molecular grade using FGFR3 mutation analysis and Ki-67 and 
histological grading and staging were significantly associated with disease progression in 
stage. In multivariable analyses, both WHO 1973 and 2004 grading systems remained statisti-
cally significant and independent predictors of progression, with p=0.005 for WHO 1973 and 
p=.004 for 2004. FGFR3 status was able to discriminate progressors from non-progressors in 
a subset of patients with high-grade UC (p=0.009).
This is the first prospective study comparing the WHO 1973 and 2004 grading systems. We 
show that both grading systems contribute valuable independent information. Therefore, it 
should be considered whether a yet better grading system could be developed that incorpo-
rates essential elements from both. The combination of WHO 2004 grading with FGFR3 status 
allows a better risk stratification for patients with high-grade non-muscle invasive UC.
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Introduction
Urothelial cell carcinoma of the bladder (UC) is a frequent neoplasm with an incidence of 
30 cases per 100,000 in the western world.1 At first presentation UC is mostly non-invasive 
or superficially invasive (i.e. pTa and pT1) and can be surgically controlled by transurethral 
resection. Up to 70% of patients have recurring disease requiring repeated surgery and about 
10-15% of all cases will progress to muscle invasive UC.2 To detect recurrent tumours, patients 
are followed by frequent cystoscopies. Bladder cancer is the second and tenth most prevalent 
cancer in males and females, respectively.3 Indeed, it has been estimated that 1:1450 persons 
in the population are under surveillance for bladder cancer.4 Consequently, the costs per 
patient of bladder cancer are the highest of all cancers.3 Thus reliable prognostic parameters 
that can distinguish between high and low risk patients might enable clinicians to introduce 
individual risk adapted follow-up regimes. 
To what extent a tumour is at risk for progression is mainly predicted by histological grade 
and stage, with higher risk attributed to higher grades. However histopathological classifica-
tion is known to be limited by interobserver variability and may have varying prognostic 
implications.5-7 In 1998, a revised grading system for UC was proposed and adopted by the 
World Health Organization (WHO) in 2004 to replace the WHO 1973 grading system8, (Pathol-
ogy and genetics of tumours of the urinary system an male genital organs, eds. JN Eble, G 
Sauter, JI Epstein and IA Sesterhenn: http://www.iarc.fr/WHO-BlueBooks/). Since then, the 
new system was discussed in a number of publications, however, its value is still a matter of 
debate.9-13 Many pathologists still use the 1973 WHO classification and clinical decisions are 
based on the presence of grade 3 disease.
Interobserver variability in pathology has induced research into various molecular markers 
to improve the assessment of UC prognosis. Among the molecular markers are cytokeratin 
20 (CK20) expression as marker of urothelial dedifferentiation, mutations in the gene for the 
fibroblast growth factor receptor 3 (FGFR3) and the proliferation marker Ki-67. Under normal 
conditions, CK20 is expressed in the superficial umbrella cells. CK20 expression in the entire 
urothelium or complete loss has been related to adverse outcome and disease recurrence in 
UC.14,15 Activating mutations in the FGFR3 gene were reported in up to 75% of low-grade and 
stage cases but are infrequent in muscle invasive UC.7, 16-18 Several reports demonstrated that 
FGFR3 mutations are associated with a favourable clinical course.7,19,20 The proliferation index 
as determined by Ki-67 labelling has been linked to progression in non-muscle invasive UC.21 
The combination of FGFR3 status and Ki-67 expression to a molecular grade was found to 
be a strong predictive factor in non-invasive and superficially invasive UC in a retrospective 
study. 7
Aim of the present study was to evaluate the prognostic value of both WHO 1973 and 2004 
grading systems and the molecular markers CK20, FGFR3 and Ki-67 and molecular grade in 
a two-centred prospective setting. The results show that the 2004 grading system performs 
Ch
ap
te
r 4
90
slightly better than the WHO 1973 system in indicating progression in a univariate analysis, 
however a multivariable analysis shows that both grading systems contribute independent 
information. We also show that FGFR3 status is able to differentiate between progressing and 
not progressing tumours in the group of high-grade carcinomas. 
Material and Methods
Tumour samples
The study was approved by the appropriate Institutional Review Boards. Informed consent 
was obtained from all patients. 221 consecutive non-muscle invasive UC (pTa and pT1) ob-
tained by transurethral resection at the Departments Urology of the University of Regensburg 
(n=111) and the Erasmus MC, Rotterdam (n=110) were investigated in a prospective study. The 
only selection criterion was the presence of sufficient tumour tissue after completion of the 
routine pathological diagnosis. Characteristics of the patients are given in table 4.1. Patients 
were followed according to appropriate guidelines22 with a mean follow-up of 35 months 
(1–102 months). All slides were blindly reviewed by two uropathologists (A. H. and T. v. d. 
K.). Tumour stage and grade were assigned according to the WHO classification of malignant 
tumours of the urinary tract 2004 (Pathology and genetics of tumours of the urinary system 
an male genital organs, Eds. JN Eble, G Sauter, JI Epstein and IA Sesterhenn: http://www.iarc.
fr/WHO-BlueBooks/). The initial grading data according to the 1973 WHO classification was 
reviewed by the same uropathologists. 
Microdissection and DNA isolation
Genomic DNA was isolated from 5 µm paraffin sections of all tumours. Manual microdissec-
tion was performed to obtain at least 80% tumour cells. DNA was isolated using the QIAmp 
DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s specifications. Elu-
tion with 2x100 µl of 70°C preheated water was performed to increase yield. Each elution step 
included a 5 min incubation of the QIAamp spin column with the preheated water at 70°C 
before centrifugation. 
FGFR3 mutation analysis
FGFR3 mutation analysis was performed using the SNaPshot method.23 Three regions of 
the FGFR3 gene, comprising all FGFR3 mutations found in bladder cancer, were amplified si-
multaneously. After removal of excess primers and dNTPs, eight SNaPshot primers detecting 
nine FGFR3 mutations (R248C, S249C, G372C, Y375C, A393E, K652E, K652Q, K652M, K652T) 
were annealed to the PCR products and extended with a labelled dideoxynucleotide. The 
extended primers were analyzed on an automatic sequencer. 
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Immunohistochemistry (IHC)
Immunohistochemical studies utilized an avidin-biotin peroxidase method with diamin-
obenzdine (DAB) chromatogen. After antigen retrieval (microwave oven for 30 min at 250W) 
IHC was carried out in a NEXES immunostainer (Ventana, Tucson, AZ, USA) following manu-
facturer’s instructions. The following primary antibodies were used: anti CK20 (monoclonal, 
clone IT KS 20.8, Progen Biotech GmbH, Heidelberg, Germany; 1:100) and anti Ki-67 (rabbit 
monoclonal, clone MIB-1; Dianova, Hamburg, Germany; 1:800). Samples from Rotterdam 
were stained with anti Ki-67 (clone MIB-1, Conepta Biosystems, Barcelona, Spain; prediluted). 
Standard procedures were used for visualization (ABC-Elite, Vector-Laboratories, Burlingame, 
CA), and diaminobenzidine was used as chromogen. As negative controls all specimens were 
incubated without primary antibody. Immunoreactivity was scored according to validated 
criteria.14,15,21 CK20 staining pattern was scored as normal if cytoplasmatic expression was 
seen in superficial umbrella cells only and as abnormal if a negative or >10% diffuse staining 
in the entire urothelium were noted. High Ki-67 labelling index was defined if ≥25% of the 
tumour cells showed nuclear immunoreactivity as previously described.7 
Molecular Grade 
Molecular grade (mG) was defined as a combination between FGFR3 mutational status and 
Ki-67.7,24 Molecular grade 1, mG1, is defined as FGFR3 mutation and a low expression of Ki-67, 
mG2 as mutant FGFR3 with high expression of Ki-67, or wild type FGFR3 with a low expression 
of Ki-67 and mG3 as FGFR3 wild-type in combination with high Ki-67 immunoreactivity.
Statistical analysis 
Statistical analyses were completed using SPSS version 12.0 (SPSS, Chicago, IL). Two-sided 
Fisher’s exact tests and Mann-Whitney-U-tests were used to study statistical associations 
between the various parameters. Progression was defined as progression in stage (i.e. pTa 
ە pT1 or higher and pT1ە pT2 or higher). Recurrence-free-survival (RFS), progression free 
survival (PFS) and overall survival (OS) curves comparing patients with the respective param-
eters were calculated using the Kaplan-Meier method, with significance evaluated by log 
rank test. Cox regression analysis was applied with a backward stepwise procedure, using 
p<0.10 for selection. All predictors for progression with p<0.05 for considered inclusion in 
the multivariable model. For the evaluation of RFS, patients were censored at the time of their 
last tumour-free clinical follow-up appointment or cystectomy. For OS analysis, patients were 
censored at the time of their last clinical follow-up appointment or at their date of death not 
related to the tumour. P values <0.05 were considered significant. 
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Table 4.1
Variable Category Patients
n %
Age at diagnosis ≤ 68 120 50
≥ 68 121 50
Gender M 171 77
F 50 23
Tumour stage pTa 179 81
pT1 42 19
WHO 1973 grade G1 86 39
G2 110 50
G3 25 11
WHO 2004 grade PUNLMP 49 22
LG 119 55
HG 50 23
Primary vs. recurrent Primary 152 69
Recurrent 69 31
FGFR3 wild type 80 36
mutant 141 64
Ki-67 IHC ≤ 25% 146 72
≥ 25% 57 28
CK20 IHC normal 69 34
abnormal 134 66
Molecular grade mG1 106 52
mG2 66 33
mG3 31 15
Clinical, histopathological and molecular characteristics of the 221 patients
Results
Clinical data
Characteristics of the patients are summarized in table 4.1. Mean age at the time of diagnosis 
was 66.2 years (range 20 to 94). Gender distribution showed the expected male predomi-
nance with 171/221 male patients (77%). Only non-muscle invasive UC (pTa and pT1) were 
included in this study. In 152 (69%) cases UC were primary and in 69 (31%) recurring disease. 
Table 4.1 also shows the distribution of stage, grade and molecular markers for the selected 
tumours. Mean time of follow-up was 35 months (range 1-102 months). Out of 221 patients, 
11 patients were lost to follow-up and 7 patients died of an unrelated disease. Recurrent 
disease was found in 72/221 (33%) patients; multiple recurrences were seen in 30/72 (41%) 
patients; two recurrences occurred in 18 (42%), three in 8 (17%) and four in 4 (7%) patients. 
Progression to higher stage was noted in 19/221 (9%) patients (11 patients with progression 
to ≥pT2 and 8 to pT1); 4 patients underwent cystectomy.  
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Relation of CK20, Ki-67 and FGFR3 and classical parameters
IHC for CK20 revealed abnormal staining pattern in 134/203 tumours (66%) cases. Ki-67 stain-
ing could be evaluated for 203 specimens and the proliferation index was high in 57 cases 
(28%). FGFR3 mutation was observed in 141/221 (64%) of tumours (Table 4.1). The mutation 
most frequently detected was S249C (83/141; 59%), followed by Y375C (29; 21%) and R248C 
(19; 13%). Molecular Grade was defined in 203 specimens; 106 (52%) were categorized mG1, 
65 (32%) mG2 and 31 (15%) as mG3, respectively (Table 4.1). Table 4.2 shows the distribu-
tion of molecular variables according to the WHO 1973 and 2004 grading systems. We found 
FGFR3 mutational status to be related to normal CK20 expression and low Ki-67 labelling 
index as detected by IHC (Table 4.3). 
Clinical outcome in relation to histopathological and molecular parameters 
A Kaplan-Meier analysis for recurrence-free survival was performed on the 152 patients who 
presented with a primary tumour. However, statistical evaluation by the log rank test showed 
Table 4.2
FGFR3 Ki-67 CK20 Molecular Grade
mut wt low high nl abnl mG1 mG2 mG3
G1 65 21 68 6 42 36 55 17 2
G2 67 43 68 35 26 75 46 40 17
G3 9 16 9 16 1 23 5 8 12
p value 0.001 < 0.001 <0.001 < 0.001
PUN-LMP 35 14 33 4 22 19 26 10 1
Low Grade 87 32 92 23 40 75 71 34 10
High Grade 16 34 18 29 5 39 7 20 20
p value < 0.001 < 0.001 < 0.001 < 0.001
WHO 1973 (G1, 2 and 3) and 2004 (PUNLMP, Low grade, High grade) grade related to molecular characteristics; P values by χ2 test, all numbers 
are absolute. Significant p values are in bold
Table 4.3 
Markers
FGFR3 mutation status
Wild Type Mutant p value
CK20
Normal pattern 15 54
0.009Abnormal pattern 54 81
Ki-67
Low 40 106
<0.001High 31 26
Molecular Markers related to FGFR3 mutation status; P values by χ2 test, all numbers are absolute
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that none of the variables measured was significantly related to the time to first recurrence 
although there was a trend towards a correlation between abnormal CK20 staining and 
recurrence (p=0.1).  
Kaplan-Meier curves for progression-free survival are shown in fig. 1 and the data are sum-
marized in table 4.4. WHO 1973 grade, WHO 2004 grade, pathological stage (pTa or pT1), CK20, 
FGFR3, Ki-67 status and molecular grade (mG) were significantly associated with progression 
in stage as determined by log rank tests (Table 4.4). The WHO 2004 grading system and 
Table 4.4 
Progression Log Rank
Prognostics n Progression
5 year 
progression free
p value a
CK20
0.05
Normal pattern 63 2 92%
Abnormal pattern 130 16 82%
Ki-67
0.007
Low 137 9 91%
High 54 9 72%
FGFR3
0.002
Mutation 134 7 91%
Wild type 76 12 74%
Molecular grade
0.0001
mG1 99 5 92%
mG2 64 6 85%
mG3 28 7 55%
WHO Grade 1973
0.003
G1 83 1 99%
G2 107 12 79%
G3 20 6 65%
WHO Grade 2004
0.0000
PUN-LMP 48 2 95%
Low grade 114 5 91%
High grade 45 12 62%
Stage
0.004
pTa 173 11 88%
pT1 37 8 69%
Effect of Potential Prognostic Molecular Variables on Stage Progression in 221 Patients with UCC of the Bladder (ap value by log-rank test)
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Molecular grade performed somewhat better in predicting progression than the WHO 1973 
grading in univariate analysis (fig 1). In a subgroup analysis we observed that FGFR3 status was 
highly significant in predicting progression in the WHO high-grade tumours (p=0.009; fig.1, 
bottom right). Next we performed a multivariable analysis in which Cox regression analysis 
was applied with a backward stepwise procedure. All predictors for progression with p<0.05 
were included in the multivariable model. After this stepwise procedure the variables WHO 
1973 grade, WHO 2004 grade and FGFR3 status remained. Both WHO 1973 and 2004 grading 
systems remained statistically significant and independent predictors of progression, with 
p=0.005 for WHO 1973 and p=0.004 for WHO 2004. Correlations between these classifications 
made the hazard ratios not interpretable. Presence of a FGFR3 mutation was associated with 
a lower risk of progression (hazard ratio=0.4, 95% confidence interval 0.1 - 1.2, p=0.095). 
Discussion
The management of non-muscle invasive or “superficial” UC of the bladder is challenging 
for urologists and patients. Although the prognosis is generally good, up to 70% of patients 
show disease recurrence and up to 15% progression in grade or stage.2 We describe here a 
prospective series of 221 non-invasive or superficially invasive UC from two urological cen-
ters (stage pTa or pT1). Recurrence was found in 72/221 (33%) and progression in 19/221 (9%) 
patients despite appropriate adjuvant therapy. The study population was followed for an av-
erage of 35 months. As in previous publications, mutant FGFR3, normal CK20 staining pattern 
and a low proliferation index (Ki-67 staining <25%) were predominant in well-differentiated 
tumours (G1/2 according to the 1973 WHO and PUNLMP/low-grade according to the 2004 
WHO classifications). In addition, the presence of an FGFR3 mutation was highly correlated 
to a normal CK20 expression pattern and lower proliferation rate as determined by Ki-67 
(p=0.009 and p<0.001 respectively). 
To date classical histopathological evaluation is the only method routinely used to determine 
the prognosis of the patients and to stratify therapy. Histopathology, however, is inherently 
subjective and displays inter- and intraobserver variability.6,7 To improve reproducibility of 
diagnosis, a novel grading system featuring a specific category called papillary neoplasm 
of low malignant potential (PUN-LMP) and two grade categories was proposed in 1998 and 
adopted by the WHO in 2004,8 (Pathology and genetics of tumours of the urinary system an 
male genital organs, eds. JN Eble, G Sauter, JI Epstein and IA Sesterhenn: http://www.iarc.
fr/WHO-BlueBooks/). There is an ongoing debate about the added value of the WHO 2004 
system versus that of 1973.9,10,13,25-27 To our knowledge this is the first report that compares 
both grading systems on a prospectively sampled series of non-muscle invasive UC. We show 
that in the univariate analysis WHO 2004 grade and Molecular Grade can predict progression 
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more acccurately than WHO 1973 grade. However, in the multivariable analysis WHO grade 
1973 and WHO grade 2004 apparently contribute independent valuable information that is 
relevant for prediction of progression in stage. In the WHO 1973 grading 12 of the progressing 
tumours were categorized as being grade 2 and 6 as being grade 3, whereas in the WHO 2004 
system the high-grade tumours encompassed 12 of the 19 progressors (table 4.4). However, 
the WHO 2004 high-grade group is much larger (n=45) than the WHO 1973 grade 3 group 
(n=20). Samaratunga also compared both grading systems in relation to progression in a 
retrospective study. The WHO 2004 high-grade tumours in their study encompassed 50% 
of the progressing tumours (10 of 29), whereas the WHO 1973 G3 group comprised only 6 
tumours of which 4 progressed.28 It is our experience that additional information relevant 
for treatment decisions is provided to the clinicians by adding the distinction WHO grade 
2 or 3 to the WHO 2004 high-grade tumours. Another matter of debate is the usefulness of 
the distinction between the PUNLMP and low-grade categories in the WHO 2004 grade.10 In 
the Kaplan-Meier analysis of this prospective series of non-muscle invasive tumours we see 
no difference between the two groups with respect to prognosis prediction (figure 4.1, top 
right). In addition, the percentage of recurrences in both groups is equal (27%). Our data 
therefore support the view that the distinction between these two grades is not useful. In 
conclusion, according to the data of this prospective study we postulate the need for ad-
ditional differentiation in the WHO 2004 high-grade category and we are not convinced that 
the distinction between PUNLMP and low-grade has additional value from a clinical point of 
view.
In order to enhance prognosis prediction, much effort is being spent on finding biomarkers 
that can be assayed in a reproducible manner and that have excellent predictive power. We 
have previously shown that FGFR3 mutation analysis is 100% reproducible and an easy-to-
perform multiplex assay for the 11 most frequent mutations has been developed (Van Oers, 
unpublished results). 7,23Interestingly, in the WHO 2004 high-grade group, almost all FGFR3 
wild type tumours (10 out of 11) progressed in the present study (figure 4.2). These results 
suggest that evaluation of FGFR3 mutation status enables the required distinction within the 
WHO high-grade group that we mentioned above. These results warrant a larger study into 
the added value of FGFR3 mutations in UC of high-grade and raise the possibility that FGFR3 
mutation analysis could define a high-grade non-muscle invasive tumour subgroup with 
very high progression risk. These patients could potentially benefit from an early aggressive 
therapy. 
Ki-67 has been reported as a prognostic marker for disease and progression-free survival in 
pTa and pT1 UC.21, 29 In the 203 pTa and pT1 tumours across all grades investigated in this 
study, we were able to confirm its relation to disease progression (p<0.03). The combination 
of Ki-67 with FGFR3 mutational status, which has been defined as molecular grade before,7 
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Figure 4.1 
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 Figure 4.1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysing the proportion of patients that developed 
progressive disease using Kaplan-Meier survival curves. 
Progressive disease is defined as progression to a higher 
stage. X-axis depicts months of follow-up Y-axis indicates 
cumulative progression-free survival.  P values (log rank test) 
are indicated in each figure. Number of patients at risk is 
indicated below curves. The Kaplan-Meier plot at the bottom 
right represents a subgroup analysis of progression in WHO 
2004 high-grade tumours with respect to FGFR3 status.
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was associated with disease progression in our series and this combination can predict 
progression more accurately than either marker alone (p<0.0001) and was as efficient as the 
WHO 2004 grading system (figure 4.1) in the log rank test. When compared in the multivari-
able backwards COX regression analysis, molecular grade did not add significant information 
to both WHO grading systems and FGFR3 status in this series of patients. However, it should 
be mentioned that the WHO 1973 and 2004 grades used in this work were based on a histo-
pathology review by two expert urogenital pathologists. It is not unlikely that FGFR3 status or 
molecular grading could significantly add to prognosis prediction in other settings because 
of their robustness and high reproducibility. 
CK20 has been perceived as a prognostic factor for disease recurrence in non-invasive UC, 14, 15 
but this has not been confirmed by others.20,30 In the present study with 152 primary pTa and 
pT1 bladder tumours, we also could not confirm the prognostic power of abnormal staining 
for CK20 in relation to 5-year recurrence-free survival (p=0.1). None of the other parameters 
showed an association with recurrence in this series of tumours. Several reports have sup-
ported or did not support a relation between the occurrence of recurrence and FGFR3, Ki-67 
and molecular grade.20, 29, 31, 32 Recently, a on-line available decision model was proposed by 
Sylvester et al. based on a retrospective analysis of 2596 EORTC UC cases to predict the risk of 
recurrent disease in non-invasive UC . 33 Parameters in this model that in combination present 
different risk levels are multifocality, size, stage, presence of CIS, grade (WHO1973) and previ-
ous recurrences in case of non-primary tumours. Considering the contradictory outcomes of 
Figure 4.2
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Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Subgroup analyses using Kaplan-Meier survival curves for proportion of patients with progression to invasive disease within the WHO 2004 
high-grade tumors (left) and tumors that were initially pT1 (right) in relation to FGFR3 status.
X-axis depicts months of follow-up; Y-axis indicates cumulative progression-free survival. p values (log-rank test) are indicated in each figure. 
Number of patients at risk is indicated below curves.
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the studies mentioned it is possible that the significance of molecular markers for recurrence 
risk can only be established from large studies as presented by Sylvester et al. These studies 
should include molecular markers like FGFR3 status, CK20 expression pattern, Ki-67 labelling 
or gene expression profiles.
In conclusion, in this prospective study we showed that both the WHO 1973 and 2004 grad-
ing systems comprise independent valuable information for prediction of progression in 
stage in non-muscle invasive UC. There is a need for a further differentiation in the WHO 
2004 high-grade group, either by making this distinction by adding WHO 1973 grade 2 and 
3 or by adding FGFR3 status, which, as we showed, enabled the identification of almost all 
progressors in the WHO 2004 high-grade non-muscle invasive UC. 
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Abstract
Superficially invasive (pT1) papillary urothelial cell carcinomas (UC) may run a variable course. 
Several attempts have been made for substaging of UC in order to identify the clinically ag-
gressive tumours. We present a new substaging system, based on the extent of invasion. 
From a series of 53 primary pT1 UC, 24 cases showed invasion of the subepithelial stroma 
by an invasive front extending over a maximum length of 0.5 mm (pT1mic) and 29 showed 
extensively (>0.5mm) infiltrating UC (pT1ext). We tested diagnostic reproducibility between 
two pathologists and found 81% agreement.  Furthermore, all cases were analysed for muta-
tions in the fibroblast growth factor receptor 3 (FGFR3) gene, which represents the favourable 
pathway of urothelial cell carcinogenesis. Mutant FGFR3 was commonly observed in pT1mic 
UC (15/24, 63%), but rarely (2/29, 7%) in pT1ext UC (χ2 – test, p-value <0.001). The presence 
of pT1ext at initial diagnosis proved to be the strongest predictor for progression, also when 
adjusted for FGFR3 mutation status in a Cox regression model. This relatively simple, new 
sub-staging system for pT1 UC may prove to be of prognostic value and supportive to clinical 
decision-making.
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Introduction
The clinical course of non-muscle invasive (pTa and pT1) papillary urothelial cell carcinoma 
(UC) is characterized by a high tendency to recur (up to 70%) and a propensity to progress 
in grade (10-30%) or stage (10-15%).1 The follow-up policy and treatment of patients with 
non-muscle invasiveUC predominantly depends on conventional parameters like grade and 
stage (pTa versus pT1) and the associated presence of flat lesions like carcinoma in situ. 2,3 
For the subset of papillary non-muscle invasiveUC that invades into the sub-epithelial con-
nective tissue (pT1), the clinical management is not standardized, since the biologic behavior 
of individual cases remains elusive.4, 5 Besides, molecular data point at the heterogeneous 
nature of pT1 UC.6 Clinicians are inclined to treat pT1-tumours, in particular the ones with 
high-grade in combination with carcinoma in situ (CIS), more aggressively, because their 
higher risk of progression to muscle invasive UC. 7, 8 
Various approaches have already been put forward to identify those with more aggressive 
behavior among pT1 UC. These include molecular characteristics such as over-expression 
of the p53 protein, proliferation markers like MIB-1 and DNA-ploidy status. 9, 10   However, 
because of the limited prognostic impact or for technical reasons these molecular markers 
have not been introduced in routine pathology of UC.11
The depth of tumour infiltration in the submucosa has also been put forward as an ap-
proach to perform substaging in pT1 UC. This could be done by direct measurement of the 
depth of invasion with a micrometer or by the assessment of invasion relative to the muscu-
laris mucosa. 12, 13  These methods have not yet gained a wide acceptance. 14 There is no fixed 
standardized orientation of tissue-structures in transurethrale-resected tissue complicating 
the quantification of perpendicular tumour invasion and identification of histological land-
marks as muscularis mucosae and vascular plexus. 15
In this study, we set out to quantify the horizontal tumour invasion. This approach for 
subdividing papillary pT1 UC is based on the extent of the invasive front. By measuring the 
maximum length of extent, parallel to the overlying epithelium, it is possible to distinguish 
micro-invasion from “extensive” infiltration. This method may be less dependent on orientation 
of the tissue specimen and represents a practical definition that is generally applicable. We 
aimed assess the reproducibility of this new sub-staging system and its prognostic value. 
Recently, two mutually exclusive molecular pathways of bladder carcinogenesis have been 
identified corresponding to UC with either a favorable or an aggressive clinical behavior. 6 
Accordingly, p53 over-expression defines UC with high recurrence rate and increased likeli-
hood of progression, as mutations in the gene encoding the fibroblast growth factor receptor 
3 (FGFR3) are characteristic of UC with favorable prognosis.  10,15 Therefore, we also evaluated 
the correlation between sub-staging and FGFR3 mutation status and assessed the prognostic 
effect of the substaging system while adjusting for FGFR3 status.
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Materials and Methods
Patients and follow-up
From a previously described cohort of 286 patients with papillary UC we extracted 63 for-
merly diagnosed pT1 UC tumours. 10 After central pathological review (ThvdK) of the pT1 
tumours, 53 tumours remained to evaluate. For reason of comparison, the files of 131 patients 
with pTa UC were retrieved to obtain data on their follow-up. The patients were seen at the 
departments of Urology at the Erasmus Medical Center Rotterdam (n=33) and at the Sint 
Franciscus Gasthuis, Rotterdam (n=20). Mean age of patients at diagnosis was 68 ± 10 years 
(range 47 - 90y). All patients were diagnosed with UC for the first time. After first diagnosis 
42 patients (79%) were treated with immuno- or chemotherapy by intra-vesicle instillation 
during median time of follow-up of 55 months (range 9-228 months). Ten patients (19%) died 
of disease, 8 patients (15%) underwent cystectomy and 28 progressed in disease. Of these 28, 
tumour recurred as muscle invasive (≥ pT2) in 16 (30%) patients, 9 progressed in grade (G3) 
with concomitant CIS and 3 were considered as clinically progressed because of repeated 
recurring pT1G3 + CIS which was treated by cystectomy. 
A recurrence was counted if it occurred after at least 3 months after diagnosis. Recur-
rence rate was calculated as the total number of recurrences divided by the total number of 
months of follow-up times 12 months. Progression was defined as a histologically diagnosed 
recurrence with higher grade, stage or the appearance of carcinoma in situ. Also included in 
the definition of progression was cystectomy performed on patients with recurring pT1G3 
associated with concomitant carcinoma in situ. Progression was the primary end-point in this 
study, since it is clinically the most relevant.
Histopathology and Immunohistochemistry
Standard haematoxylin and eosin (H&E) stained slides of formerly diagnosed pT1 UC were 
reviewed by a specialized genitourinary pathologist (THvdK) and for reasons of comparison 
graded, both according to the 1973 WHO classification for urothelial neoplasm and according 
to 1998 WHO/ISUP system. 16 Tumours were staged according to WHO 2002 TNM classifica-
tion guidelines. 1 All 53 specimens showed invasion into the underlying lamina propria but 
no infiltration into the muscularis propria (pT1). 
Next, two different types of tumour invasion were distinguished, i.e. focal or micro-invasive 
and extensive pattern of invasion (Figure 5.1). Micro-invasion was defined as a single focus of 
invasion of the subepithelial stroma by an invasive front, parallel to the overlying (neoplastic) 
urothelium over a maximum distance of 0.5 mm (within one high power field, objective X 40). 
Extensive infiltration could either be multifocal micro-invasive areas or invasion by tumour 
areas that would not fit within one high power field. All slides were independently reviewed 
by two specialized pathologists (THvdK&GvL) for the extent of infiltration into the stroma.
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To assess proliferative capacity all samples were stained with a murine monoclonal antibody 
MIB-1 (Immunotech, Marseille, France) using antigen retrieval by microwave and visualization 
was achieved by an avidin-biotin peroxidase complex method as previously described. 17 Mo-
lecular grading is defined as combination of FGFR3 status with MIB-1 expression.10 Pathologi-
cal review of the slides was carried out without knowledge of the clinical or molecular status. 
Molecular analysis for FGFR3 mutation
The HE-slides served as templates for dissection to obtain DNA from tumour, avoiding 
contamination with stroma, normal mucosa. The samples used for FGFR3 mutation analysis 
contained a minimum of 70% tumour cells, as assessed by histological examination. DNA 
was extracted using the DNeasy Tissue Kit (Qiagen GmbH, Hilden Germany). FGFR3 mutation 
analysis was performed by polymerase chain reaction-single strand conformation polymor-
phism (PCR-SSCP) analysis on tumour DNA and, if available, control DNA from venous blood 
samples of the patients as previously described. 18, 19, 20 Three regions of interest encompass-
ing activating FGFR3 mutations previously described in severe skeletal dysplasias and cancers 
were amplified by PCR. The primer sequences were as reported. The laboratory analyses were 
performed without knowledge of clinical or histopathological status. A detailed description 
of FGFR3 mutation analysis was given previously. 10 
Statistics
Statistical analyses were performed using SPSS 11.0 software (SPSS Inc., Chicago, IL). The statis-
tical significance of the correlation between pattern of invasion and clinical and pathological 
variables was assessed using Chi-square tests and Mann-Whitney tests. The cumulative inci-
dences of progression were estimated by means of the Kaplan-Meier Method and compared 
using the log-rank test. Cox regression model was used to analyze combinations of the extent 
of infiltration and other prognostic factors. P < 0.05 was considered statistically significant. 
Results
Twenty-four of the 53 pT1UC displayed focal invasion (pT1mic) and 29 were categorized as 
extensively invasive (pT1ext). The histopathological classification of non-muscle invasiveUC 
is subdued to a significant interobserver variability. In order to test the diagnostic reproduc-
ibility of tumour invasion as presented in this study, two pathologists revised all 53 primary 
tumours for stage and substage (table 5.1). In 43 (81% agreement) tumours both pathologists 
scored the same diagnosis regarding the extent of invasion. The tumour characteristics in 
relation to the two patterns of invasion in this series of 53 patients are listed in table 5.2. Grad-
ing (WHO ’73 and WHO/ISUP ’98), FGFR3 mutation status, MIB-1 expression and molecular 
grading were significantly correlated with the extent of invasion. 
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Figure 5.1
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Figure 5.1 
 
 
 
 
 
 
Photomicrographs illustrate pT1 UC with extensively infiltrating (A-D) and micro-invasive (E, F) patterns. In A and B, the invasive tumor fronts 
are not contained within 1 HPF, or multiple foci of invasion are present (C, D). Details are given at high power in B, D, and F (x200).
Table 5.1
81% agreement Pathologist 2
Pathologist 1 pTa PT1foc PT1ext Total
PT1 foc 8 14 2 24
PT1 ext 0 0 29 29
Total 8 14 31 53
Scores in agreement of substaging pT1 by two expert pathologists. Agreement (in %) in histological data of 53 patients formerly diagnosed with 
primary papillary pT1 UC scored by two expert urogenital pathologists for the new system for substaging
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To evaluate the clinical importance of pT1 UC in these two subsets, its prognostic impact 
was compared with that of other potentially prognostic variables for progression as endpoint 
(Table 5.3). Micro-invasion was the most important predictor of progression. The Kaplan-
Meier curves further illustrate the significant impact of pT1 sub-staging (Figure 5.2a) and the 
impact of FGFR3 gene mutation (Figure 5.2b) on progression. A highly significant difference 
in progression was noted between patients with an initial diagnosis of pT1mic and pT1ext 
UC. 
Table 5.3 shows the hazard ratios of the different variables. Extended invasion has a three 
times higher risk of progression, HR=3.0 in univariate analysis. Taking into account the pos-
sible impact of other variables, we found that the risk of progression remained almost similar 
(multivariate, HR=2.7).
Table 5.2
Variables Micro-invasion (n=24) Extensive Invasion (n=29) P value a
Mean Age (years) ± SD - 69 ± 10 - 67 ± 10 0.40
Gender
- male
- female
 
- 19
- 5 
 
- 23
- 6 0.99 
Grade WHO ‘73
- G1
- G2
- G3
 
- 2    (8%)
- 15  (63%)
- 7    (29%)
 
- 0
- 9    (31%)
- 20  (69%) .002 
Grade WHO/ISUP ‘98
- Low-grade
- High-grade
- 10 (42%)
- 14 (58%)
- 4    (14%)
- 25  (86%) .022 
Molecular Status
- FGFR3 mutation o
- wild type
 
- 15 (63%)
- 9   (37%)
- 2   (7%) 
- 27 (93%) .000 
IHC, MIB-1 Staining
- MIB < 25%
- MIB ≥ 25%
- 12  (50%)
- 12  (50%)
- 4   (14%)
- 25 (86%) .004 
Molecular Grading
- mG1 (mt/≤ 25%)
- mG2
- mG3 (wt /≥25%)
- 6  (46%)
- 3  (23%)
- 4  (31%)
- .
- 6   (21%)
- 23 (79%) .000 
CiS at Diagnosis
- yes 
- no
- 2   (8%)
- 22 (92%)
- 5   (17%)
- 24 (83%) .340 
Pathological and molecular characteristics related to the extent of infiltration, micro- and extensive invasion, of 53 patients with primary pT1 
UCC of the bladder a P value by χ2 test
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Discussion 
We describe a new system for substaging pT1 tumours that is valuable as prognostic factor 
and supportive in clinical decision-making. We found that scoring of the extent of invasion, 
using this method, is reasonably reproducible. There is a clear correlation with other prog-
nostic factors, especially with FGFR3 mutation status. Furthermore, the extent of invasion 
was the most independent predictor for progression. 
Invasive pT1 UC may be derived from carcinoma in situ of the urothelium or from papillary 
UC. It is well recognized that pT1 UC originating from carcinoma in situ (CIS) carries a substan-
tial risk of progression to muscle invasive UC. For a subset of invasive UC accompanied by CIS, 
some authors employed the term “micro-invasive” UC. 4, 21, 22 The definition of micro-invasive 
carcinoma in the context of CIS in these studies was invasion over a front > 2mm or < 5 mm. 
Figure 5.2
 24 
Figure 5.2 
 
Kaplan-Meier Curves; 
A Distribution of Time to Progression in Population 
of 53 pT1 UC and 131 pTa UC 
B Distribution of Time to Progression for FGFR3 
status in Population of 53 pT1 UC
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Some authors considered this cut-off point of 5 mm too advanced, since about 6% of these 
patients had metastatic disease. 23, 13 
Despite a proposal in 1993 to distinguish micro-invasive from other pT1 UC, the terminol-
ogy of micro-invasive carcinoma for papillary UC is not well established. 12 The latter study 
emphasized the heterogeneity of the pT1 tumour group and the problem in the assessment 
of micro-invasion. The authors hypothesized a difference in behavior but did not examine 
the biologic basis and clinical value of a sub-staging system. In a more recent study on TUR 
specimens, it was demonstrated that the depth of lamina propria invasion, as measured 
by a micrometer, proved to be predictive for progression. A highly significant difference in 
progression was noted between patients with UC with infiltration depth < 0.5 mm and > 1.5 
mm. 24 This finding provides strong support to the concept that separation of micro-invasive 
papillary UC from those with a deeper infiltration is of real clinical importance. 
A potential disadvantage of the measurement of the depth of invasion as a single criterion 
may be the lack of orientation of the tissue from a TUR specimen or bladder biopsy. To cir-
cumvent the lack of tissue orientation, similar approaches have been put forward, but based 
on the depth of infiltration of pT1 UC in relation to the vascular plexus in the submucosa.13 
Table 5.3
 
 Prognostics n
 
 Progression
5y progression 
free P value a
Univariate
HR 
[CI 95%] b
Multivariate
HR
[CI 95%] b
Micro-invasion
- Micro-invasion o
- Extensive invasion
24
29
9
19
69%
50% .009
3.0
[1.3-7.2]
2.7
[0.9-8.4]
Tumor Grade WHO ’73
- G1
- G2
- G3
2
24
27
0
12
16
100%
50%
64% .85
1.9
[0.5-2.0]
Tumor Grade WHO/ISUP ‘98
- Low-grade
- High-Grade
14
39
5
23
58%
59% .95
0.97
[0.4-2.6]
Molecular Status
- FGFR3 mutation
- wild type
17
36
7
21
66%
55% .07
0.4
[0.2-1.1]
0.8
[0.2-3.0]
IHC, MIB-1 Staining
- MIB < 25%
- Mib ≥ 25%
16
37
7
21
66%
55%  .18
1.9
[0.8-4.6]
Molecular grading
- mG1
- mG2
- mG3
10
13
30
4
6
18
72%
65%
52% .14
1.8
[1.0-3.2]
CiS at Diagnosis
- yes 
- no
7
46
6
22
57%
59% .87
0.9
[0.3-2.5]
Effect of potential prognostic variables on clinical progression in 53 patients with primary pT1 UCC of the bladder. a P value by log-rank test b 
Hazard Ratio and 95% confidence interval by Cox regression analysis
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Unfortunately it has been shown to be difficult for the proposed sub-staging systems to gain 
a wide acceptance. This may be attributed to discrepant literature data on clinical relevance, 
inter-observer variation among pathologists and practical problems in the application 
of the sub-staging due to lack of orientation of the specimen. Orientation in biopsies and 
transurethral resection specimens as well as cauterization artifacts may indeed underlie the 
variability in interpretation by pathologists. A recent study, however, claimed to improve the 
accuracy of substaging pT1 UC into pT1a and pT1b with the aid of immunohistochemistry 
using antibodies to desmin and cytokeratin. 21 
Here, we report on a relatively simple, dichotomized categorization of papillary pT1 UC, 
separating those with focal or micro-invasion from pT1 UC with an extensive invasion pattern. 
By taking into account the maximum length of infiltration parallel to the urothelial surface, 
the problem of poor orientation is largely circumvented. Our definition of micro-invasive 
papillary pT1 UC on the basis of the length of the infiltrating tumour area confined within 1 
hpf may be considered rather inaccurate, but its advantage is the relative simplicity, which 
may increase the compliance of the pathologist. 
To test diagnostic reproducibility a second pathologist, instructed only by a manual, in-
dependently scored substage in all 53 pT1 tumours. Both pathologists found agreement in 
81% of cases. As shown in table 5.1 there was disagreement in 8 cases, tumours diagnosed 
pT1mic by the first pathologist, were considered pTa (mimicking invasion into the submucosa, 
caused by tissue damage) by the second pathologist, the reviewer. Considering agreement 
between pathologists on histological features, this substaging system should be reasonably 
applicable. 14,25
The observation of the frequent occurrence of the FGFR3 mutation in pT1mic as compared 
to pT1ext UC can be considered as a strong argument that this simple method of patho-
logic sub-staging of pT1 UC is of biologic relevance. On the other hand, we note that FGFR3 
mutation had no independent effect on progression when taking into account the extent 
of invasion. However, the extent of invasion proved to be the most important independent 
prognostic factor for progression free survival, clearly surpassing FGFR3 mutation status.
Since progression is largely determined by the stage and grade of subsequent recurrent 
UC, it may seem curious that features in the pT1 UC, removed at diagnosis can serve as a 
prognosticator. Currently, evidence has been given that the majority of primary and recur-
rent UC have a monoclonal origin. 13, 24 This offers a good explanation for the phenomenon 
that primary and recurrent UC share a common biology, and that the pattern of invasion at 
diagnosis reflects a future pathway. 
Although it would be advantageous to perform substaging of pT1 UC, the problem of 
understaging in TUR specimens should also be considered: one study reported that 25% of 
high-grade UC diagnosed on the TUR as pT1 revealed a pT2 or pT3 UC in the corresponding 
cystectomy specimen. 9 Thus, it maybe that a proportion of our pT1ext represent underdiag-
nosed pT2 UC.
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In a previous study we demonstrated that the recurrence rate of UC was related to the 
FGFR3 mutation status, i.e. those patients with (pTa and pT1) UC carrying the FGFR3 mutation 
genotype showed less frequent recurrences as compared to those with the wild type FGFR3 
genotype. 5, 27 In this series of patients with pT1 UC we could not confirm this observation. 
Time to first recurrence is considered an important parameter to determine the optimal in-
terval for clinical follow-up in surveillance of UC. Mean time to first recurrence was 21 months 
(range 4 – 116 months). This series of pT1 UC included 16 patients who did not develop a 
recurrence. Thirteen of these patients were free of recurrence for a longer period of follow-
up than the mean time to first recurrence in this study. We were not able to demonstrate a 
specific prognostic feature present in these 16 patients. It is likely that these UC had a good 
therapy response, leading to complete eradication of the UC after TUR in the absence of 
implantation of UC cells elsewhere in the bladder mucosa.
The frequency of FGFR3 mutations in the pTa and pT1mic tumours were respectively 78% 
and 63% (data not shown). We could speculate that pT1mic is similar to pTa. This could imply 
that distinction of pTa and pT1mic UC would not be of relevance. However the progression 
rate in 131 patients with pTa was substantially lower than in patients with pT1mic. 
If confirmed in a larger series of pT1 UC, preferably in a prospective study, the sub-staging 
of papillary pT1 UC in pT1mic and pT1ext could be performed routinely. It provides the urolo-
gist additional information to identify patients with more aggressive tumours, to optimize 
therapy and adjust intensive surveillance. 
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Abstract
Microsatellite analysis (MA) on voided urine samples has been promoted as an alternative 
for cystoscopy surveillance (UCS) of patients with low-grade non-muscle invasive papillary 
urothelial carcinoma (UC). To assess the feasibility and clinical utility of microsatellite analysis 
(MA) on voided urine samples in a routine setting to detect or predict bladder cancer recur-
rences. We evaluated 228 patients monitored by MA on voided urine samples and synchro-
nous cystoscopic examination, who participated in a longitudinal prospective study in 10 
hospitals. Follow-up started after diagnosis of a primary or recurrent pTa, pT1, grade 1 or 2 
papillary UC. Clinico-pathological parameters and FGFR3 mutation status of the inclusion 
tumour were determined. MA outcome was analyzed in 1012 urine samples during a mean 
follow-up of 41 months. Poor DNA quality prevented MA in 19% (197/1012) of the samples, 
leaving 815 visits for a cross-sectional analysis of sensitivity and specificity. We determined 
the predictive value (PPV) in a longitudinal analysis for 458 series with persistent MA results. 
Factors influencing diagnostic quality of MA were investigated. Kaplan Meier analysis was 
performed to relate MA results to recurrence. Cross-sectional sensitivity and specificity of MA 
for detection of a recurrence was 58% (49/84) and 73% (531/731), respectively. One pT1 grade 
3 UC was missed. In a longitudinal analysis, the 2-year risk to develop a recurrence reached 
83% if MA outcome was persistently positive and 22% when persistently negative. PPV of MA 
was higher with wild type FGFR3 gene status and smoking habits. All 4 upper urinary tract 
tumours detected were preceded by a positive MA test. Consecutive positive MA results are a 
strong predictor for future recurrences, but sensitivity needs to be improved, e.g. by patient 
selection and testing of additional genetic markers in urine samples.  
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Introduction 
Bladder cancer is the fifth most common malignancy in Europe and accounts for 5% of all 
diagnosed cancers1. In 80% of the patients the bladder tumour will primarily appear as a pap-
illary non-muscle invasive (stage pTa and pT1) urothelial carcinoma (NMI UC). Up to 70% of 
these tumours will recur and 15% will progress in stage or grade2. Therefore patients require 
extensive surveillance, currently based on cystoscopy and cytology. Although cystoscopy is 
a reliable method, it is an invasive and costly procedure3. Several studies reported on the 
use of microsatellite analysis (MA) for detection of cells with loss of heterozygosity (LOH) in 
voided urine samples as a tool for detection of recurrent UC in the urinary bladder and in the 
upper urinary tract4-7. For a new method to compete with cystoscopy it needs to be feasible 
in routine clinical practice: highly reproducible and accurate at acceptable costs. Moreover, 
sensitivity needs to be high, since 89% of the patients would prefer flexible cystoscopy if the 
sensitivity of a urinary test were lower than 90%8. One of the most promising prognosticators 
of NMI UC is the mutation status of the fibroblast growth factor receptor 3 (FGFR3)9-12. This 
mutation is associated with genetically stable bladder cancer and an indicator for favour-
able prognosis13. We therefore studied the impact of the FGFR3 gene mutation status on the 
performance of MA. In our Cost-effectiveness of Follow-up of Urinary Bladder Cancer (CEFUB) 
trial we aimed to assess the feasibility and clinical utility of MA on voided urine samples in 
a routine clinical practice in a prospective multicenter study on a large patient group with 
low-grade NMI UC. We used cross-sectional analysis to assess the diagnostic value of a MA 
result at a single follow-up visit. Furthermore we performed a longitudinal analysis to reflect 
the positive predictive value (PPV) of a positive MA result preceding a cystoscopically visible 
tumour. 
Materials and Methods
Study design
A total of 448 patients with NMI UC (i.e. TNM 1997 stage pTa, pT1, and WHO 1973 grade 1 
or 2) were recruited by 10 Dutch hospitals for participation in the randomized CEFUB trial 
after signing an informed consent form (registration: ClinicalTrials.gov NCT00126958). They 
were randomized after resection of NMI UC for a follow-up either by 3-monthly cystoscopy 
alone (control arm) or by cystoscopy at 3 months, 12 months and 24 months and 3-monthly 
MA on voided urine samples (test arm). Inclusion of patients in the CEFUB-trial was from 
June 2002 until June 2006 and their follow-up by MA was ended in November 2006. During 
the first year of the study MA was also performed in the control arm, but the results were 
not communicated to the urologist. For the test arm, the protocol recommended imaging 
of the upper urinary tract if positive MA outcome was incongruent with cystoscopy during 
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two follow-up visits. Patients with a history of carcinoma in situ or grade 3 UC were excluded 
from participation. The study presented in this publication concerns 228 participants (UCS 
arm n= 102, MA arm n= 126) of both trial arms whose cystoscopy and synchronous MA data 
were both available in 1012 follow-up visits. Follow-up ranged between 16 and 71 months 
(mean time of follow-up 41 months). The ethical committees of the participating institutions 
approved the study. 
Sample Collection
At the outpatient clinics of the 10 participating hospitals 10 ml heparinized whole venous 
blood and urine samples (15-100ml) were collected and stored at +4°C until transportation 
at +4°C by courier service to the department of Pathology Erasmus MC, Rotterdam. DNA 
from the blood samples was isolated using the DNeasy Blood Kit (Qiagen GmbH, Hilden 
Germany). Histopathological reports along with the corresponding HE-slides and paraffin 
blocks were submitted to Erasmus MC for determination of the FGFR3 mutation status. A 
pathological review was not performed. Freshly voided urine was collected before cystos-
copy. Time between collection of urine and arrival at the molecular laboratory at the Erasmus 
MC, Rotterdam varied between 1 and 240 hours (median 24 hours). If the concentration of 
leukocytes in the urine samples was > 20 leukocytes per microscopic field (magnification x 
400) the patient was asked to collect a urine sample again. Urine samples were washed twice 
with phosphate-buffered saline (PBS). The final pellet was resuspended in 1.0 mL PBS and 
stored at -20 °Celsius until DNA isolation. The QIAamp Viral RNA kit (Qiagen GmbH, Hilden, 
Germany) was used, according to the manufacturers protocol, for isolation of DNA. Isolation 
finally provided an 80-μl sample of DNA product. Clinical data of follow-up results of cystos-
copy, additional diagnostics and (intra-vesical) therapy of these patients were obtained from 
standardized case record forms. 
Microsatellite Analysis
DNA from each urine sample was amplified by PCR using primers for 20 polymorphic micro-
satellite markers localized on 10 chromosomes4, 6, 7. PCR amplification was carried out in PCR 
buffer (Promega, Madison, WI) and FAM fluorescent-labelled primers (Applied Biosystems, 
Foster City, CA; range of primer concentration 0.2-1.75 pM). Amplified fragments were an-
alysed by using the ABI 3100 Genetic Analyser. LOH was defined: the ratio of allelic loss as 
quantified by calculation of the blood/urine-ratio (i.e. peak height in blood (allele 1/ allele 
2): peak height in urine (allele 1/ allele2). LOH was established when 0.7 > blood/urine ra-
tio > 1.42. All LOHs were confirmed by a second independent polymerase chain reaction 
(PCR). LOH of ≥ 1 marker is sufficient for diagnosis of LOH. The peak height ratio of blood-
determined alleles was the average of the ratios of 4 independent PCRs separate for each 
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marker. A marker was excluded for a patient when its standard deviation was ≥ 15%. We 
applied a lower limit for peak heights of 700 to exclude possible preferential amplification 
of one of the two alleles due to insufficient input DNA. All reactions with off-scale signals 
were diluted and rerun.  A result was only taken into account when at least 10 MA markers in 
a sample were informative. The laboratory analyses were performed without knowledge of 
clinical or histological status. 
Molecular analysis for FGFR3 mutation 
Tissue samples used for FGFR3 mutation analysis contained a minimum of 70% tumour cells, 
as assessed by histological examination. DNA from tumour and control DNA from venous 
blood samples of all patients was extracted using the DNeasy Tissue Kit (Qiagen GmbH, 
Hilden Germany). Exons 7, 10 and 15, encompassing the 11 activating FGFR3 gene mutations 
most commonly involved with UC were amplified by PCR. A detailed description of FGFR3 
mutation analysis was given previously14. The laboratory analyses were performed without 
knowledge of clinical or histopathological status. 
Statistical Analysis
All data was compiled into a Microsoft Access database. Descriptive and statistical analyses 
were performed using SPSS 11.5 software (SPSS Inc., Chicago, Ill). Recurrence was defined by 
histological diagnosis of UC. Sensitivity and specificity were determined by cross-sectional 
analysis for every follow-up visit with synchronous cystoscopy and MA results. PPV was de-
termined by longitudinal analysis of one or more subsequent follow-up visits (MA series) with 
either positive MA outcomes (persistent positive MA) or negative MA outcomes (persistent 
negative MA). A series of MA was thus defined as one or more consecutive positive or nega-
tive MA outcomes ending at the time of 1) a recurrence, including UUT, 2) a change in MA 
outcome from positive to negative or from negative to positive or 3) at end of further follow-
up. In case of a NMI UC recurrence or a change of MA outcome, a new series would start for 
this patient. Recurrences in longitudinal series were analysed by the Kaplan-Meier method 
and compared using the log-rank test. P < 0.05 was considered statistically significant. 
Results
Patients, tumours and voided urine samples 
Table 6.1 shows the clinical features of the 228 patients, as well as the histopathological 
and molecular tumours characteristics. Patients from both trial arms were evaluated (test 
arm, n=126; control arm, n=102), if matched MA and cystoscopy results were available. The 
3-monthly surveillance provided 1012 urine samples. In 197/1012 (19%) urine samples the 
MA test failed, in 11 samples due to technical failure and in 186 samples no detectable signal 
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was observed. This was attributable to prolonged periods of storage between moment of 
sampling and processing  (Figure 6.1a). Figure 6.1b demonstrates that up to about 6 months 
after intravesical chemo/immunotherapy the MA test failed slightly more often in treated 
versus untreated patients during the same time period. Mean time of reporting of MA to the 
urologist after requisition of the sample was 10 working days (range 4-33 days). 
Quality of microsatellite markers
All microsatellite markers were performing well. Few LOHs were found with D4S242, FGA, 
D11S488, D17S960, D18S51 and D20S454. Most LOHs were found with the markers from 
chromosome 9. D9S171 revealed fewer LOHs than other 9p markers, probably because its 
location is in the vicinity of the p16 gene in which homozygous deletions often occur in 
bladder cancer. We further noticed that tetranucleotide repeat markers were easier to work 
with than CA-repeat-containing markers due to fewer stutter peaks.  
Sensitivity and specificity of MA for detection of recurrences: cross-sectional analysis 
A total of 815 follow up visits with both MA data and synchronous cystoscopy findings could 
be analysed for 84 detected histologically proven recurrences (Table 6.2). The sensitivity, 
specificity of the MA test was 58% (49/84), 73% (531/731) respectively. If our analysis was 
confined to the patients of the MA arm, a sensitivity of 70% (42/60) of the MA test was found. 
Table 6.3 describes the characteristics of the patients and tumours at inclusion that devel-
oped a recurrence during follow-up of the trial and compares the clinico-pathological and 
Table 6.1
Clinical features in 228 patients
Disease status at start of study
Primary 
n=118
1st 
recurrence 
n=45
2nd 
recurrence 
n=30
3rd 
recurrence 
n=16
≥4th 
recurrence 
n=19
Total      
 n= 228
Patient characteristics
Age, mean ± sd 63y ± 12
Gender Male 91 (77%) 34 (77%) 22 (71%) 13 (81%) 14 (74%) 174 (76%)
Smoking behaviour Smoker 77 (76%) 28 (78%) 19 (73%) 6 (50%) 13 (81%) 143 (75%)
Tumor characteristics at start of study of 228 patients
Stage pTa 100 (85%) 38 (86%) 26 (84%) 15 (94%) 16 (84%) 195 (86%)
pT1 18 (15%) 6 (14%) 5 (16%) 1 (6%) 3 (16%) 33 (14%)
Grade G1 51 (43%) 23 (52%) 16 (52%) 7 (44%) 12 (63%) 109 (48%)
G2 67 (57%) 21 (48%) 15 (48%) 9 (56%) 7 (37%) 119 (52%)
FGFR3 Mutant type 60 (61%) 26 (67%) 20 (74%) 12 (80%) 11 (61%) 129 (65%)
Wild type 38 (39%) 13 (33%) 7 (26%) 3 (20%) 7 (39%) 68 (35%)
Focality Solitary 77 (73%) 24 (60%) 12 (40%) 10 (67%) 9 (64%) 132 (64%)
Multifocality 29 (27%) 16 (40%) 18 (60%) 5 (33%) 5 (36%) 73 (36%)
Characteristics of 228 Patients and their Tumors at Start of Study Surveillance
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molecular characteristics of the recurrences detected and missed by MA. The recurrences 
missed by MA are predominantly pTa Grade 1 and 2 UC, but they include also one pT1 Grade 
3 UC. On the other hand, three cases of CIS, all four ≥ pT2 UC recurrences and 7 of 8 recurrent 
Grade 3 cancers were detected in the MA positive group. 
MA as a predictor for future bladder cancer recurrences; a longitudinal analysis
To appreciate the predictive value of MA for the detection of future recurrences we performed 
a longitudinal analysis on a total of 458 series of MA outcomes from 228 patients with a 
median follow-up of 34 months. The flowchart (Figure 6.2) shows the possible endpoints 
and the accompanying numbers of events during follow-up. In this longitudinal analysis 86 
recurrences were detected including 4 upper urinary tract tumours, identified after a positive 
MA test by radio-diagnostic imaging (X-ray, CT scan or intravenous urogram). Kaplan Meier 
analyses (Figure 6.3) showed that patients with consecutive series of persistently MA positive 
Table 6.2
MA outcome UC recurrence No UC recurrence Total
MA + 49 200 249
MA - 35 531 566
Total 84 731 815
Figure 6.1
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Figure 6.1
a Influence of storage and duration of urine transport
iv therapy
No iv therapy
Log Rank Test p= .3
b Influence of interval between intravesical therapy and MA
Prolonged duration between urine collection and MA and intravesical therapy negatively affect quality of MA in 19% (197/1012) of the samples.
a. Effect of time till analysis of urine sample. After 2 weeks of delay MA failed in 80%. 
b. Effect of intra-vesical immune/chemotherapy (iv therapy). In the first 6 months after intra-vesical therapy MA of 15% of urine samples failed, 
compared to 8% in samples from patients without iv therapy. A total of 88 patients was treated with intravesical therapy after TUR.
Sensitivity 58% (49/84) 95% CI [0.47-0.69]
Specificity 73% (531/731) 95% CI [0.69-0.76]
Positive Predictive Value 20% (49/200) 95% CI [0.15-0.25]
Negative Predictive Value 94% (531/566) 95% CI [0.92-0.96]
MA outcome and histologically proven recurrences detected at synchronous cystoscopy findings during 815 follow-up visits.
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Table 6.3
Characteristics of 57 patients and tumours at inclusion developing recurrences
Gender Male 42 (74%)
Randomised Groups Control Arm (UCS) 18 (32%)
Smoking Yes 35 (70%)
Stage pTa 47 (82%)
Grade G1 28 (49%)
Multifocality Multifocal 21 (44%)
FGFR3 at inclusion Mutant 31 (60%) 
Characteristics of 84 recurrences
Detection of recurrences by MA
Yes (%) No (%)
Univariate
p value
Stage pTa 38 (53) 34 (47)
pT1 7 (88) 1 (12)
≥pT2 4 (100) 0 (0)
Concomitant CIS CIS 3 (100) 0 (0) 0.03
Grade G1 24 (57) 18 (43)
G2 16 (50) 16 (50)
G3 9 (90) 1 (10) 0.4
Multifocality Multifocal 20 (54) 17 (46)
Solitary 24 (62) 15 (38) 0.2
Clinicopathological and molecular features of 84 recurrences in 57 patients related to synchronous MA findings.
Figure 6.2
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228 patients 
and 458 MA series 
persistent MA + (n=172) 
persistent MA – (n=286) 
Recurrence (n=59) 
End of study 
Change MA +  -  (n=62) 
Change MA -  + (n=93) 
End of study 
Recurrence (n=27) 
Restart surveillance* 
Restart surveillance* 
Restart surveillance* 
Restart surveillance* 
- No event in Fup (n=45) 
- early withdrawal (n=2) 
- Lost to Fup (n=2) 
- Death (n=2) 
- No event in Fup (n=157) 
- early withdrawal (n=2) 
- Lost to Fup (n=1) 
- Death (n=6) 
pTaG1 (n=15) 
pTaG2 (n=11) 
pTaG1 (n=27) 
pTaG2 (n=20) 
pT1G2 (n=2) 
 
End of study 
End of study CIS,G3,≥pT2 (n=10) 
 
CIS,G3,≥pT2 (n=1) 
 
* Restart 
surveillance 
(n=230) 
Flowchart showing the possible endpoints after completion of a MA series and the accompanying numbers of events. Endpoints were final (end 
of study or progressive recurrence) or temporary (change of MA result or NMI-UC). Temporary endpoints and series ending with a histologically 
proven non-muscle invasive recurrence re-started a new MA series (*). 
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follow-up visits had an 83% risk of recurrence after 24 months (59 recurrences predicted). In 
contrast, after a series of one or more persistently negative MA tests the probability to miss a 
developing recurrence in 24 months was 22% (27 recurrences missed, in 21 patients). Series 
of positive MA tests preceded recurrences by 1 to 24 months (Figure 6.4). 
Fgure 6.3
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Figure 6.3
MA +
MA -
Log Rank Test: p< .000
Kaplan Meier Curve shows the proportion of recurrences 
in 458 MA events detected by consecutive continuous 
positive or negative results of MA. Time (in months) 
reflects the length of time of continuous MA results 
without visible suspicious lesion in the bladder. After 24 
months, 83% of recurrences is detected, 22% is missed. 
Figure 6.4
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Figure 6.4 
 
 
 
 
 
Example of follow-up by cystoscopy and MA:
Female, 62 years at time of primary tumor, non smoker. History: June 2000 Nephrectomy, pTaG2; Nov 2000 primary UC Bladder, pT1G2; April 
2002 3 recurrences in bladder, pTaG2, wt (FGFR3 gene mutation status). Time is in months after inclusion. D9S242, D9S252, D16S476, 
D17S786, D17S960, D18S51 and D20S454 are MA markers quantified by NP (No DNA product) or by the ratio of allelic loss as quantified by 
calculation of the blood/urine-ratio (LOH was established when 0.7 > blood/urine ratio > 1.42); MA results are (LOH+) suspect for UC or (LOH-) 
not suspect; cystoscopy shows lesion suspect for tumor (Pos) or no visual lesions (Neg); clinical policy could be Trans Urethral Resection (TUR), 
outpatient clinic visit in 3 months (C/3) or adjuvant imaging (X/IVP or CTscan).
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Parameters influencing positive predictive value of MA
The predictive value of MA was considerably higher in patients included with a FGFR3 wild 
type tumour (24/31, 77%) when compared to patients with a mutant tumour (28/46, 61%). 
FGFR3 mutation status of the initial tumour, tumour focality, (Figure 6.5) and gender and 
smoking habits (Figure 6.6 and 6.7) all revealed significant differences with regard to detec-
tion of recurrences by MA.
Discussion
This prospective study was designed to evaluate the feasibility and clinical utility to perform 
MA on voided urine samples derived from different hospitals in a central molecular-genetic 
laboratory. Although the vast majority of urine samples (81%) were of sufficient quality to al-
low MA, transportation times longer than 48 hours to the central laboratory adversely affected 
the proportion of samples giving satisfactorily results. Thus, adequate logistics are required 
prior to implementation of MA testing in a routine setting. The main finding of our study is 
the relatively low cross-sectional sensitivity 58% (49/84) and specificity 73% (531/731) of MA 
on voided urine samples to detect recurrences. A potential limitation of our study is that our 
main analysis is based on the combined data from two trial arms, one of which comprised the 
unblinding of the urologist for the MA outcome. It is conceivable that awareness of a positive 
MA outcome may have prompted a higher detection rate of UC recurrences by cystoscopy. 
Indeed, separate analysis of the patients of the MA arm showed an improved cross-sectional 
sensitivity (70%) of the MA test. From the perspective of cost-effectiveness it must be noted 
that our semi-automated high-throughput MA is a labour-intensive technique and its routine 
application can be improved by a better selection of markers and a further automatization 
Figure 6.5
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Figure 6.5
multifocality
solitary
Log Rank Test: p < .000
(MA+) series and tumor focality(MA+) series and FGFR3 mutatio
Wild Type
Mutation
Log rank Test: p=0.02
a n status b
Kaplan-Meier curves relating FGFR3 mutation status (a) and tumour multifocality (b) at entry to MA detected recurrences. 
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of the procedure15, 16. In a meta-analysis on urine markers it was reported that the sensitiv-
ity and specificity of MA during follow-up of patients with UC varies between 75-92% and 
79-100% respectively17. Contrary to these latter studies, our series was entirely composed 
of grade 1 and 2 NMI UC. These patients may especially benefit from surveillance tests other 
than cystoscopy. MA is more sensitive for detection of higher stage and grade recurrences, 
although one T1G3 tumour was missed. Since the WHO 1973 grade 2 UC comprise a consider-
able proportion of High-grade UC according to the more recent WHO/ISUP 2004 grading 
system, it follows that MA misses a larger number of the latter category of UC. Longitudinal 
analysis revealed that the relatively low specificity of 73% was mainly due to positive MA 
outcomes preceding a cystoscopically visible recurrence by many months. We showed in an 
earlier study that MA can anticipate the occurrence of recurrences7. Other urine tests also 
Figure 6.6
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Figure 6.6
Males
Females
Log rank Test: p=0.02
Smokers
Non-Smokers
Log rank Test: p=0.04
Smokers
Non-Smokers
Log rank Test: p=0.2
Males
Females
Log rank Test: p=0.08
a
b (MA+) series and Smoking Behaviour (MA-) series and Smoking Behaviour
(MA+) series and Gender (MA-) series and Gender
Kaplan Meier curves relating gender (a), smoking habits (b), FGFR3 mutation status of the tumour (c) and tumour focality at entry (d) to MA 
detected recurrences.  
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demonstrated a better prediction of UC recurrence during longitudinal follow-up (18). Amira 
et al. were the first who analysed subsequent MA results in a systematic study design19. They 
found that a positive MA test preceded a visible recurrence between 1 month and 9 months 
in 75% of patients. Similarly, our study of NMI UC demonstrates that the PPV was 83% for 24 
months of follow-up with persistent positive MA results. Our findings also confirmed previous 
studies that MA is able to detect upper urinary tract UC4, 7, 20. Multiple subsequent positive or 
negative MA tests are important for the likelihood of detecting a recurrence. We hypothesize 
that the missed recurrences were mainly genetically stable UC (pTa, low-grade).
The positive predictive value of MA is much higher in patients with an FGFR3 wild type 
tumour reaching 100% in 24 months (Fig. 6.5a). This is in line with the finding that FGFR3 
gene mutations are associated with genetically more stable UC21. We also noted that MA 
misses more recurrences in non-smoking patients and surveillance by MA could be especially 
valuable for smoking patients with an FGFR3 wild type tumour. The somewhat enhanced 
sensitivity of MA to detect UC recurrences in patients with smoking habits may be explained 
by their propensity to develop genetically more unstable bladder cancers22. For patients with 
an FGFR3 mutant tumour, surveillance by FGFR3 mutation analysis could be envisaged14, 23 .
The FDA approved UroVysion FISH test is a methodologically different test, but is also based 
on the detection of genetic abnormalities in cells shed in urine. In a recent paper on 250 
patients, including patients with a high-grade UC using UroVysion on cytological specimens 
of voided urine, the predictive rather than diagnostic capacity of this test (sensitivity 60%) 
was emphasized24. In this study three high-grade, high stage cancers were missed. In 35/56 
Figure 6.7
Kaplan Meier curves relating gender and smoking habits demonstrate that smoking habits determine the proportion of MA detectable 
recurrences.
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(63%) patients with a positive UroVysion test, the cystoscopy became positive at a later time 
during a total follow-up period of 29 months. 
Our findings in NMI UC are thus very much in line with 1) the somewhat lower than 
expected cross-sectional sensitivity of these genetic tests (MA and UroVysion-FISH)25 and 
2) the evolving concept that genetic changes detected in urine samples often precede the 
cystoscopically detectable recurrence by several months26. 
Conclusion
A positive MA test is a strong predictor for future recurrences. Testing of additional genetic 
markers in urine samples and stratification of NMI UC and patients based on genetic insta-
bility may improve accuracy of MA. However, MA on voided urine samples is currently not 
sufficiently sensitive to recommend implementation in routine clinical practice.
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Abstract
The aim of this study was to evaluate the influence of knowledge of a urine-test outcome 
on the accuracy of cystoscopy (diagnostic review bias) during surveillance of patients with 
low-grade non-muscle invasive urothelial carcinoma (NMI UC). Prospective, single blinded, 
randomized multicenter clinical trial evaluating the cost-effectiveness of surveillance by a 
urine test (i.e. microsatellite analysis) of 448 patients presenting with primary or recurrent 
NMI UC (pTa, pT1, G1, G2). Urine test results (positive or negative) were only communicated 
to the urologist in the intervention arm (n=226), where patients had cystoscopy if the test 
was positive and at 3, 12, and 24 months. Results were not communicated in the control arm 
(n=222) with standard 3-monthly cystoscopy. Primary outcome measure was the number of 
histologically proven bladder cancer recurrences. : During a median follow-up of 34 months, 
218 recurrences were detected in the intervention arm, compared to 163 in the control arm 
(p<0.001). In 131 cystoscopies performed with knowledge of a positive urine test, 42 recur-
rences were detected. Only 6 recurrences were found for the 120 cystoscopies without infor-
mation on the positive test result (chi-square p< 0.001). There was no difference in detection 
of recurrences when urine test results were negative (intervention arm: 18/260 (7%), control 
arm 18/326 (6%), p=0.45). 
Awareness of a positive urine test result significantly improves the UC detection rate by 
cystoscopy. This diagnostic review bias should be considered in the evaluation of (point of 
care) urine tests for bladder cancer monitoring.
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Introduction 
Looking inside the hollow organs and body cavities of human beings is a concept that 
was first put forward in 1806 by Philipp Bozzini. Already in 1877 Maximilian Carl-Friedrich 
Nitze (1848-1906) performed the first cystoscopy in Vienna (1). Since then, cystoscopy has 
developed as the mainstay in diagnosis of urinary bladder disease with a high sensitivity and 
specificity for the detection of papillary lesions (2-4). The availability of flexible cystoscopes 
further improved its acceptance as a diagnostic tool. Nevertheless, alternative non-invasive 
diagnostic methods are being investigated in order to reduce the cystoscopy frequency, 
because cystoscopy is considered an invasive, time-consuming and costly procedure and 
burdensome for the patient (5,6). Several authors suggested that implementation of urine 
tests, such as microsatellite analysis (MA) for detection of tumour cells in voided urine 
samples, may represent an acceptable alternative for diagnosis of both recurrent UC of the 
urinary bladder and detection of upper urinary tract UC (7-9).
For detection of flat lesions, like hyperplasia, dysplasia and carcinoma in situ white light 
cystoscopy has a lower sensitivity compared to papillary lesions. Nonetheless, hand, the 
sensitivity of cystoscopy for detection of papillary lesions is by definition very high since 
alternative diagnostic tests are not in routine use for detection of UC recurrence and – as a 
consequence – its alleged high sensitivity cannot be verified independently.
We embarked on a randomized multicenter study on the safety and the cost-effectiveness 
of surveillance of patients with low-grade (WHO 1973 grade 1 and 2) NMI UC using microsat-
ellite analysis on voided urine samples as an alternative for cystoscopy(10). In the control arm 
of this study the urine test outcome was not communicated to the attending urologist during 
the follow-up visits, but for the patients randomized to the test arm the urologist in charge 
was aware of the urine test outcome. In this paper we investigated whether diagnostic review 
bias may have caused the observation that the number of recurrences was higher in the test 
arm than in the control arm.
Materials and Methods
Study design
A total of 484 patients with primary or recurrent NMI UC (i.e. TNM 1997 stage pTa, pT1, and 
WHO 1973 grade 1 or 2) were recruited by 10 Dutch hospitals for participation in the random-
ized CEFUB trial (Cost-Effectiveness of Follow-up of Bladder Cancer Trial). Of the 10 participat-
ing hospitals, three (one community and 2 academic centres) have an urologist residency-
training program. The mean number of patients contributed by each hospital was 45 patients 
(range8- 128). White light cystoscopy was employed for surveillance by the 10 hospitals. All 
participating urologists were informed about the literature on the performance of MA for 
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the detection of recurrent UC (6,7). Patients with a history of carcinoma in situ or grade 3 UC 
were excluded from participation. After transurethral resection (TUR) of the bladder tumour, 
448 were randomized after signing an informed consent form (registration: ClinicalTrials.
gov NCT00126958, Supplemental Figure 7.3). The patients were stratified for hospital (ten 
hospitals), histopathological diagnosis (grade and stage) and FGFR3 gene mutation status 
(mutation, wild type).  Participants were assigned to two trial arms by block randomisation 
in order of appearance. Urologists of attendance received Case Record Forms (CRFs) with a 
unique trial number linked to a database in the centre of coordination. Study started at the 
first cystoscopy at 3 months after the TUR of inclusion with a follow-up either by 3-monthly 
cystoscopy alone (control arm) or by cystoscopy at 3 months, 12 months and 24 months and 
3-monthly MA on voided urine samples (intervention arm). The urine test on voided urine 
samples, i.e. microsatellite analysis, was performed in both randomized groups as described 
in detail before (6,10). The laboratory analyses were performed without knowledge of clinical 
or histological status. Urine test results were only communicated (by mail) to the urologist 
of attendance in the test arm, and according to protocol a positive test was followed by a 
cystoscopy. The protocol did not prescribe (random) biopsies in the test arm in case of a 
positive urine test outcome. If (in the test arm) positive urine test outcome was incongruent 
with cystoscopy during two subsequent follow-up visits the protocol recommended imaging 
of the upper urinary tract. The primary outcome of the study was tumour recurrence, defined 
as the presence of a histopathologically confirmed UC detected by a cystoscopy during the 
follow-up. The ethical committees of the participating institutions approved the study. 
Statistical Analysis
Data analysis of randomized groups was performed on an intention-to-treat basis, with log 
rank tests for Kaplan-Meier curves to compare the time to recurrence. Patients with a recur-
rence during follow-up remained in the same trial arm, with a similar follow-up scheme as 
after inclusion in the study. Subsequent recurrences were analyzed with modulated renewal 
(11). Recurrence rates per follow-up visit were compared using chi-square tests. The random-
ized study was originally powered to demonstrate equivalence between randomized groups, 
since follow-up of patients with microsatellite analysis on voided urine would be preferred in 
case of similar recurrence rates in the two arms. Equivalence was defined as that the arm with 
surveillance by urine tests was not more than 5% worse than the cystoscopy only arm, which 
implies that the 2-year recurrence risk is not less than 45% compared to 50%. Statistical power 
was set to 80% and the one-sided significance level set to 5%. Based on standard formulas 
for the required number of events in a log-rank test, 290 events should be registered during 
follow-up. To evaluate the influence of knowledge of the urine test outcome, chi-square tests 
would have 97% power to demonstrate differences in recurrence rates of 30% vs 10% with 50 
recurrences among 250 follow-up visits with positive urine test results. Data were collected 
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using standardized CRFs and analyzed with SPSS 11.5 software (SPSS Inc., Chicago, Ill). P-
values below 5% were considered statistically significant.
Results
Patients, tumours and urine samples
Patient recruitment was from July 2002 till June 2006 and follow-up ended by November 
2006, with a median follow-up of 34 months. Patients in the intervention (unblinded for urine 
test outcome) (n=222) and control (blinded for urine test outcome; n=226) arms were com-
parable with regard to gender, pack years of smoking and age distribution, histopathology 
and disease status (primary versus recurrence) of their NMI UC at entry (Table 7.1). A total of 
3,138 cystoscopies were performed (1501 in intervention arm, 1637 in control arm). A total of 
1,398 voided urine samples were collected of which 1073/1398 (77%) samples were informa-
tive and in 23 % (325/1398) of urine samples the urine test failed due to various reasons (10). 
For 837 follow-up visits both cystoscopy and corresponding urine test results were available, 
i.e. for 391 and 446 follow-up visits in the intervention arm and control arm, respectively.
Detection of urinary bladder recurrences by cystoscopy in the two trial arms
More recurrences were detected in the intervention arm as compared to control arm (log 
rank p=0.008, Figure 7.1A). Figure 7.1B-F shows the breakdown of the recurrences by rank of 
recurrence of each patient. In the intervention arm, 218 recurrences were detected at 1501 
follow-up visits (14.5%), compared to 163 at 1637 visits (10.0%) in the control arm (chi-square 
test p<0.001, supplemental table 7.1). The false detection rates, that is the proportion of 
resected lesions not representing histologically confirmed carcinomas was slightly lower (i.e. 
12%; 45/381) in the intervention arm than in the control arm (i.e. 16%; 52/319).
Table 7.1 
Patient Characteristics (n=448)
intervention arm
n = 222
control arm
n = 226
Gender Male 174 172
Age at study entry (years) Mean ± sd 65 ± 12 66 ± 12
Smoking years  Mean ± sd 22 ± 18 25 ± 18
Histopathology pTaG1 95 88
pTaG2 88 95
pT1G1 4 4
pT1G2 35 39
Primary Tumor number 133 149
Clinico-pathologic features of participants at entry of the trial
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Subset analysis of follow-up visits with synchronous cystoscopy and urine test results
A subset analysis was performed on the 391 follow-up visits in the intervention arm and 446 
follow-up visits in the control arm, for which both cystoscopy and urine test results were 
available. Hence, we were able to find an explanation for the difference in the number of 
recurrences between the two trial arms. The number of follow-up visits without any interven-
tion was lower in the intervention arm (81%; 317/391) as compared to the control arm (92%; 
412/446, chi-square p < 0.001, Supplemental Table 7.2). A larger number of transurethral 
Figure 7.1 A - F
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Kaplan Meier analyses of histologically proven UC recurrences during follow-up of all patients in the UCS-MA and UCS arm
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resections was performed after the follow-up visits in the intervention arm (n=61; 16%) than 
in the control arm (n=25; 6%, chi-square p < 0.001). Presence of a visible lesion did not lead to 
a resection in 21 out of 88 (24%) and in 14 out of 47 (30%) follow-up visits in the intervention 
and control arm, respectively (chi-square p=0.45). 
Table 7.2 relates the number of histologically proven UC recurrences to cystoscopy results 
and to urine test outcome in both trial arms for those follow-up visits of which both cystos-
copy and urine test outcome data were available. The proportion of histologically proven 
recurrences was significantly higher (p< 0.001) for the follow-up visits where a positive urine 
outcome was communicated to the urologist (intervention arm, 42/131, 32%) compared 
to the proportion of recurrences while the urologist was blinded for a positive urine test 
outcome (6/120, 5%). On the other hand, such a difference was not observed (p=0.45) for 
follow-up visits with a negative urine test outcome in the intervention arm (18/260, 7%) and 
control arm (18/326, 6%). 
We also compared the performance of the urine test in both trial arms. Both if the analysis 
was done for all visits for which matched urine test and cystoscopy results were available 
(data not shown) or for those follow-up visits of the subset of patients whose cystoscopy was 
at the time of the MA test at the planned moments for cystoscopy (Table 7.3) the performance 
of the urine test in the intervention arm was much better than in the control arm. 
Difference between hospitals with or without residence-training
The three hospitals with a urologist residency-training program (two academic and one 
community hospital) had a higher UC detection rate than the seven community centres 
without training program, i.e. 22% (271/1251) and 16% (332/2128), respectively (p<0.001). 
The seven community hospitals without a residency program had UC detection rates of 17% 
(195/1126) and 14% (137/1002) in the intervention and control-arms, while these numbers 
were 23% (141/616) and 21% (130/635) for the 3 hospitals with a residency training program, 
respectively. 
Table 7.2
Urine test result Trial arm
Number of follow-up 
visits
Number of recurrences (%) P value*
positive
intervention 131 42 (32)
< .0001
control 120 6 (5)
negative
intervention 260 18 (7)
.45
control 326 18 (6)
* Pearson Chi-Square Test
Distribution of histologically confirmed UC recurrences according to MA outcome and trial arm detected in 837 follow-up moments for which 
both MA and cystoscopy results were available.
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Discussion
We found an increased number of recurrences by cystoscopy if information of a positive urine 
test was communicated to the urologist, but not if the result was kept blinded. If our analysis 
was restricted to the follow-up visits of the patients in which cystoscopy was planned next 
to the MA test, at the moments, we continued to discover more recurrences in the unblinded 
arm (Table 7.3). Hence, the increased detection rate in the unblinded study arm (‘interven-
tion arm’) could not be attributed to ascertainment bias , but to diagnostic review bias (12). 
The positive urine test outcome may have changed the interpretation of the urologist of 
the findings during cystoscopy and/or increased the scrutiny of the cystoscopic examination 
resulting in the much higher number of histologically proven recurrences. In the blinded 
control arm no difference was observed between urine test positive (5%) and urine test nega-
tive (6%) follow-up visits. 
The randomized design with a relatively large number of included patients allowed a reli-
able comparison of the number of recurrences detected in each trial arm. A limitation of our 
study is the modest compliance to the designed follow-up protocol, and informative urine 
samples were obtained only in 1073 / 3379 (32%) of the time a cystoscopy was performed. 
3B
Test arm; urine test results were communicated to urologists before cystoscopic examination
Urine test outcome UCC recurrence No UCC recurrence Total
Positive 20 45 65
Negative 8 105 113
Total 28 150 178
Table 7.3
Comparison of accuracy of microsatellite analysis in the two trial arms
3A. Control arm; urine test results were blinded for urologists
Urine test outcome UCC recurrence No UCC recurrence Total
Positive 0 53 53
Negative 10 164 174
Total 10 217 227
Sensitivity 71% (20/28) 95% CI [0.51-0.87]
Specificity 70% (105/150) 95% CI [0.62-0.77]
Positive Predictive Value 31% (20/65) 95% CI [0.19-0.43]
Negative Predictive Value 93% (105/113) 95% CI [0.87-0.97]
Sensitivity 0% (0/10) 95% CI [0.0-0.26]
Specificity 76% (164/217) 95% CI [0.69-0.81]
Positive Predictive Value 0% (0/53) 95% CI [0.0-0.06]
Negative Predictive Value 94% (164/174) 95% CI [0.89-0.97]
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The reduction in number of cystoscopies in the intervention arm as anticipated during the 
study design was not achieved and a lack of compliance by both patients and urologists 
may have contributed to this observation. Patients participating in the trial did not consider 
cystoscopy as very burdensome and they prefered to have an immediate result at the time 
of cystoscopy rather than to wait for a week for the outcome of the urine test (13)It is strik-
ing that the number of cystoscopically detected recurrences was also larger (n=33) during 
follow-up visits in the intervention arm when the synchronous urine test outcome was not 
available. Many of the patients with a recurrence had a positive urine test result antedating 
the follow-up visit at which the cystoscopy was performed (10) and knowledge of a positive 
urine test in the same patient, several months prior to the cystoscopy may also have influ-
enced cystoscopy findings. 
Importantly, the increased number of recurrences associated with the awareness of a posi-
tive urine test outcome was not associated with an increased false detection rate of recur-
rences by cystoscopy in the intervention arm. The false detection rate in both arms (12%,16%) 
is in the same range as previously reported for cystoscopy in other European series (13, 14). 
Supplemental table 7.3
Interventions during 837 follow-up visits when MA outcome was available at time of cystoscopy in the UCS-MA (A) and UCS (B) arm
A. UCS-MA Group:  MA results communicated to the urologist 
MA result
Cystoscopy result
+
+
-
+
+
-
-
-
Total
Decision no treatment
Continue Fup 0 0 75 221 296
Continue Fup despite a visible lesion in bladder 8 12 1 0 21
Treatment and additional diagnostics
Outpatient clinic coagulation 1 2 0 0 3
Random Biopsy 2 4 0 0 6 
Trans Urethral Resection (TUR) 39 19 1 2 61
Upper Urinary Tract lesion 1 0 3 0 4
Total number of follow-up visits 51 37 80 223 391
B. UCS-group: MA results NOT communicated to the urologist 
MA result
Cystoscopy result
+
+
-
+
+
-
-
-
Total
No treatment 
Continue Fup 0 0 101 297 398
Continue Fup despite a visible lesion in bladder 11 3 0 0 14
Treatment and additional diagnostics
Outpatient clinic coagulation 0 2 0 0 2
Random Biopsy 1 6 0 0 7 
Trans Urethral Resection (TUR) 7 17 0 1 25 
Total number of follow-up visits 19 28 101 298 446
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We also noted that the diagnostic review bias was somewhat more pronounced in the 
community hospitals without urologist-residency training program, implying a lower accu-
racy of the cystoscopy in these hospitals as compared to the three hospitals (including two 
academic hospitals) with a residence training program.  
Several attempts are now being made to improve the sensitivity of cystoscopy for papillary 
and flat lesions of the urinary bladder by using photodynamic diagnosis. Photosensitizers 
proved their use in enhancing the visual demarcation between normal and neoplastic tissue 
(13-15). Therefore photodynamic cystoscopy has been used as a tool to assess the sensitivity 
of white light cystoscopy for the detection of papillary and flat lesions. In two studies, white 
light cystoscopy was performed first, followed by fluorescence cystoscopy on the same set of 
patients and both reported a sensitivity of white light cystoscopy and fluorescence-guided 
cystoscopy of respectively 83% and 95% (15, 16) for detection of papillary UC if analysed per 
lesion, and 97% and 100% respectively if analysed per patient (16). Our study points at much 
lower levels of sensitivity of cystoscopy, raising further doubt about the value of cystoscopy 
as the gold standard for UC recurrences. Probably, the threshold of urologists to decide 
whether a lesion observed during cystoscopy represents an urothelial neoplasm could be 
Figure 7.2
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lowered, triggering more frequent transurethral resections. Alternatively, ancillary detection 
techniques like our urine test may be of benefit to enhance the visibility and discrimination of 
urothelial neoplasms, providing a new gold standard for detection of these lesions. 
Obviously, an important remaining question is whether the additional UC detected in the 
intervention arm represented clinically relevant tumours. A few papers have reported the 
lack of clinical impact of early detected recurrences raising the possibility that such lesions 
are amenable for expectant management (15,16). Comparison of the urinary bladder UC 
detected in both arms did not reveal differences in grade and stage contribution (data not 
shown). However, the only 3 carcinomas in situ detected by cystoscopy during follow-up 
were in the intervention arm. Further, fluorescence cystoscopy studies have shown that 
improved bladder cancer detection during surveillance may reduce long-term recurrence 
rates and costs of treatment (15).
We conclude that communication of a positive urine test outcome to the urologist is associ-
ated with a substantial diagnostic review bias. This will lead to an underestimation of the 
sensitivity of a urine test when the urologist is blinded for a positive test outcome while per-
forming cystoscopy. As a consequence, the interpretation of the results of (newly developed) 
point of care urine tests should take this potentially strong bias into account. In addition, 
our resutls question the value of cystoscopy as the gold standard for detection of NMI UC 
recurrence. 
ZON-MW, The Netherlands Organization for Health Research and Development, funded this 
study grant number 945-02-046. The funding source had no involvement in the trial.
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Abstract
Patients with non-muscle invasive low-grade (pTa / pT1, G1/G2) urothelial cell carcinoma of 
the urinary bladder are recommended to adhere to regular urethrocystoscopic surveillance 
(UCS). We assessed patients’ perceived burden of flexible cystoscopy.
A total of 220 participants of a randomized trial comparing cystoscopic examination and 
surveillance by microsatellite analysis (MA) in voided urine were asked to fill out question-
naires one week after cystoscopy or urine sample collection. We assessed discomfort and 
pain as experienced during cystoscopy, experiences with MA and the waiting time for the 
result, and physical symptoms, medical consumption and general functioning. We analysed 
data from 732 questionnaires (197 patients) completed after cystoscopy and 184 question-
naires (67 patients) after collection of urine. Introduction of the cystoscope was reported 
to cause discomfort in 39% and pain in 35% of questionnaires. Collection of urine was not 
burdensome, but the waiting time for the results was reported as burdensome in 19%. Painful 
micturition was significantly more frequent in the week after cystoscopy than after MA (30% 
and 11%, respectively). The frequency of fever (1% and 2%) and haematuria (7% and 6%) was 
similar in both groups. Older patients reported significantly less pain and discomfort from 
cystoscopy, and this was not related to a larger number of previous cystoscopies. Flexible 
cystoscopy was quite burdensome in about one third of cases. The results of the present 
study are a further motivation in the search for less invasive surveillance tests.
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Introduction
Bladder cancer is the fifth most common malignancy in Europe and the fourth most common 
malignancy in the United States. It affects one in 4000 people and accounts for 5% of all 
diagnosed cancers1. In 80% of the patients the bladder tumour will primarily appear as a pap-
illary non-muscle invasive urothelial cell carcinoma (UC). The clinical course of non-muscle 
invasive (pTa and pT1) papillary UC is characterized by a high tendency to recur (up to 70%) 
and a propensity to progress in grade (10-30%) or stage (10-15%)2, 3. Therefore, patients are 
recommended to adhere to regular cystoscopic surveillance (UCS). The European Associa-
tion of Urology (EAU) recommended 2 cystoscopies in the first year after diagnosis and then 
annual cystoscopies for up to five years in low-risk patients, but considerable practice varia-
tion is observed4. The effectiveness of cystoscopy on survival has been shown5-8. However, 
cystoscopy is an invasive procedure that may be associated with pain and discomfort. No 
studies systematically evaluated the impact of cystoscopy as perceived by patients9-13. The 
present study aimed at evaluation of the impact or burden of cystoscopy as perceived by 
patients under UCS in a randomized comparison with patients monitored by microsatellite 
analysis of urinary samples (MA). 
Methods 
Patients
This questionnaire study was part of a randomized clinical trial evaluating the cost-effective-
ness of surveillance of patients with non-muscle invasive bladder cancer (CEFuB-trial) by mic-
rosatellite analysis (MA) of urinary samples for detection of cells with loss of heterozygosity in 
the DNA extracted from voided urine samples14, 15 compared with conventional cystoscopic 
surveillance (UCS). The trial recruited patients with non-muscle invasive bladder cancer (pTa, 
pT1, G1/G2) from 14 centres in The Netherlands (2 teaching hospitals, 12 general hospitals) 
after informed consent. Patients were randomized into two groups: the UCS group, where 
patients had 3-monthly cystoscopy during 24 months; and the MA group, where patients 
had 3-monthly analysis of voided urine samples during 24 months. In the MA group, patients 
also had cystoscopy at 3, 12 and 24 months, and in case of a positive MA-test result. For the 
empirical evaluation of the burden of cystoscopy, a total of 220 patients from 10 centres from 
both trial arms were asked to fill out questionnaires at one week after cystoscopy or one week 
after collection of a urine sample for MA in the period between July 2003 and January 2006. 
Ethics approval
The Medical Ethical Review Board of Erasmus MC – University Medical Center Rotterdam, The 
Netherlands, approved of the study.
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Cystoscopy procedure
All patients underwent cystoscopy in lithotomy position with flexible cystoscopes for adults. 
Before introduction, the tip of the cystoscope was covered with an installation gel containing 
lidocaine. The result of the cystoscopy was communicated to the patient directly after the 
procedure.
MA procedure
Patients collected a urine sample in a vial during a scheduled visit at the outpatient clinic. The 
result of the MA was communicated to the patient by the urologist two weeks after delivery 
of the urine sample. 
Questionnaires 
Discomfort and pain during cystoscopy (Cystoscopy questionnaire)
Discomfort and pain were assessed by separate series of 4 items each for the 4 stages of the 
procedure: the preparation for the cystoscopy, the introduction of the cystoscope, undergo-
ing the cystoscopy itself, and the hours directly after cystoscopy. Subjects were offered three 
response options (‘not’, ‘quite’ and ‘very’ painful or discomforting, respectively). Items were 
adapted from earlier studies16-18. 
Discomfort during MA procedure (MA questionnaire)
We assessed patients’ experienced discomfort with urine collection, delivery at the outpa-
tient clinic and the waiting period for the test result using similar items with three response 
options (‘not’, ‘quite’ or ‘very’ discomforting).
Physical symptoms and medical consumption in the week after cystoscopy / delivery of 
urine sample (both questionnaires)
We assessed occurrence and duration of painful micturition, urge and frequency symptoms 
and haematuria in the first week after cystoscopy / urine delivery with items with 3 response 
options (‘no’, ‘yes, < 7 days’, ‘yes, > 7 days’). The occurrence of fever (> 38 degrees Celsius) was 
asked with a yes / no response format; if ‘yes’, patients were requested to enter the number 
of days. The need for medication (oral analgesics and antibiotics), and whether a general 
practitioner had been consulted for problems related to the cystoscopy or bladder problems 
(MA group) in the subsequent week were asked with a yes/no response format. 
Impact on general functioning (both questionnaires)
Patients’ general functioning in the week after cystoscopy or urine delivery for MA was as-
sessed as the perceived impact of the cystoscopy or MA procedure, respectively, on daily 
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activities and social life in the week afterwards using two separate items with five response 
options (‘not at all’, ‘little’, ‘quite’, ‘lots’ and ‘all the time’.) 
Patient satisfaction (both questionnaires)
Satisfaction regarding the reception at the outpatient clinic, waiting time at the outpatient 
clinic, explanation of the procedures were assessed with 3 items with 3 response options 
(‘not’, ‘quite’ and ‘very’ satisfied). Items were based on previous work19. 
Determinants of perceived pain and discomfort, physical symptoms, general functioning 
and satisfaction(both questionnaires)
Data on age, gender, type of hospital (teaching or general), number of previous cystoscopies 
in an outpatient setting (cystoscopy experience), and number of previous Trans Urethral Re-
sections (TURs) of non-muscle invasive bladder cancer (procedures requiring hospitalisation) 
were obtained from the case record forms of the CEFuB-trial. 
Statistics
We analysed pain, discomfort, overall burden, physical symptoms, medical consumption, 
general functioning and satisfaction after cystoscopy or urine delivery for MA using all data 
from all questionnaires that were completed. The correlation between assessments from the 
same person was taken into account by using formal multilevel analysis (ProcMixed with 
REML, SAS version 9.1, SAS Institute Inc, Cary NC).  
We estimated overall burden of either cystoscopy or MA by averaging item scores for pain 
and discomfort as experienced during cystoscopy, or the MA procedure, respectively. The 
averaged overall burden of cystoscopy consisted of the items on pain and discomfort related 
to introduction of the cystoscope, undergoing the cystoscopy and the period immediately 
afterwards (Cronbach’s alpha = 0.88; scoring range 1 (no burden) - 3 (much burden)). The 
average overall burden of the MA procedure consisted of the sum of the ratings of discomfort 
experienced during collection of the urine sample, delivering the sample at the outpatient 
clinic, and the waiting for the test result. 
We analysed the effects of determinants (age, gender, number of previous cystoscopies, 
number of previous TURs, and type of hospital on overall burden, physical symptoms (average 
score of 4 items on painful micturition, urge, fever and haematuria), medical consumption 
(average score of 3 items on pain medication or antibiotics and general practitioner visits), 
general functioning (average score of 2 items on daily and social functioning) and satisfaction 
(average score of 3 items for reception, waiting time and explanation) in univariate analyses 
using Spearman’s ρ (using SPSS release 11.0.1 (SPSS Inc., Chicago, IL). We corrected for depen-
dency in the data by using the ProcMixed procedure of SAS. P-values < 0.05 were considered 
statistically significant. Additionally, we analysed correlations between the determinants and 
a number of specific separate items. 
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Results 
Response
A total of 201 out of 220 patients (92%) filled out at least one questionnaire. Of these 201 re-
spondents, 108 had been randomized into the UCS-arm and 93 into the MA-arm. Subjects in 
the MA-arm underwent either MA analysis or cystoscopy at different moments during follow-
up, and 62 of 93 subjects from the MA arm completed questionnaires both after cystoscopy 
and after MA. A total of 916 questionnaires were available for analysis: 732 questionnaires 
filled out by 197 patients after cystoscopy (mean 3.6 questionnaires per patient, range 1 to 8) 
and 184 questionnaires filled out by 67 patients after collection of urine (mean 2.8 question-
naires per patient, range 1 to 5). The characteristics of patients in both arms were very similar 
(Table 8.1).
Discomfort and pain as experienced during the procedure
Table 8.2 shows the percentages of reported discomfort and pain as experienced during the 
subsequent stages of cystoscopy and the MA procedure. The introduction of the cystoscope 
was considered most frequently as burdensome, being at least ‘quite’ discomforting in 
273/697 (39%) and at least ‘quite’ painful in 240/695 (35%) of the questionnaires. Spearman 
correlations between pain and discomfort scores for the same stage of cystoscopy were 0.7 
or higher, indicating that many subjects who reported discomfort for e.g., introduction of the 
scope, also reported this stage of cystoscopy to be burdensome. 
Table 8.1
Characteristics of 201 patients with papillary urothelial cell carcinoma included in the CEFuB trial and participating in the questionnaire study.
UCS MA
Response 99% (108/110) 85% (93/110)
Gender Male 73% (79/108) 77% (72/93)
Previous cystoscopies 1 15% (16/108) 22% (20/93)
2-5 41% (45/108) 34% (32/93)
> 5 44% (47/108) 44% (41/93)
Previous TURs 1 67% (72/108) 50% (47/93)
2-5 23% (25/108) 38% (35/93)
>5 10% (11/108) 12% (11/93)
Age (years) Mean (SD) 68.3 (13.0) 68.2 (11.5)
UCS = urethrocystoscopic surveillance group
MA = microsatellite analysis (in voided urine) group
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For MA, the period of waiting for the results of the urinary test was reported as at least 
‘quite’ discomforting in 31/161 (19%) questionnaires. As expected, urine collection and deliv-
ery were not associated with discomfort.
Averaged overall burden of cystoscopy was 1.33 (standard error 0.017), of MA 1.09 (stan-
dard error 0.017), p-value of the difference <0.001. Among 48 patients for whom we had 
complete data on pain and discomfort after a cystoscopy and of an MA procedure, averaged 
overall burden of cystoscopy was 1.37 and of MA 1.09 (p<0.001, paired sample t-test). 
Physical symptoms in the first week after cystoscopy / urine sampling
Painful micturition was reported in 219/719 (30%) of the questionnaires after cystoscopy 
and in 21/176 (12%) of the questionnaires after collection of urine (p<0.001). Symptoms of 
urge and frequency were reported in 243/715 (34%) and 45/177 (25%) of the questionnaires 
after cystoscopy and MA, respectively (p=0.09, Table 8.2). Haematuria and fever occurred 
infrequently (Tables 8.2 and 8.3). 
Medical consumption in the week after cystoscopy / urine collection
Use of pain medication or antibiotics after cystoscopy was reported in 23/714 (3%) and 
69/719 (10%) of the questionnaires, respectively, and in 9/175 (5%) and 18/177 (10%) of 
the questionnaires completed in the MA procedure. The general practitioner was consulted 
Table 8.2
Frequency of pain and discomfort experienced during cystoscopy and physical symptoms in the week after cystoscopy (data from 732 
questionnaires)
No Quite Very n
Discomfort
Preparation 614 (85.9%) 89 (12.4%) 12 (1.7%) 715
Introduction 424 (60.8%) 229 (32.9%) 44 (6.3%) 697
Undergoing 472 (67.9%) 193 (27.8%) 30 (4.3%) 695
Hours after 
cystoscopy 
517 (73.8%) 151 (21.5%) 33 (4.7%) 701
Pain
Preparation 673 (94.0%) 41 (5.7%) 2 (0.3%) 716
Introduction 455 (65.5%) 215 (30.9)% 25 (3.6%) 695
Undergoing 544 (77.9%) 135 (19.3%) 19 (2.7%) 698
Hours after 
cystoscopy
535 (76.2%) 152 (21.7%) 15 (2.1%) 702
1 week after cystoscopy No Yes, < 7 days Yes, > 7 days
Painful micturition 500 (69.5%) 206 (28.7%) 13 (1.8%) 719
Urge and frequency 472 (66.0%) 194 (27.1%) 49 (6.9%) 715
Fever > 38C 709 (98.7%) 9 (1.3%) 0 718
No Yes, some Yes, a lot
Haematuria 664 (92.5%) 47 (6.5%) 7 (1.0%) 718
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infrequently in the week after either procedure (8/721 after cystoscopy (1%) and 3/177 in the 
MA group (2%)).
General Functioning
After cystoscopy, at least ‘a little’ impact on daily activities was reported in 134/720 (19%) of 
questionnaires, and at least ‘a little’ impact on social activities was reported in 86/723 (12%). 
Similar results were reported after MA: 33/175 (19%) reported at least ‘a little’ impact of the 
MA procedure on daily activities and 25/173 (14%) on social activities.
Satisfaction
Dissatisfaction with the reception at the outpatient clinic, the waiting time for cystoscopy, 
and the explanations by the staff was reported in 13/718 (2%), 51/709 (7%) and 25/710 (4%) 
of the questionnaires completed after cystoscopy. For MA these figures were 12/157 (8%), 
13/173 (8%) and 20/167 (12%), respectively. 
Determinants of burden of cystoscopy or MA 
Averaged overall burden of cystoscopy (ρ=-0.16, p<0.001) and of MA (ρ=-.23, p=0.024) cor-
related only significantly with age. This significant correlation of overall burden of MA was 
attributable to the waiting time for the result (ρ=-0.17, p=0.03)
The correlation of overall burden of cystoscopy with the other determinants, including 
the number of previous cystoscopies and gender, were non-significant. The significant cor-
relation of reported burden with age was not attributable to a larger number of previous 
cystoscopies. Regarding specific aspects of the cystoscopy, men did not report significantly 
more burden from either introducing or undergoing the cystoscopy than women. 
Physical symptoms, medical consumption and general functioning in the week afterwards 
were not correlated with any of the determinants investigated. Satisfaction correlated signifi-
cantly with age (ρ=0.19, p<0.001). 
Table 8.3
Frequency of discomfort and physical symptoms in the week after delivery of urine for MA analysis (data from 184 questionnaires) 
 No Quite Very n
Discomfort
Collection 158 (98.1%) 2 (1.3%) 1 (0.6%) 161
Delivery 168 (97.6%) 4 (2.4%) 0 172
Waiting for result 130 (80.7%) 24 (14.9%) 7 (4.3%) 161
 1 week after urine collection No Yes, < 7 days Yes, > 7 days
Painful micturition 155 (88.1%) 19 (10.8%) 2 (1.1%) 176
Urge and frequency 132 (74.6%) 30 (16.9%) 15 (8.5%) 177
Fever > 38C 175 (98.3%) 3 (1.7%) 178
No yes, some yes, a lot
Haematuria 166 (93.3%) 10 (5.6%) 2 (1.1%) 178
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Increasing age was associated with less reported overall burden of cystoscopy, and less 
discomfort from the waiting time for the result of MA analysis. Older subjects were more 
satisfied with the procedure. The correlations were however rather low. 
Discussion
We analysed the burden of cystoscopy as perceived by patients under regular surveillance 
for non-muscle invasive UC during the different stages of cystoscopy and in the subsequent 
week. We found that cystoscopy was reported to be associated with pain and discomfort 
in about one-third of the questionnaires. In comparison with patients who underwent 
MA analysis of voided urine as surveillance test, the average overall burden reported after 
cystoscopy was significantly higher that after MA. The MA group was considered an appropri-
ate control group as they shared the same underlying disease and the randomized design 
precluded selection bias. Burden of MA appeared fully attributable to the waiting time for 
the test result. 
The burden of cystoscopy was most related to the introduction of the cystoscope, which 
was frequently reported to cause pain and discomfort. Herr et al reported an average pain 
score of 2 on a 10-point visual analogue scale ranging from 1 (no pain) to 10 (most pain) for 
men with non-muscle invasive bladder cancer who underwent  flexible cystoscopy13. In our 
study, men did not report more pain and discomfort in association with the introduction of 
the cystoscope than women. In the study by Vriesema et al 56/85 (66%) of patients reported 
urethrocystoscopy to be bothersome, which was also similar for male and female patients9. 
We found a weak but significant inverse association of overall burden of cystoscopy and age, 
while Vriesema found no such association9. 
Cystoscopy is an invasive procedure, but the test result is immediately available to the pa-
tient. With MA analysis patients have to wait 10 – 14 days for the test result, and if it is positive, 
they are referred for cystoscopy in second instance. Vriesema et al9 showed that patients 
may not easily exchange cystoscopic surveillance for a less sensitive method for detection of 
recurrences, even if the latter is associated with much less discomfort. In their study, patients 
were offered two alternative surveillance tests (cystoscopy and a hypothetical test based 
on urinary analysis). If the sensitivity of the urinary test fell below 90%, 89% of the patients 
would prefer flexible cystoscopy for surveillance of non-muscle invasive bladder cancer. Thus, 
patients seem to choose for the safe side. If there is a recurrence, they want their surveillance 
test to detect it, even if it means that they have to undergo an invasive surveillance test. 
Micturition was reported to be painful in the week after cystoscopy in about 30% of the ques-
tionnaires, suggesting an effect of the cystoscopy. However, the 12% prevalence of painful 
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micturition in the MA group was unexpectedly high and goes sofar unexplained. Non-muscle 
invasive bladder cancer is not associated with irritative voiding symptoms. Symptoms of 
urge and frequency of voiding were reported to be about equally prevalent in the week after 
cystoscopy and delivery of a urine sample for MA. Fever and haematuria were not reported 
more frequently after cystoscopy than after MA. 
In the comparison of our results with the few other reported empirical studies on the burden 
of cystoscopy, the association of symptoms after cystoscopy with the underlying disease must 
be kept in mind. Kortmann evaluated 103 men with lower urinary tract symptoms undergo-
ing urodynamic evaluation with or without flexible cystoscopy11. Fifty-six % of the men in this 
study reported urge symptoms after urodynamic evaluation combined with cystoscopy. After 
urodynamic evaluation alone, 29% reported voiding discomfort, after urodynamic evaluation 
+ cystoscopy this was 35%. 
Denholm compared flexible and rigid cystoscopy in the early years after the introduction 
of the technique of the flexible cystoscopy. In this study, 89% of patients who underwent 
flexible cystoscopy for various reasons reported it to be painless, and 33% of them had physi-
cal symptoms in the week afterwards12. 
We showed further that surveillance by itself had an impact on patients, regardless of the 
surveillance test. Similar proportions of patients from both arms reported an impact on daily 
life and social life, irrespective of having undergone cystoscopy or MA. This seems to confirm 
the findings from the study reported by Yoshimura, who found that Japanese patients with 
non-muscle invasive bladder cancer had significantly impaired general health perceptions 
and mental health. However, mental health appeared to return to normal in patients with a 
longer history of disease. Yoshimuri et al concluded that, despite the favourable prognosis of 
non-muscle invasive bladder cancer, urologists should be aware of the considerable effect on 
patients’ general health-related quality of life20. 
Our study has some limitations. The general functioning scores of our study may be affected 
by the timing of the assessments: at the time of completion, the results of cystoscopy were 
known to the subjects, whereas the MA result was still to be expected. The bother of the test 
itself is only one part of the burden of surveillance. The present report does not elaborate 
on the burden caused by being a bladder cancer patient and awareness of the prognosis of 
bladder cancer. 
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Conclusion
The clinician must be aware of the burden that is caused by cystoscopy of patients with 
non-muscle invasive bladder cancer. Patients will adhere to cystoscopic surveillance as long 
as cystoscopy is considered the golden standard; however, the test itself was reported to 
cause pain and discomfort in one third of the cases. We need to find alternative surveillance 
tests, diagnostically as good as or better than this invasive and truly burdensome procedure. 
The present study underscores and emphasizes the need for new less invasive methods for 
surveillance and hopefully encourages both scientists as urologists to continue this search.
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Abstract
Patients just diagnosed with non-muscle invasive bladder cancer (NMI UC) have the prospect 
of an intensive surveillance scheme by urethrocystoscopy (UCS) in order to detect tumour 
recurrences. Sexual dysfunction associated with this urological condition is commonly over-
looked. We aimed to describe the prevalence of sexual dysfunction in this patient population 
and evaluated risk factors.  We performed a cross-sectional survey on 150 patients just diag-
nosed with primary or recurrent NMI UC. Patients were participating in a randomized clinical 
multicenter trial (CEFuB), comparing two surveillance schemes. Patients were asked to fill in 
questionnaires at study entry 3 months before the start of the study-surveillance scheme 
(Demographic characteristics, validated Visual Analog Scale and validated subset of ques-
tions concerning sexual function and performance derived from QLQ-BLS-24). Results were 
compared to the age-matched healthy population. The response rate was 95% (142/150). A 
total of 61% (87/142) of the respondents was sexually active in the past four weeks after diag-
nosis, 66% of  (70/105) males and 46% (17/37) of females. Although libido was not negatively 
affected, 54% (47/87) of the patients experienced sexual dysfunction, 23% (17/73) was afraid 
to inflict harm to their partner by sexual contact. Sexually active patients perceive a higher 
state of general health (p=.03). The prevalence of sexual dysfunction in patients with NMI UC 
is very high (54%) compared to an age and gender matched healthy population (20-45%). 
No predictors for sexual dysfunction were found. These patients and partners would benefit 
from proper sexual information in the outpatient clinic.
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Introduction
Bladder cancer is the fifth most common malignancy in Europe and the fourth most com-
mon malignancy in the United States. It affects one in 4000 people and accounts for 5% of 
all diagnosed cancers1. In 80% of the patients the bladder tumour will primarily appear as 
a papillary non-muscle invasive (stage pTa and pT1) urothelial carcinoma (NMI UC). Up to 
70% of these tumours will recur and 15% will progress in stage or grade2. Therefore, patients 
are recommended to adhere to regular cystoscopic surveillance (UCS). Besides patients with 
recurrent disease experience repeated transurethral resections and intravesical chemo / im-
munotherapy may be required to treat recurrences. Although the effectiveness of cystoscopy 
on survival has been shown3-6, several studies have proven that cystoscopy is an invasive 
procedure that is perceived as burdensome and is associated with pain and discomfort6-12. 
Research of the impact on sexual function in patients with bladder cancer is limited and 
mostly focused on the treatment modalities of muscle invasive UC by cystectomy. Allareddy 
reported an adverse effect in sexual function after cystectomy in patients with muscle invasive 
bladder cancer13. However, less is known of the sexual function in patients under surveillance 
with non-muscle invasive UC. A study by Stav et al showed that rigid cystoscopy, performed 
on males and females, transiently impairs functional sexual performance and libido in sexu-
ally active patients14. The present cross-sectional questionnaire study aimed to describe the 
sexual function in patients who are just diagnosed with primary or recurrent NMI UC and 
face a 3-monthly intensive surveillance scheme. Prevalence of sexual dysfunction and sexual 
activity was compared to age and gender matched healthy populations. Furthermore we 
aimed to identify risk factors for sexual dysfunction.
Patients and Methods
Patients
We performed a cross-sectional questionnaire survey of sexual function in patients just 
diagnosed with primary or recurrent NMI UC prior to initiation of a surveillance protocol. This 
questionnaire study was part of a randomized controlled clinical trial (registration: ClinicalTri-
als.gov NCT00126958) evaluating the cost-effectiveness of surveillance of patients with NMI 
UC (CEFUB trial). A total of 448 patients with NMI UC (i.e. TNM 1997 stage pTa, pT1, and WHO 
1973 grade 1 or 2) were recruited by 10 Dutch hospitals for participation after signing an 
informed consent form. In this questionnaire study we approached a subset of 150 patients 
in 7 hospitals who participate in the CEFUB trial and included patients randomly assigned 
by appearance in a period from July 2004 till September 2006. Patients were asked to fill in 
questionnaires at start of surveillance less than 3 months after diagnosis of primary or recur-
rent NMI UC. Patients in both randomized groups were monitored and treated equally at this 
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point. Data on age, gender, history of recurrent UC and intra-vesical therapy were obtained 
from the case record forms of the CEFUB trial. 
Ethics Approval
The Medical Ethical Review Board of Erasmus MC - University Medical Center Rotterdam, and 
Leids University Medical Center, Leiden, The Netherlands, approved of the study.
Cystoscopy Procedure
All patients were monitored with surveillance by cystoscopy in lithotomy position. Flexible 
17 Charier cystoscopes were used for male patients and rigid 20 Charier scopes for female 
patients. Before introduction, male urethra was instilled with 20cc lidocaine containing jelly 
or the tip of the rigid scope was covered with the lidocaine containing jelly. The result of the 
cystoscopy was communicated to the patient directly after the procedure. 
Questionnaires 
Visual Analog Scale (VAS) 
We assessed patients’ opinion about their general state of health by using a vertical posi-
tioned graduated ruler scaled from 0-100% (a validated generic health-related quality of life 
(HRQOL) instrument). Patients in both groups were asked to draw a line from a point left of 
the ruler to the experienced percentage of their present state of health.
Sexual function
We assessed patients’ sexual life using a validated subset of 8 questions concerning sexual 
performance (erectile and ejaculatory function in male, level of lubrication in females) and 
function and libido (interest, enjoyment, level of activity, fear harming the partner) extracted 
from the EORTC QLQ-BLS 24 questionnaire.  Subjects were offered four response options (‘not 
at all’, ‘rather’, ‘a little’ and ‘very’). The appendix lists the different questions. 
Statistics
We analysed all data using SPSS release 11.5 (SPSS Inc., Chicago, Ill). We analysed patients’ 
assigned health state and sexual function using all data from all questionnaires that were 
completed. Differences in sexual activity (yes/no) between gender and smoking behaviour 
were analysed by Chi-square Test, between Age and score on the VAS by Students T Test and 
between the demographic variables by One-way ANOVA Test. Relation between various clini-
cal characteristics and the fear to inflict harm to their partner by sexual contact is analysed by 
Students T Test (age, VAS, number of recurrences) and by Chi-square Test (gender, intravesical 
therapy (yes/no), history (just diagnosed with a primary tumour / with recurrent tumour), 
sexual performance and libido). P-values < 0.05 were considered statistically significant.
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Results
A total of 142 out of 150 patients (95%) completed the questions concerning sexual contact 
in the past four weeks. 61% (87/142) of the respondents was sexually active in the past four 
weeks. Table 9.1 shows the demographic characteristics related to the sexual activity. Males 
showed significantly more sexual activity than females (chi square test; p=.02). Aging has 
a negative effect on sexual activity (independent students T-test; p=.02). Noticeable is the 
significantly higher perception of general health state in patients who are sexually active 
(independent students T-test; p=.03). Reasons for sexual inactivity were related to the 
single status, disablement and aging. Table 9.2 lists the perceived sexual function in the 87 
sexual active patients according to 70 males and 17 females. Although the libido (interest in 
sexual contact) of the majority of the respondents was not scored as negatively affected, 54% 
(47/87) of the patients experienced some degree of erectile dysfunction or problems with 
Table 9.1
Demographic characteristics of 142 patients with diagnosis of NMI UC concerning sexual activity 
Characteristics of 142 patients
Sexual Non-active
(n=55)
Sexual Active
(n=87) p value
Gender
Male 35 (33%) 70 (67%)
.02Female 20 (54%) 17 (46%)
Age
Mean ± sd in years 69 ± 12 65 ± 10
.02Median [range] in years 72 [35-89] 66 [37-83]
Smoke
Yes 45 (38%) 75 (62%)
.4No 9 (47%) 10 (53%)
Education
Vocational Education 14 (45%) 17 (55%)
.3
Secondary school 17 (39%) 27 (61%)
Advanced secondary school 7 (41%) 10 (59%)
Higher Vocational Education 10 (29%) 24 (71%)
University 6 (40%) 9 (60%)
Marital Status
Married / Cohabitation 37 (33%) 75 (67%)
.1
Single 4 (80%) 1 (20%)
Divorced 5 (42%) 7 (58%)
Widow (-er) 7(78%) 2 (22%)
Current domestic situation
Together 34 (33%) 68 (67%)
.006
Together + kids 4 (29%) 10 (71%)
Single 15 (68%) 7 (32%)
Profession
Steady job 10 (25%) 30 (75%)
.5
Voluntary job 6 (46%) 7 (54%)
Disablement Insurance Benefit 7 (78%) 2 (22%)
Retirement 32 (40%) 48 (60%)
VAS Mean ± sd 78 ± 14 84 ± 12 .03
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Table 9.2
Sexual function in 87 sexually active males and females with NMI UC 
Sexual Function
Female
(n=17)
Male
(n=70)
Total
(%)
Interest in sexual contact
Yes 15 62 89%
No 2 7 11%
Erectile or Vaginal* Dysfunction
Yes 7 40 55%
No 9 29 45%
Trouble ejaculation
Yes 25 35%
No 44 65%
Uncomfortable thinking of sexual contact
Yes 2 10 17%
No 14 46 83%
Afraid to harm your partner
Yes 3 14 24%
No 13 43 76%
Enjoyed sex
Yes 15 56 93%
No 1 4 7%
* non-lubricating vagina
Table 9.3
Characteristics of 73 sexually active patients related to the fear to inflict harm to their partner by sexual contact 
Afraid to harm their partner by sexual contact
Not afraid
(n=56)
Afraid
(n=17) p value
Clinical Characteristics
Age in years Mean ± sd 64 ± 11 63 ± 7 .6
VAS in % Mean ± sd 84 ± 13 86 ± 10 .5
Number of recurrences Mean ± sd 1.7 ± 1.5 1.7 ± 1.1 .9
Gender
Male 43 14
.6Female 13 3
IV
No 45 17
.04Yes 11 0
History
Primary 40 12
.9Recurrent 16 5
Sexual performance and libido
Interest
Yes 56 12
< .000No 0 5
Uncomfortable with thought of sexual contact
Yes 7 5
.07No 49 12
Erectile or Vaginal* Dysfunction
Yes 26 10
.5No 30 7
* non-lubricating vagina
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vaginal lubrication. Thereby 23% (17/73) of the sexually active patients answered to be afraid 
to inflict harm to their partner by sexual contact; 85 patients answered this latter question, 
12 were sexually inactive (9 males, 3 females). We found that three of the sexual inactive 
patients (3/12, 25%) were afraid to harm their partner; all three were males and reported to 
be sexually interested (Table 9.3). Questionnaires revealed that 12/73 (16%) patients were 
uncomfortable with the thought of sexual contact, in 42% (5/12) was this thought related to 
the fear to harm their partner in sexual contact (p= .07). 
Discussion
The present cross-sectional questionnaire study aimed to describe the prevalence of sexual 
dysfunction and its components associated with the diagnosis of primary or recurrent NMI 
UC and the prospect of a 3-monthly intensive surveillance scheme. Our findings, based on a 
population of patients just diagnosed with primary or recurrent UC, are compared to age and 
gender matched healthy population surveys. Our results indicate that although 61% (87/142) 
of the patients reported to be sexually active, more than half (54%) of these patients perceive 
some degree of erectile dysfunction or vaginal lubrication problems. Percentages that evi-
dently differ from calculations in age and gender matched healthy populations. Furthermore 
we found that almost one fourth (23%) of the sexually active participants was afraid to inflict 
harm to their partner in sexual contact. Risk factors such as gender, age, duration of bladder 
cancer diagnosis, number of recurrences, treatment, and marital status could not predict 
sexual activity or dysfunction. 
Lindau et al report the prevalence of sexual activity in the United States to decline with 
age15. In a national probability sample of 3005 adults (1550 women, 1455 men) she reported 
73% activity among respondents in the age of 57 to 64 years, 53% in the age of 65-74 years, 
and 26% who were 75-85 years of age, disregarding gender or the presence of partnership. 
Beutel et al showed, in a representative sample of a German population of 1271 women and 
1070 men, that sexual activity is strongly dependent on age, gender and the presence of a 
partner16. The latter reported the prevalence of sexual activity according to gender in the 
presence of a partner; 93% and 84% younger than 60 years of age, 79% and 63% between 
the age of 61-70 years and 54% and 31% if older than 70 years of age, in males and females 
respectively. If we respect the presence of a partner and categorize age in our series of 142 
adults (37 women, 105 men), we found a prevalence of sexual activity of 72% and 72%, of 
88% and 63% and 53% and 29%, in males and females respectively. In comparison to the 
adults younger than 60 years of age in the healthy German population, the young patients 
with NMI UC in our study clearly showed less sexual activity. A possible explanation could be 
a poor general physical condition of the bladder cancer patients (i.e. 78% (29/37) of these 
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young patients are smokers). Men and women who rated their health as being poor were less 
likely to be sexually active and, respondents who answered to be sexually active, were more 
likely to report sexual problems15. This is confirmed in our series, we found the lowest health 
state in patients aged 51-60 years (p=.02 by One way ANOVA test). Patients who are sexually 
active perceive a significantly higher state of general health. 
Sexual dysfunction has been evaluated in various studies. Laumann et al reported a higher 
prevalence in females (43%) than in males (31%), besides he showed that the experience of 
sexual dysfunction is more likely in patients with poor physical and emotional health17. Nico-
losi et al collected data from 27,500 men and women in 29 countries and showed 10% erectile 
difficulties in men and 16% lubrication difficulties among women18. Lewis et al reported that 
20-30% of adult men and 40-45% of adult women have at least one manifestation of sexual 
dysfunction19. Furthermore he described that concurrence of a genitourinary disease, next 
to other risk factors like presence of diabetes and smoking behaviour, are associated with 
sexual dysfunction. A large-scale multinational survey in the US and six European countries 
showed that LUTS (lower urinary tract symptoms) is an independent risk factor for sexual 
dysfunction in males, 49% of the males reported some degree of erectile dysfunction20. In the 
first 3 months after diagnosis, we found in our series of bladder cancer patients under surveil-
lance a much higher rate of erectile and vaginal dysfunction rate as ever been described in 
previous studies, 58% and 78% in males and females respectively.
This study is the first to report that patients with bladder cancer are afraid to inflict harm 
to their partner by sexual contact. The patients in our series were evaluated for their sexual 
performance within three months after diagnosis of UC. Experiencing this fear was not re-
lated to a history of previous recurrences, however we found a positive effect of treatment by 
intra-vesical instillations on the degree of fear to harm the partner. Sexually active patients 
with a status of a long-term surveillance (multiple recurrences) treated with intravesical instil-
lations tended to show less fear to harm their partner compared to long-term monitored 
patients without intra-vesical treatment (respectively 0/7 versus 5/14 patients with multiple 
recurrences experienced fear, p=.09), implying that treatment could have a positive effect on 
the sexual function of patients under surveillance with NMI UC. Many studies report about 
the fear for sexual contact as a known cause for avoidance of intercourse in patients with 
chronic or oncological diseases. These patients and possibly their partners fear an increased 
risk for cardiac arrest in cardiovascular diseases or acquiring infections in onco-hematological 
diseases21, 22. It is presumable that bladder cancer patients and their partners consider them-
selves protected in sexual contact after treatment with intra-vesical instillations. However, we 
cannot conclude this from the evaluation of our series.
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As one of the very few studies in the literature, Stav et al evaluated the use of rigid cystoscopic 
examination in a longitudinal study and analysed sexual performance14. Fifty-one percent of 
the patients were sexually active (45 men and 6 women). The study was performed on a het-
erogeneous patient group, 62% (69/112) of the patients was under surveillance for bladder 
cancer. The authors reported a transient impair of libido (56% and 50% in males and females 
respectively) and satisfaction from sexual intercourse (77% of the sexually active patients) 
in patients monitored by rigid cystoscopy (in males and females) in the first two weeks after 
examination compared to pre-cystoscopic evaluation. Libido and satisfaction from sexual 
intercourse returned to baseline after one month. None of the parameters was influenced by 
gender or findings at examination. Unfortunately the authors did not report the prevalence 
of sexual dysfunction. In our NMI UC series only females were monitored by rigid cystoscopy, 
male patients were examined by flexible 17Ch cystoscope. It is conceivable that the findings 
regarding rigid cystoscopy can be compared to flexible cystoscopic examination. 
Each bladder cancer patient in this series was questioned under identical circumstances 
in the course of surveillance. The cross-sectional analysis showed the prevalence of sexual 
function at that time-specific moment after bladder cancer diagnosis and before the start of 
an intensive surveillance scheme. However, several questions remain unanswered. Whether 
the sexual function is impaired by the diagnosis or by the impact of surveillance must be 
answered in future longitudinal surveys. Besides, we report the unique finding that a consid-
erable amount of patients is mistakenly afraid to harm their partner by sexual contact; the 
present report however does not elaborate on the fear to inflict harm to a partner caused by 
being a bladder cancer patient and with the prospect of intensive surveillance by cystoscopy. 
This latter question will be answered by extended questionnaires.
We found a larger proportion of sexual dysfunction in our NMI bladder cancer patient group 
(54%) as ever been described. No risk factors were recognized. This problem warrants rec-
ognition as a significant public health concern. Diagnosis of NMI UC can be considered as 
a diagnosis of a chronic disease cause of the necessity to intensive long-term monitoring. 
Therefore the long-term sexual performance of these patients and partners would be likely 
to benefit from proper sexual information in the outpatient clinic. 
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Questionnaire I
Patients received simultaneously 8 copies of the following questionnaire together with the 
announcement in which trial arm they were randomized, a patient information guide and 
another questionnaire. Patients randomized in the Cystoscopy-arm were asked to fill out the 
following questionnaire concerning pain and discomfort in the first week after they under-
went cystoscopic examination, they were asked to repeat the questionnaire every time  they 
underwend cystoscopic examination.
Pain and discomfort questionnaire addressed to patients in the cystoscopy-arm
Een week geleden bent u op de polikliniek urologie geweest voor onderzoek van de 
blaas (cystoscopie). Met  een cystoscoop is toen in uw blaas gekeken. Als gevolg van 
een cystoscopie kunnen bij sommige mensen bepaalde klachten optreden. Daarover 
gaan de volgende vragen.
Vragen 1,2 en 3 gaan over het bezoek aan de polikliniek 1 week geleden; direct voor, 
tijdens en direct na cystoscopie. Kruis op elke regel het antwoord aan dat het best op 
u van toepassing is:
1. Hoe vervelend vond U: niet vervelend vrij vervelend zeer vervelend
a. de voorbereiding voor de cystoscopie   
b. het inbrengen van de cystoscoop   
c. het ondergaan van de cystoscopie   
d. de uren direct ná de cystoscopie   
2. Hoe pijnlijk vond U:  niet pijnlijk vrij pijnlijk zeer pijnlijk
a. de voorbereiding voor de cystoscopie   
b. het inbrengen van de cystoscoop    
c. het ondergaan van de cystoscopie   
d. de uren direct ná de cystoscopie   
3. Hoe tevreden was / bent u met: niet tevreden vrij tevreden zeer  tevreden
a. de ontvangst op de polikliniek   
b. de wachttijd op de polikliniek   
c. de uitleg op de polikliniek   
Vragen 4 tot en met 12 gaan over de periode 1 week na cystoscopie. Beantwoord elke 
vraag door één hokje aan te kruisen. Als u niet zeker weet welk antwoord u moet geven, 
geef dan het best mogelijke antwoord.
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4. Heeft u in de week na de cystoscopie pijn gehad bij het plassen?
 Nee
 Ja, maar dat was binnen een week over
 Ja, en dat heb ik nog steeds
5. Heeft u in de week na cystoscopie het gevoel gehad vaak maar kleine beetjes te kunnen plassen?
 Nee
 Ja, maar dat was binnen een week over
 Ja, en dat heb ik nog steeds
6. Heeft u in de afgelopen week pijnstillers gebruikt in verband met pijn als gevolg van de cystoscopie ?
 Nee, niet nodig
 Ja en dat heeft geholpen
 Ja, maar het helpt niet
7. Heeft u in de week na de cystoscopie antibiotica geslikt?
 Nee
 Ja
8. Heeft u in de week na de cystoscopie koorts (boven 38°C) gehad?
 Nee
 Ja, gedurende dagen  (in het vierkantje hebt u ruimte om het aantal dagen in te vullen)
9. Heeft u in de week na de cystoscopie bloed in de urine gehad?
 Nee
 Ja, maar de urine kleurde lichtrood
 Ja, er zat veel bloed in de urine
10. Heeft u in verband met de cystoscopie in de afgelopen week de huisarts bezocht?
 Nee
 Ja 
11. Hebben klachten als gevolg van de cystoscopie u gedurende de AFGELOPEN WEEK gehinderd bij uw dagelijkse 
bezigheden (zoals werk buitenshuis, huishoudelijk werk)?
Helemaal niet Een klein beetje Nogal Veel Heel erg veel
    
12. Hebben klachten als gevolg van de cystoscopie u gedurende de AFGELOPEN WEEK gehinderd bij uw sociale leven (zoals 
vrienden of familie bezoeken, etc.)?
Helemaal niet Een klein beetje Nogal Veel Heel erg veel
    
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Questionnaire II
Patients received simultaneously 5 copies of the following questionnaire together with the 
announcement in which trial arm they were randomized, a patient information guide and 
another questionnaire. Patients randomized in the MA-arm were asked to fill out the follow-
ing questionnaire concerning pain and discomfort in the first week after they went to the 
outpatient clinic for the result of the urinary test, they were asked to repeat this question-
naire every time a urinary test was performed. Note: patients randomized in the MA-arm 
received at the same time 5 questionnaires concerning pain and discomfort after cystoscopic 
examination. 
Pain and discomfort questionnaire addressed to patients in the MA-arm
Ongeveer drie weken geleden bent u op de polikliniek urologie geweest, en heeft u 
urine ingeleverd voor onderzoek van de blaas. Ongeveer een week geleden bent u op 
de polikliniek geweest voor de uitslag van de urinetest of heeft u telefonisch contact 
gehad met uw uroloog over de uitslag van de urinetest. Hierover gaan de volgende 
vragen. 
Vragen 1 en 2 gaan over het bezoek aan de polikliniek 1 week geleden; kruis op elke 
regel het antwoord aan dat het best op u van toepassing is:
1. Hoe vervelend vond U: niet vervelend vrij vervelend zeer vervelend
e. het opvangen van urine   
f. het brengen van urine naar de poli   
g. het wachten op de uitslag   
2. Hoe tevreden was u met:: niet tevreden vrij tevreden zeer  tevreden
d. de ontvangst op de polikliniek   
e. de wachttijd op de polikliniek    
f. de uitleg op de polikliniek   
Vragen 3 tot en met 11 gaan over de afgelopen week. Beantwoord elke vraag door één 
hokje aan te kruisen. Als u niet zeker weet welk antwoord u moet geven, geef dan het 
best mogelijke antwoord.
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3. Heeft u de afgelopen week pijn gehad bij het plassen?
 Nee
 Ja, maar dat was binnen een week over
 Ja, en dat heb ik nog steeds
4. Heeft u de afgelopen week het gevoel gehad vaak maar kleine beetjes te kunnen plassen?
 Nee
 Ja, maar dat was binnen een week over
 Ja, en dat heb ik nog steeds
5. Heeft u de afgelopen week pijnstillers gebruikt in verband met uw blaasaandoening?
 Nee, niet nodig
 Ja en dat heeft geholpen
 Ja, maar het helpt niet
6. Heeft u de afgelopen week antibiotica geslikt?
 Nee
 Ja
7. Heeft u de afgelopen week koorts (boven 38°C) gehad?
 Nee
 Ja, gedurende dagen (in het vierkantje hebt u ruimte om het aantal dagen in te vullen) 
8. Heeft u de afgelopen week  bloed in de urine gehad?
 Nee
 Ja, maar de urine kleurde lichtrood
 Ja, er zat veel bloed in de urine
9. Heeft u de afgelopen week de huisarts bezocht in verband met blaasklachten?
 Nee
 Ja
10. Heeft u gedurende de AFGELOPEN WEEK klachten gehad die in verband staan met uw blaasaandoening en u 
gehinderd hebben bij uw dagelijkse bezigheden (zoals werk buitenshuis, huishoudelijk werk)?
Helemaal niet Een klein beetje Nogal Veel Heel erg veel
    
11. Heeft u gedurende de AFGELOPEN WEEK klachten gehad die in verband staan met uw blaasaandoening en u 
gehinderd hebben bij uw sociale leven (zoals vrienden of familie bezoeken, etc.)?
Helemaal niet Een klein beetje Nogal Veel Heel erg veel
    
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Questionnaire III
Patients received the following questionnaire together with 8 questionnaires concerning 
pain and discomfort, a patient information guide and the announcement in which trial arm 
they were randomized. They were asked to instantly fill out the questionnaire and send it 
back as soon as possible. 
Zet bij iedere vraag in de lijst hieronder een kruisje in het hokje voor de zin die past bij 
uw gezondheidstoestand van VANDAAG.
1. Mobiliteit
 Ik heb geen problemen met lopen
 Ik heb enige problemen met lopen
 Ik ben bedlegerig
2. Zelfzorg
 Ik heb geen problemen om mijzelf te wassen of aan te kleden
 Ik heb enige problemen om mijzelf te wassen of aan te kleden
 Ik ben niet in staat mijzelf te wassen of aan te kleden
3. Dagelijkse activiteiten 
 (bijv. werk, studie, huishouden, gezins- en vrijetijdsactiviteiten)
 Ik heb geen problemen met mijn dagelijkse activiteiten
 Ik heb enige problemen met mijn dagelijkse activiteiten
 Ik ben niet in staat mijn dagelijkse activiteiten uit te voeren
4. Pijn / klachten
 Ik heb geen pijn of andere klachten
 Ik heb matige pijn of andere klachten
 Ik heb zeer ernstige pijn of andere klachten
5. Stemming
 Ik ben niet angstig of somber
 Ik ben matig angstig of somber
 Ik ben erg angstig of somber
Gezondheidsmeetschaal
Wij willen u vragen op een meetschaal (thermometer) aan te geven hoe goed of hoe 
slecht volgens u uw gezondheidstoestand NU is.
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Op de thermometer hieronder betekent ‘100’ de beste gezond heids toestand die men 
zich kan voorstellen, en ‘0’ de slechtste gezondheids toestand die men zich kan voor-
stellen.
6. Teken nu een pijl vanaf “Uw gezondheids toestand nU”  naar het punt op de ther-
mometer dat volgens u aan geeft hoe goed of hoe slecht uw gezondheids toestand nU is. 
Wij zijn geïnteresseerd in uw lichamelijke en emotionele toestand gedurende de AFGELOPEN 
WEEK. Wilt u alle vragen beantwoorden door op elke regel het getal te omcirkelen dat het 
meest op u van toepassing is. 
Laat de pijl beginnen bij de stippellijn 
en trek een lijn naar een punt op de 
Thermometer.
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Gedurende de afgelopen week: (omcirkel 1 cijfer op elke regel)
Helemaal 
Niet
Een beetje Nogal Heel erg
7. Heeft u moeite gehad met het doen van inspannende 
activiteiten zoals bijv. het dragen van een zware 
boodschappentas en/of een koffer? 
1 2 3 4
8. Heeft u moeite gehad met het maken van een lange 
wandeling?
1 2 3 4
9. Heeft u moeite gehad met het maken van een korte 
wandeling, buitenshuis?
1 2 3 4
10. Was het nodig overdag in bed / een stoel te blijven? 1 2 3 4
11. Heeft u hulp nodig gehad met eten, aankleden, uzelf te 
wassen of naar het toilet gaan?
1 2 3 4
12. Was u beperkt bij het doen van uw werk of andere 
dagelijkse bezigheden?
1 2 3 4
13. Was u beperkt in het uitoefenen van uw hobby’s of bij 
andere bezigheden die u in uw vrije tijd doet?
1 2 3 4
14. Was u kortademig? 1 2 3 4
15. Heeft u pijn gehad? 1 2 3  4 
16. Heeft u behoefte gehad te rusten? 1 2 3 4
17. Heeft u moeite met slapen gehad? 1 2 3 4
18. Heeft u zich slap gevoeld? 1 2 3 4
19. Heeft u gebrek aan eetlust gehad? 1 2 3 4
20. Heeft u zich misselijk gevoeld? 1 2 3 4
21. Heeft u overgegeven? 1 2 3 4
22. Heeft u last gehad van obstipatie? (Was u verstopt?) 1 2 3 4
23. Heeft u last gehad van diarree? 1 2 3 4
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Gedurende de afgelopen week: (omcirkel 1 cijfer op elke regel)
 Helemaal 
Niet 
Een beetje Nogal Heel erg
24. Bent u moe geweest?  1  2 3  4
25. Heeft pijn u gehinderd in uw dagelijkse bezigheden?  1  2 3  4
26. Heeft u moeite gehad met het concentreren op dingen, 
zoals een krant lezen of televisie kijken?
 1  2 3  4
27. Voelde u zich gespannen?  1  2 3  4
28. Heeft u zich zorgen gemaakt?  1  2 3  4
29. Heeft u zich prikkelbaar gevoeld?  1  2 3  4
30. Heeft u zich neerslachtig gevoeld?  1  2 3  4
31. Heeft u moeite gehad met het herinneren van dingen?  1  2 3  4
32. Heeft uw lichamelijke toestand of medische behandeling 
uw familieleven in de weg gestaan?
1  2 3  4
33. Heeft uw lichamelijke toestand of medische behandeling 
u belemmerd in uw sociale bezigheden?
 1  2 3  4
34. Heeft uw lichamelijke toestand of medische behandeling 
financiële moeilijkheden met zich meegebracht?
 1  2 3  4
Wilt u voor de volgende vragen een getal tussen 1 en 7 omcirkelen dat het meest op u 
van toepassing is.
35. Hoe zou u uw algehele gezondheid op dit moment beoordelen?
1 2 3 4 5 6 7
Erg slecht Uitstekend
36. Hoe zou u uw algehele ‘kwaliteit van leven’ op dit moment beoordelen?
1 2 3 4 5 6 7
Erg slecht Uitstekend
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Patiënten melden ons soms dat zij de volgende klachten of problemen hebben. Gelieve 
aan te duiden in welke mate u deze symptomen of problemen heeft ondervonden 
gedurende de afgelopen week. Gelieve op elke regel het cijfer te omcirkelen dat op u 
van toepassing is.
Gedurende de afgelopen week: (omcirkel 1 cijfer op elke regel)
Helemaal 
Niet 
Een beetje Nogal Heel erg
37. Moest u overdag vaak plassen?  1  2 3  4
38. Moest u ’s nachts vaak plassen?  1  2 3  4
39. Toen u voelde dat u moest plassen, moest u zich 
dan haasten om naar het toilet te gaan?
 1  2 3  4
40. Kon u niet voldoende slapen, omdat u ’s nachts 
vaak naar het toilet moest?
 1  2 3  4
41. Kon u moeilijk het huis verlaten omdat u altijd dicht 
in de buurt van een toilet moest blijven?
 1  2 3  4
42. Had u onvrijwillig urineverlies (lekken van urine?)  1  2 3  4
43. Had u pijn of een brandend gevoel toen u plaste?  1  2 3  4
44. Had u koorts?  1  2 3  4
45. Voelde u zich ziek of onwel?  1  2 3  4
46. Was het moeilijk uw leven te organiseren rond de 
herhaalde afspraken voor behandelingen van de 
blaas (cystoscopieën of instillaties)?
 1  2 3  4
47. Maakte u zich zorgen over het feit dat u meermaals 
behandelingen van de blaas moest ondergaan 
(cystoscopieën of instillaties)? 
 1  2 3  4
48. Maakte u zich zorgen over uw gezondheid in de 
toekomst?
 1  2 3  4
49. Maakte u zich zorgen over de resultaten van de 
tests en onderzoeken?
 1  2 3  4
50. Maakte u zich zorgen over eventuele 
behandelingen in de toekomst?
 1  2 3  4
51. Had u een opgeblazen gevoel in de buik?  1  2 3  4
52. Had u last van winderigheid?  1  2 3  4
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Gedurende de afgelopen 4 weken: (omcirkel 1 cijfer op elke regel)
Helemaal 
Niet 
Een beetje Nogal Heel erg
53. Hoeveel zin in seks had u?  1  2 3  4
54. In welke mate was u seksueel actief (met of zonder 
geslachtsgemeenschap)?
 1  2 3  4
55. Enkel voor mannen: Kon u moeilijk een erectie 
krijgen of behouden?
 1  2 3  4
56. Enkel voor mannen: Had u problemen met de 
zaadlozing (bijv. klaarkomen zonder zaadlozing)?
 1  2 3  4
De onderstaande 4 vragen alleen beantwoorden indien u seksueel actief was gedurende 
de afgelopen 4 weken:
(omcirkel 1 cijfer op elke regel)
Helemaal 
Niet 
Een beetje Nogal Heel erg
57. Maakte de gedachte aan seksueel intiem worden, u 
ongemakkelijk?
 1  2 3  4
58. Was u bang dat u, tijdens het seksueel contact, uw 
partner zou kunnen schaden door de behandelingen 
die u voor de blaas onderging?
 1  2 3  4
59. In welke mate heeft u van seks genoten?  1  2 3  4
60. Enkel voor vrouwen: had u een droge vagina of 
andere problemen tijdens de geslachtsgemeenschap? 
 1  2 3  4
Hieronder vindt u vragen over de kans dat er bij u weer een blaaspoliep zal worden 
gevonden. We willen graag van u weten hoe u daarover denkt. Kruis de mogelijkheden 
aan die voor u het meest van toepassing is.
61. Hoe groot schat u de kans dat er binnen 3 jaar weer een blaaspoliep bij u zal worden gevonden? De kans dat er 
weer een blaaspoliep bij mij wordt gevonden in de komende 3 jaar is:
 Minder dan 5%
 Tussen 5 en 20% 
 Tussen 20 en 40%
 Tussen 40 en 60% 
 Tussen 60 en 80% 
 Meer dan 80% maar minder dan 100%
 Absoluut zeker, namelijk 100%
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62. Hoe zou u deze kans omschrijven als u op uw gevoel afgaat ? Ik ervaar de kans dat er bij mij binnen 3 jaar weer 
een blaaspoliep wordt gevonden als:
 erg klein
 klein
 redelijk klein
 niet klein en niet groot
 redelijk groot
 groot
 erg groot
63. Hoe erg zou u het vinden als er bij u weer een blaaspoliep zou worden gevonden? (geef d.m.v. van een kruisje op 
de balk aan, hoe erg u dit zult vinden)
0% 100%
64. Hoe groot schat u de kans dat er bij een eerstvolgende controle weer een blaaspoliep bij u zal worden gevonden? 
De kans dat er bij de eerstvolgende controle een blaaspoliep wordt gevonden schat ik op:
 Heel waarschijnlijk minder dan 5%
 Ongeveer  5%
 Ongeveer 10%
 Ongeveer 25%
 Tussen 30 en 40%
 Tussen 40 en 50%
 Tussen 50 en 75%
 Tussen 75 en 99%
 Absoluut zeker, namelijk 100%
Gaat u er voor de volgende vraag vanuit dat cystoscopie en urineonderzoek precies
even betrouwbaar zijn voor het opsporen van blaaspoliepen.
65. Als de betrouwbaarheid van cystoscopie en urineonderzoek precies gelijk is en u mag kiezen, voor welk 
onderzoek zou u dan kiezen?
 zeker de cystoscopie
 waarschijnlijk de cystoscopie
 geen voorkeur
 waarschijnlijk het urineonderzoek
 zeker het urineonderzoek
De volgende vragen dienen er voor om te weten te komen hoe u zich emotioneel voelt. 
Lees iedere vraag en geef uw antwoord aan met een kruisje in het hokje dat het best 
weergeeft hoe u zich gedurende de afgelopen week gevoeld heeft. Denk niet te lang na 
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over uw antwoord. Het gaat bij al deze vragen over uw eigen indruk. Er bestaan geen 
foute antwoorden, elk antwoord is goed, als het maar uw eigen indruk weergeeft.
66. Ik voel me gespannen
 Meestal
 Vaak 
 Af en toe, soms
 Helemaal niet
67. Ik geniet nog steeds van de dingen waar ik vroeger van genoot
 Zeker zo veel
 Niet zoveel als vroeger
 Weinig
 Haast helemaal niet
68. Ik krijg een soort angstgevoel alsof er elk moment iets vreselijks kan gebeuren
 Heel zeker en vrij erg
 Ja, maar niet zo erg
 Een beetje, maar ik maak me er geen zorgen over
 Helemaal niet
69. Ik kan lachen en de dingen van de vrolijke kant zien
 Net zoveel als vroeger
 Niet zo goed als vroeger
 Beslist niet zoveel als vroeger
 Helemaal niet
70. Ik maak me vaak ongerust
 Heel erg vaak
 Vaak
 Af en toe maar niet vaak
 Alleen soms
71. Ik voel me opgewekt
 Helemaal niet
 Niet vaak
 Soms
 Meestal
186
Q
ue
st
io
nn
ai
re
s 
I-I
V
72. Ik kan rustig zitten en me ontspannen
 Zeker
 Meestal
 Niet vaak
 Helemaal niet
73. Ik voel alsof alles moeizamer gaat
 Bijna altijd
 Heel vaak
 Soms
 Helemaal niet
74. Ik krijg een soort benauwd, gespannen gevoel in mijn maag
 Helemaal niet
 Soms
 Vrij vaak
 Heel vaak
75. Ik heb geen interesse meer in mijn uiterlijk
 Zeker
 Niet meer zoveel als zou moeten
 Waarschijnlijk niet zoveel
 Evenveel interesse als vroeger
76. Ik heb helemaal geen rust en voel dat ik iets te doen moet hebben
 Heel erg
 Tamelijk veel
 Niet erg veel
 Helemaal niet
77. Ik verheug me van tevoren al op dingen
 Net zoveel als vroeger
 Een beetje minder dan vroeger
 Zeker minder dan vroeger
 Bijna nooit
78. Ik krijg plotseling gevoelens van panische angst
 Zeer vaak
 Tamelijk vaak
 Niet erg vaak
 Helemaal niet
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79. Ik kan van een goed boek genieten, of van een radio- of televisieprogramma
 Vaak
 Soms
 Niet zelden
 Heel zelden
Probeert u zich voor te stellen dat een cystoscopie wel in uw eigen ziekenhuis kan 
plaatsvinden maar het urineonderzoek niet. Als u liever het urineonderzoek wilt 
laten doen moet u de urine voor het urineonderzoek ZELF naar een ander ziekenhuis 
brengen. Het wegbrengen van de urine kost u reistijd (de kosten maken niet uit; de 
verzekering zou de extra reiskosten vergoeden).
80. Hoeveel uren reistijd bent u bereid in totaal (heen en terugreis) te reizen voor een urineonderzoek in plaats van 
een cystoscopie?
 0 uur
 1 uur
 2 uur
 3 uur
 4 uur
 5-6 uur
 7-8 uur
 9-10 uur
 meer dan 10 uur
Stelt u zich nu voor dat u na een cystoscopie direct hoort of u wel of geen nieuwe po-
liepen heeft, maar dat u op de uitslag van urineonderzoek een aantal dagen moet wa-
chten. Als u dus direct de uitslag wilt hebben, zou u moeten kiezen voor cystoscopie. 
81. Hoeveel dagen zou u bereid zijn te wachten op de uitslag van een urineonderzoek?
 0 dagen
 1 dag
 2-3 dagen
 4-7 dagen
 8-10 dagen
 11-14 dagen
 meer dan 14 dagen
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82. Tenslotte; het urineonderzoek kan om technische redenen mislukken. Om met zekerheid te kunnen vaststellen 
of uw blaaskanker is teruggekomen, zal worden geadviseerd alsnog een cystoscopie te ondergaan (1 op de 20 
urinetesten kan mislukken) Zou u het dan erg vinden om alsnog een cystoscopie te ondergaan :
Ja, omdat ………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
………………………………………………………………
Nee, omdat …………………………………………………………………………………………….………………………
…………………………………………………………………………………………………………………………………
………………………………………………………………
Hieronder vindt u een aantal uitspraken die mensen kunnen doen over gedachten en 
gevoelens omtrent blaaskanker. Bekijk de uitspraken één voor één. U kunt in de hokjes 
aankruisen in hoeverre elke uitspraak op u van toepassing was tijdens de afgelopen 7 
dagen. Als de uitspraak niet van toepassing is, zet u een kruisje bij ‘helemaal niet’. 
83.  Helemaal 
Niet
Zelden Soms Vaak
a. Ik moest aan blaaskanker denken zonder dat ik dat wilde.    
b. Iedere keer als ik aan blaaskanker herinnerd werd, deed ik mijn 
uiterste best om te voorkomen dat ik van streek zou raken
   
c. Ik deed mijn best om gedachten aan blaaskanker uit te bannen    
d. Omdat ik steeds aan blaaskanker moest denken sliep ik slecht.    
e. Ik kon overspoeld raken door mijn gedachten aan blaaskanker.    
f. Ik heb over blaaskanker gedroomd.    
g. Ik ging mensen of situaties uit de weg die me aan blaaskanker 
deden denken.
   
h. Ik heb er zo’n onwerkelijk gevoel over, alsof er niks aan de hand is.    
i. Ik heb mijn uiterste best gedaan niet over blaaskanker te praten.    
j. Beelden over blaaskanker konden zomaar in mijn gedachten 
schieten.
   
k. Er gebeurde aldoor wel iets waardoor ik er plotseling weer aan 
herinnerd werd.
   
l. Ik wist wel dat ik nog steeds veel gevoelens erover had, maar ik 
wil er liever niet aan denken.
   
m. Ik wilde gewoon niet aan blaaskanker denken.    
n. Als ik aan blaaskanker moest denken, kwamen meteen weer alle 
gevoelens erover terug.
   
o. Mijn gevoelens over blaaskanker waren als het ware verdoofd.    
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84. OPLEIDING Wat is de hoogste opleiding die u met een diploma heeft afgesloten ?
 lager onderwijs (basisonderwijs)
 lager beroepsonderwijs (bijv. LTS, LHNO, huishoudschool, lager land- en tuinbouwonderwijs)
 middelbaar algemeen onderwijs (bijv. LAVO, ULO, MULO, MAVO, 3-jarige HBS)
 middelbaar beroepsonderwijs (bijv. MTS, MEAO)
 voortgezet algemeen onderwijs (bijv. HBS, MMS, gymnasium, HAVO, VWO)
 hoger beroepsonderwijs (bijv. HTS, HEAO, sociale academie, PABO, lerarenopleiding)
 wetenschappelijk onderwijs (universiteit)
 anders, nl…………………………………………………
85. BURGERLIJKE STAAT Wat is uw burgerlijke staat ?
 Gehuwd / geregistreerd partnerschap
 Ongehuwd en nooit gehuwd geweest
 Gescheiden
 Weduwe / weduwnaar
86. LEEFSITUATIE Welke situatie is op dit moment voor u van toepassing ?
 Ik woon samen met mijn echtgenoot / partner
 Ik woon samen met mijn echtgenoot / partner en kinderen
 Ik heb een duurzame relatie, maar we wonen niet samen
 Ik woon samen met kinderen
 Ik woon samen met mijn ouders
 Ik ben alleenstaand
 anders, nl…………………………………………………
87. WERK Welke situatie is voor u op dit moment het meest van toepassing ?
 Ik heb betaald werk
 Ik heb geen betaald werk
o want ik zorg voor de huishouding en evt. kinderen
o meer vanwege mijn blaasproblemen
o meer vanwege andere gezondheidsproblemen
o om andere redenen (bijv. onvrijwillig werkloos, vrijwilligerswerk, etc.)
 Ik ben gepensioneerd of met de VUT
 Ik ben scholier of student
88. Heeft u ooit gerookt ?
 Ja, zoveel jaar ……………………………………………………………………..
 Nee
89. Wat voor werk heeft u gedaan / doet u?
…………………………………………………………………………………………………..
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Questionnaire IV
Patients were asked to fill out this questionnaire in the waiting room before cystoscopic 
examination.
Allereerst stellen wij u 3 algemene vragen
1. Vult u eerst de datum in van vandaag: 
(dag – maand – jaar;  bijv. 01-04-05  voor 1 april 2005, binnen de lijntjes blijven a.u.b.)
2. Uw geboortedatum:
(dag – maand – jaar;  bijv. 01-04-05  voor 1 april 2005, binnen de lijntjes blijven a.u.b.)
3. Uw geslacht:
Man / Vrouw (omcircel) 
Het kan zijn dat u al meedoet aan een onderzoek naar “een nieuwe methode om uw 
blaas te controleren.” U heeftdan vergelijkbare vragenlijsten thuis ontvangen, een 
aantal vragen zullen u bekend voorkomen. Wij willen u vragen om deze vragenlijst ook 
in vullen, 
De volgende vragen gaan over de cystoscopie:
Gezondheidsmeetschaal
We willen u vragen op een meetschaal (thermometer) aan te geven hoe goed of hoe 
slecht volgens u uw gezondheidstoestand NU is.
4. Doet u al mee met het onderzoek “een nieuwe methode om uw blaas te controleren?” en ontvangt u thuis ook 
vragenlijsten
 Ja, uw achternaam / initialen
 Nee
5. Hoe vaak heeft u een cystoscopie gehad?
…………………………………………….
6. Om welke reden dient u vandaag een cystoscopie te ondergaan?
………………………………………………………………………………………………………….………………………
………………………………………………………………………………….
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Op de thermometer hieronder betekent ‘100’ de beste gezond heids toestand die men 
zich kan voorstellen, en ‘0’ de slechtste gezondheids toestand die men zich kan voor-
stellen.
7. Teken nu een pijl vanaf “Uw gezondheids toestand nU”  naar het punt op de ther-
mometer dat volgens u aan geeft hoe goed of hoe slecht uw gezondheids toestand nU is. Laat 
de pijl beginnen bij de stippellijn.
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Zelf-beoordelings vragenlijst
Hieronder vindt u een aantal uitspraken die mensen hebben gebruikt om zichzelf te 
beschrijven. Lees iedere uitspraak door en omcirkel op elke regel het cijfer rechts van 
die uitspraak om daarmee aan te geven hoe u zich nu voelt, dus nu op dit moment. 
Er zijn geen goede of slechte antwoorden. Denk niet te lang na en geef uw eerste indruk, 
die is meestal de beste. Het gaat er dus om dat u weergeeft wat u op dit moment voelt.
Gedurende de afgelopen week: (omcirkel 1 cijfer op elke regel)
Helemaal 
Niet 
Een beetje Nogal Heel erg
8. Ik voel me kalm 1  2 3  4
9. Ik voel me veilig 1  2 3  4
10. Ik ben gespannen 1  2 3  4
11. Ik voel me onrustig 1  2 3  4
12. Ik voel me op mijn gemak 1  2 3  4
13. Ik ben in de war 1  2 3  4
14. Ik pieker over nare dingen die kunnen gebeuren  1  2 3  4
15. Ik voel me voldaan 1  2 3  4
16. Ik ben bang 1  2 3  4
17. Ik voel me aangenaam 1  2 3  4
18. Ik voel me zeker 1  2 3  4
19. Ik voel me nerveus 1  2 3  4
20. Ik ben zenuwachtig 1  2 3  4
21. Ik ben besluiteloos 1  2 3  4
22. Ik ben ontspannen 1  2 3  4
23. Ik voel me tevreden 1  2 3  4
24. Ik maak me zorgen 1  2 3  4
25. Ik voel me gejaagd 1  2 3  4
26. Ik voel me evenwichtig 1  2 3  4
27. Ik voel me prettig 1  2 3  4
Hoe vaak heeft u in de afgelopen week, als gevolg van gedachten en gevoelens over de komende cystoscopie, 
de volgende verschijnselen gehad?
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Gedurende de afgelopen week: (omcirkel 1 cijfer op elke regel)
Helemaal 
Niet 
Een beetje Nogal Heel erg
28. Had ik slaapproblemen  0  1  2  3
29. Was mijn eetlust veranderd  0  1  2  3
30. Was ik ongelukkig of neerslachtig  0  1  2  3
31. Was ik bang en paniekerig  0  1  2  3
32. Was ik nerveus en gestresst  0  1  2  3
33. Voelde ik mij onder spanning staan  0  1  2  3
34. Merkte ik dat ik dingen verzweeg voor degene die 
me na staan
 0  1  2  3
35. Merkte ik dat ik me afreageerde op anderen  0  1  2  3
36. Merkte ik dat ik me duidelijk terugtrok van 
degenen die me na staan
0  1  2  3
37. Had ik moeite met dingen die ik gewoonlijk in en 
om het huis doe
 0  1  2  3
38. Had ik moeite met het nakomen van mijn werk en 
andere verplichtingen
 0  1  2  3 
39. Was ik bezorgd over de toekomst  0  1  2  3 
De volgende vragen dienen er voor om te weten te komen hoe u zich emotioneel voelt. 
Lees iedere vraag en geef uw antwoord aan met een kruisje in het hokje dat het best 
weergeeft hoe u zich gedurende de afgelopen week tot op dit moment heeft gevoeld. 
Denk niet te lang na over uw antwoord. Het gaat bij al deze vragen over uw eigen in-
druk. Er bestaan geen foute antwoorden, elk antwoord is goed, als het maar uw eigen 
indruk weergeeft.
40. Ik voel me gespannen
 Meestal
 Vaak 
 Af en toe, soms
 Helemaal niet
41. Ik geniet nog steeds van de dingen waar ik vroeger ook van genoot
 Zeker zo veel
 Niet zoveel als vroeger
 Weinig
 Haast helemaal niet
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42. Ik krijg een soort angstgevoel alsof er elk moment iets vreselijks kan
 Zeker
 Heel zeker en vrij erg
 Ja, maar niet zo erg
 Een beetje, maar ik maak me er geen zorgen over
43. Helemaal niet
 Ik kan lachen en de dingen van de vrolijke kant zien
 Net zoveel als vroeger
 Niet zo goed als vroeger
 Beslist niet zoveel als vroeger
44. Helemaal niet
 Ik maak me vaak ongerust
 Heel erg vaak
 Vaak
 Af en toe maar niet vaak
45. Alleen soms
 Ik voel me opgewekt
 Helemaal niet
 Niet vaak
 Soms
46. Meestal
 Ik kan rustig zitten en me ontspannen
 Zeker
 Meestal
 Niet vaak
 Helemaal niet
47. Ik voel me alsof alles moeizamer gaat
 Bijna altijd
 Heel vaak
 Soms
 Helemaal niet
48. Ik krijg een soort benauwd, gespannen gevoel in mijn maag
 Helemaal niet
 Soms
 Vrij vaak
 Heel vaak
Questionnaires I-IV 195
49. Ik heb geen interesse meer in mijn uiterlijk
 Zeker
 Niet meer zoveel als zou moeten
 Waarschijnlijk niet zoveel
 Evenveel interesse als vroeger
50. Ik heb helemaal geen rust en voel dat ik iets te doen moet hebben
 Heel erg
 Tamelijk veel
 Niet erg veel
 Helemaal niet
51. Ik verheug me van tevoren al op dingen
 Net zoveel als vroeger
 Een beetje minder dan vroeger
 Zeker minder dan vroeger
 Bijna nooit
52. Ik krijg plotseling gevoelens van panische angst
 Zeer vaak
 Tamelijk vaak
 Niet erg vaak
 Helemaal niet
53. Ik kan van een goed boek genieten, of van een radio- of televisieprogramma
 Vaak
 Soms
 Niet zelden
 Heel zelden
 Helemaal niet
Stel u voor dat er een urinetest bestaat waardoor u geen cystoscopie dient te onder-
gaan. Een cystoscopie kan wel in uw eigen ziekenhuis plaatsvinden maar het urine-
onderzoek niet. Als u liever het urineonderzoek wilt laten doen moet u de urine voor 
het urineonderzoek ZELF naar een ander ziekenhuis brengen. Het wegbrengen van de 
urine kost u reistijd (de kosten maken niet uit; de verzekering zou de extra reiskosten 
vergoeden).
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80. Hoeveel uren reistijd bent u bereid in totaal (heen en terugreis) te reizen voor een urineonderzoek in plaats van 
een cystoscopie?
 0 uur
 1 uur
 2 uur
 3 uur
 4 uur
 5-6 uur
 7-8 uur
 9-10 uur
 meer dan 10 uur
Na een cystoscopie hoort u direct of uw blaas wel of niet in orde is, maar op de uitslag 
van urineonderzoek moet u een aantal dagen wachten. Als u dus direct de uitslag wilt 
hebben, zou u moeten kiezen voor cystoscopie. 
81. Hoeveel dagen zou u bereid zijn te wachten op de uitslag van een urineonderzoek?
 0 dagen
 1 dag
 2-3 dagen
 4-7 dagen
 8-10 dagen
 11-14 dagen
 meer dan 14 dagen
82. Tenslotte; het urineonderzoek kan om technische redenen mislukken. Om met zekerheid te kunnen vaststellen 
of uw blaas gezond is, zal worden geadviseerd alsnog een cystoscopie te ondergaan (1 op de 20 urinetesten kan 
mislukken) Zou u het dan erg vinden om alsnog een cystoscopie te ondergaan :
Ja, omdat ………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
………………………………………………………………
Nee, omdat …………………………………………………………………………………………….………………………
…………………………………………………………………………………………………………………………………
………………………………………………………………
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Abstract
To determine how good microsatellite analysis (MA) markers on voided urine samples should 
be to make a surveillance procedure cost-effective in which cystoscopy is partly replaced by 
MA for patients with non-muscle invasive urothelial carcinoma (NMI UC). We constructed a 
semi-Markov model with a time horizon of two years, and a man aged 65 as reference case. 
Data were used from a randomized trial (including 448 patients with NMI UC from 10 hos-
pitals), and from other data sources. The costs and effects (probability of being in a specific 
health state) were compared for two surveillance strategies: 1) cystoscopy of the urinary 
bladder every three months (conventional arm), and 2) semi-automated MA on voided urine 
samples to identify loss of heterozygosity (LOH) every three months with a control cystoscopy 
performed at 3, 12 and 24 months (test arm). Various sensitivity analyses were performed to 
determine the MA sensitivity, MA specificity, and costs of MA-urine for which the test arm was 
as cost-effective as the conventional arm. 
The probability of being without recurrence after two years of surveillances was approxi-
mately the same (86.6% conventional arm versus 86.3% test arm) with currently available 
MA markers (sensitivity of 58% and specificity of 73%). However, the test arm led to higher 
costs (€4,104 versus €3,433 per capita). The test arm would be as effective and cost the same 
as the conventional arm if the sensitivity of the currently available MA-markers increased at 
least to 61%, had a specificity of 73%, and decreased the costs of MA-urine test per follow-up 
moment from €158 to below €70.Over the course of two years, surveillance in which cystos-
copy is partly replaced by currently available urinary microsatellite analysis to reduce patient 
burden can only provide a cost-effective alternative to the conventional surveillance if the 
MA urine test would slightly increase its sensitivity and its costs can be reduced.
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Introduction
In the Western world bladder cancer is the fourth most common malignancy among men, 
following prostate, lung, and colon cancers1. Histologically, 90-95% of bladder cancers in 
the western world are urothelial carcinoma (UC). UC not only originate from urothelial lining 
of the bladder, but they may also occur in pyelum, the ureters or the urethra. Clinically, a 
distinction is made between non-muscle-invasive (NMI) and muscle-invasive UC. NMI UC 
are generally treated surgically by a transurethral resection (TUR). Although these NMI UC 
generally behave rather indolent, their recurrence rate is high (up to 75%). Close monitoring 
of patients with a NMI UC is warranted since about 10-20% of recurrent tumours may show 
progression to muscle invasive UC. Muscle invasive UC is a life-threatening disease, since 
the 5-year survival is about 50%, even after curative surgery (i.e. cystectomy). Surveillance of 
patients with NMI UC is by regular cystoscopy (in combination with cytologic examination in 
case of high-risk NMI UC). Although cystoscopy is considered as the reference standard for 
detection of tumour recurrences, a drawback of the method is its inability to demonstrate 
recurrences in the upper urinary tract (pyelum, ureter). Moreover, cystoscopy is an invasive 
procedure, which may be associated with subsequent complaints of anxiety, dysuria and uri-
nary tract infections, adversely influencing the quality of life of the patients2-4. It is for these 
reasons that substantial efforts have been undertaken to design strategies that could reduce 
the frequency of cystoscopy in patients with NMI UC5, 6. One of these strategies is to replace 
cystoscopy partly by microsatellite analysis (MA) to identify loss of heterozygosity (LOH) in 
urine samples; literature showed that MA is a highly-sensitive and specific marker for UC 
diagnosis and its monitoring, especially in patients with low-stage and low-grade tumours7. 
Van der Aa et al.8 showed in a randomized controlled trial that MA has the ability to detect 
tumours earlier and to detect tumours in the upper urinary tract, which might be missed by 
cystoscopy. However, the sensitivity of MA (58%) and specificity of MA (73%) for detecting 
recurrences in the bladder were both worse than cystoscopy (98% and 88%, respectively)8. 
In the present study, we determined the requirements in terms of sensitivity, specificity, 
and real costs of microsatellite analysis (MA) markers on voided urine samples to achieve cost-
effectiveness of a surveillance procedure of patients with NMI UC whose cystoscopy is partly 
replaced by MA. We hereto used data from the randomized controlled Cost-effectiveness of 
Follow-up of urinary Bladder Cancer (CEFUB) trial. 
Patients and Methods
Main study
We conducted the randomized controlled CEFUB trial (n=448 patients with NMI UC; recruited 
by 10 Dutch hospitals; registration ClinicalTrials.gov NCT00126958) to evaluate the efficacy of 
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MA on voided urine to detect tumour recurrences in the follow-up of patients. Patients were 
included with a primary or recurrent NMI UC (pTa, pT1, G1 or G2) of the urinary bladder, based 
on histopathological examination of the surgically removed tumour.  Figure 10.1 shows the 
interventions in the conventional and test arm of the randomized study during two years. 
The conventional arm consisted of cystoscopy of the urinary bladder every three months. The 
test arm consisted of semi-automated MA of DNA (for 20 polymorphic microsatellite markers 
localised 10 chromosomes) extracted from voided urine samples from patients with a NMI UC 
every three months. A blood sample was taken as a control for the MA of the subsequent urine 
samples, and was used during the entire study period. A control cystoscopy was performed 
at 3, 12 and 24 months after TUR, and in case of positive MA outcome. If a tumour recurrence 
was found by cystoscopy, irrespective of conventional or test arm, it was removed by TUR. 
In case of progression to muscle-invasive UC or G3 NMI UC after adjuvant intravesical treat-
ment, a cystectomy was considered. If the outcome of MA and cystoscopy were discordant, 
i.e. MA was positive but no tumour was detected by cystoscopy during two subsequent visits 
(i.e. a persistently positive MA), an upper urinary tract radio-imaging was performed in order 
to examine the upper urinary tract (UUT) for the presence of UC. The UUT  radio-imaging was 
not performed immediately in case of positive MA and negative cystoscopy, since previous 
studies showed that a positive MA test outcome frequently antedates cystoscopically detect-
able recurrences8, 9. In case of suspicion for an UC in the UUT, a unilateral nephroureterectomy 
was considered.  
Decision model
We constructed a semi-Markov model to assess costs and effects (probability of being in a 
specific health state) of both bladder cancer surveillances (i.e. test arm and conventional 
Figure 10.1
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arm). The model was implemented in DATA software (Version TreeAge PRO 2007, TreeAge 
Software, Boston, Massachusetts). Figure 10.2 highlights the core of the surveillance model: 
monitoring patients with NMI UC can prevent progression to muscle-invasive UC by detect-
ing and treating recurrent tumours first (i.e. it is possible to prevent progression).  Appendix 1 
shows the underlying conceptual model: missing patients with recurrent tumours can lead to 
cystectomy and a higher probability of death due to progressive tumours. Poor health states 
indicate dead, no bladder, progression (i.e. muscle-invasive UC or G3 NMI UC) and recurrent 
UC, and all other health states indicate ‘well’. Noteworthy, after a detected recurrent UC, the 
patient will go back to the health state ‘well’ again. Transition probabilities per three months 
were used to correspond with the moments of follow-up. The reference case was a man aged 
65 years, and the time horizon was two years. To retain some memory in the Markov model 
some health states were constructed with a sub health state. The sub health states indicated 
whether the MA was positive and the cystoscopy negative in the last visit of surveillance. 
When this was also the case in the subsequent visit, an IVU was assumed to be performed. 
Baseline assumptions
Table 10.1 shows the variables used in our Markov model for insight into the current effects 
and costs of both strategies. Data from the trial (n=448) were used to determine the three-
months probabilities of recurrence (prec=0.058) and progression after recurrence NMI bladder 
Figure 10.2
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cancer (pprog=0.157)
8. Also, three-months probabilities to undergo a cystoscopy, sensitivity 
(58%) and specificity (73%) of MA, and sensitivity and specificity of cystoscopy in the bladder 
(98% and 88% respectively) were determined by our trial data. Detailed, integral cost data of 
the MA analysis (blood and urine analysis) were obtained from the Department of Pathology 
of the Erasmus Medical Centre Rotterdam. Cost data of cystoscopy, IVU, TUR, cystectomy, 
and unilateral nephroureterectomy were obtained from the Department of Finance of the 
Academic Medical Centre Amsterdam. Unit prices were determined by following the micro-
costing method10, which is based on comprehensive bottom-up analyses and included costs 
of employment, material, and equipment. A societal perspective was adopted. Costs of one 
cystoscopy procedure were calculated as €168 per patient (the including personal costs were 
Table 10.1
Baseline assumptions Markov-model
Description SE & SP (%) Note Source
Sensitivity MA in bladder 58 Study
Sensitivity MA in UUT 58 Study
Specificity MA in bladder 73 Study
Specificity MA in UUT 73 Study
Sensitivity cystoscopy in bladder 98 Study
Sensitivity cystoscopy in UUT 0 Study
Specificity cystoscopy in bladder 88 Study
Specificity cystoscopy in UUT 100 Study
Sensitivity IVU 60 http://www.guideline.gov
Specificity IVU 100 False positives are not possible
Description
3-months 
probability
Note Source
Dead after progression probability
0.12
0.085
3-months risk in 1st year
3-months risk in 2nd year
Dutch Comprehensive cancer centres
Dutch Comprehensive cancer centres
Progression after recurrence 
probability
0,157 Study
Recurrence probability 0,058
Selection primary tumour to 
third recurrence
Study
Recurrence probability UUT 0,1 Given there is a recurrence Dutch Comprehensive cancer centres
Recurrence bladder after nefro-
ureterectomy probability
0,12 Raman JD et al (2007, Urology 69(2))
Description Costs Source
MA blood analysis € 357 Dep. Of Pathology, Erasmus MC (NL)
MA urine analysis € 158 Dep. Of Pathology, Erasmus MC (NL)
Cystoscopy € 168 Dep. Of Finance, AMC (NL) 
IVU € 165 Dep. Of Finance, AMC (NL) 
TUR € 1,409 Dep. Of Finance, AMC (NL) 
Cystectomy € 7,997 Dep. Of Finance, AMC (NL) 
Nephro-ureterectomy € 3,333 Dep. Of Finance, AMC (NL) 
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relatively low (€63.4 per patient) due to the short diagnostic time and efficient organisation 
in the participating hospitals). We compared these costs with the determined unit prices of 
the Department of Finance of Erasmus Medical Centre Rotterdam. The costs were about the 
same. Confidentially agreements did not allow us to give more detailed information. Costs of 
a single MA-blood analysis and MA-urine analysis were respectively €357 and €158. MA-blood 
acted as reference value for MA-urine analysis. Therefore, during two years of surveillance 
costs of MA-blood analysis were made only once (i.e. all costs were made at the beginning of 
the surveillance). However, costs of MA-urine analysis were made every moment of follow-
up. 
In our study we made the following assumptions: 1) progression takes place after recur-
rence, 2) only one recurrence can take place at the same time, 3) the health states ‘recurrence 
in UUT after nephroureterectomy’ does not exist; this prevents a second possible nephroure-
terectomy in the model, 4) only patients, who had a progression of the tumour at a certain 
moment, have a higher probability of death than the background mortality, 5) a cystoscopy 
never reveals a progressive recurrence, which originated in the UUT and invades the bladder, 
6) upper urinary tract imaging has a specificity of 100%, 7) in case of progression to muscle 
invasive UC the next step was a cystectomy, 8) after cystectomy the surveillance stops, and 9) 
in case of a positive IVU the next step was a nephroureterectomy.
Sensitivity analysis
One-way sensitivity analyses were performed to evaluate the effects of varying costs, recur-
rence rate, progression rate, sensitivity rates, and specificity rates. All point estimates of these 
variables were halved or doubled, except the point estimates of the sensitivity and specificity 
rates which were increased and decreased based on literature8, 11. 
Finally, by performing a two-way sensitivity analysis between sensitivity and specificity 
of MA, we determined a threshold line at which both surveillance strategies were equally 
effective. Various combinations of MA sensitivity, MA specificity, and costs of MA-urine were 
determined in which the test arm was as effective and costs the same as the conventional 
arm. 
Results
Table 10.2a and Table 10.2b show the current costs and effects based on the Markov model 
for the conventional arm and the test arm respectively for different moments of follow-up. 
Over the course of two years, total costs of surveillance were lower (€3,433 per capita, €1,283 
diagnostic and €2,150 therapeutic costs) for the conventional arm, than for the test arm 
(€4,104 per capita, €2,347 diagnostic and €1,757 therapeutic costs) (see column 3, stage 24 
months). For the conventional arm the cost per capita decreased by every subsequent stage 
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(column 2), because the probability to be in health states “Dead” (column 4) or “No bladder” 
(column 5) increased over the time. For the test arm the costs per capita at stage three months 
were more than twice as high as the conventional arm. At stage three months not only MA 
urine-analysis took place, but also a MA blood-analysis and a cystoscopy. Stages 12 and 24 
months were more expensive than the conventional arm due to the control cystoscopy. 
Over the course of two years, there was a probability of 6.1% to lose the bladder in the 
conventional arm and 7.9% in the test arm (see column 5, stage 24 months). The probability 
of having a progressive tumour in the bladder was very low, but higher (0.04%) in the test 
arm compared to the conventional arm (0.01%) (column 7, stage 24 months). The study 
protocol indicated an IVU and/or CT after two-times discordant outcomes between MA and 
cystoscopy in subsequent visits in the test arm. In the control arm were additional images 
of the upper urinary tract executed if clinical performance was suspect. This resulted in a 
higher detection of UUT carcinomas in the test arm compared to the control arm; 5 UUTca 
by 52 imaging examinations in the test arm and 2 by 28 examinations in the control arm. 
However, the test arm detected more tumours because of early suspicion by the urinary test 
Table 10.2
A: detailed overview of costs and effects in the conventional arm
Stage Costs per 
stage
Cum. 
costs
Pdead Pno 
bladder
Pprog-
UUT
Pprog-
bladder
Prec-
UUT
Prec-
bladder
Pwell
months € € % % % % % % %
3 451 451 0,37 0,80 0,09 0,02 0,49 0.09 98,15
6 447 897 0,75 1,61 0,25 0,02 0,89 0.09 96,40
9 440 1337 1,15 2,40 0,44 0,02 1,21 0.09 94,69
12 433 1769 1,57 3,18 0,66 0,02 1,48 0.08 93,01
15 426 2195 1,99 3,94 0,92 0,02 1,70 0.08 91,35
18 419 2615 2,43 4,68 1,19 0,02 1,87 0.08 89,73
21 412 3027 2,89 5,41 1,47 0,02 2,01 0.08 88,13
24 406 3433 3,37 6,12 1,74 0,01 2,12 0.08 86,57
B: Detailed overview of costs and effects in the test arm
Stage Costs per 
stage
Cum. 
costs
Pdead Pno 
bladder
Pprog-
UUT
Pprog-
bladder
Prec-
UUT
Prec-
bladder
Pwell
months € € % % % % % % %
3 964 964 0,37 0,80 0,09 0,02 0,49 0,09 98,15
6 336 1300 0,75 1,27 0,21 0,36 0,76 1,91 94,75
9 355 1655 1,18 2,05 0,34 0,60 0,98 3,37 91,47
12 713 2367 1,66 3,81 0,46 0,04 1,11 0,11 92,81
15 323 2690 2,06 4,26 0,59 0,35 1,21 1,85 89,68
18 346 3036 2,50 5,02 0,70 0,58 1,27 3,22 86,72
21 366 3402 2,97 6,00 0,79 0,76 1,29 3,93 84,27
24 702 4104 3,45 7,94 0,86 0,04 1,30 0,11 86,29
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and detected more UUT carcinomas, hence patients in the test arm were in a slightly worse 
health state. Therefore, the current conventional and the test arm were more or less equally 
effective over the course of two years (Figure 10.3). Thus, the Markov model suggested, as 
expected, that the conventional arm dominated the test arm in terms of cost-effectiveness. 
The conventional arm had lower costs and a slightly higher number of patients in a good 
Table 10.3
Sensitivity analysis on costs and effects for both surveillance arms over the course of two years
Cum. costs 
test arm (€)
Cum. costs 
conv. Arm (€)
Diff. in cum. 
Costs (test 
arm minus 
conv arm) (€)
Prob. of being 
well in test 
arm 
(%)
Prob. of being 
‘well’ in conv 
arm (%)
Diff. in prob. 
Of being ‘well’
(test arm 
minus conv 
arm) (€)
Variability
Recurrence Rate
0.029 3,629 3,053 576 91.48 91.69 -0,21
0.116 4,954 4,135 819 77.04 77.08 -0,04
Progression Rate
0.079 3,905 3,276 629 90.17 89.52 0.65 **
0.314 4,440 3,731 709 79.65 80.94 -1,29
Costs cystoscopy (€)
84 3,745 2,792 953 86.29 89.57 -3,28
336 4,823 4,716 107 86.29 86.57 -0,28
Costs MA blood (€)
179 3,926 3,433 493 86.29 89.57 -3,28
714 4,460 3,433 1027 86.29 86.57 -0,28
Costs MA urine (€)
79 3,502 3,433 69 86.29 89.57 -3,28
316 5,308 3,433 1875 86.29 86.57 -0,28
Sens rate MA
0.29 4,079 3,433 646 83.87 86.57 -2,70
0.70 4,111 3,433 678 87.27 86.57 0,70 **
Spec rate MA
0.69 4,181 3,433 748 86.30 86.57 -0,27
0.76 1,048 3,433 615 86.28 86.57 -0,29
Sens rate cystoscopy
0.84 4,093 3,432 661 84.63 85.31 -0,68
0.98 4,104 3,433 671 86.29 86.57 -0,28
Spec rate cystoscopy
0.79 4,583 4,327 256 86.29 86.57 -0,28
0.98 3,572 2,439 1133 86.29 86.57 -0,28
*  Test arm is more expensive than conventional arm over the course of two years
** Test arm is more effective than conventional arm over the course of two years
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health state (86.6% versus 86.3%; see Tables 10.2a and 10.2b respectively, column 10, stage 
24 months). Figure 10.3 also showed that 1) if patients would only get MA without a control 
cystoscopy at stage 3, 12, and 24 months, the probability of being in a poor health state 
would increase steeply, and 2) if patients would only get a cystoscopy at stage 3, 12, and 24 
months without MA, a lower number of patients would be in a good health state compared 
with the test arm.
Table 10.3 shows various one-way sensitivity analyses on costs and effects for both surveil-
lance arms over the course of two years. Changing the variables over plausible ranges did not 
make the test arm cheaper than the conventional arm. Only if the progression rate was halved 
Table 10.4
Combinations of MA sensitivity, MA specificity, and costs of MA-urine in which the test arm is as effective and cost the same as the conventional 
arm
Sensitivity MA Specificity MA Costs of MA-urine
(%) (%) (€)
60,5 47 0,0
60,7 53 17,0
61,4 73 69,6
62,8 100 130,5
Figure 10.3
Figure 10.3 
Probability (%) of being in a poor health state in either surveillance strategy (conventional or test 
arm) for different moments of follow-up. Poor health states indicate dead, no bladder, progression 
and recur ence UC. 
 
 Probability (%) of being in a poor health state in either surveillance strategy (conventional or test arm) for different moments of follow-up. Poor 
health states indicate dead, no bladder, progression and recurrence UC.
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(i.e., 0.079) the probability of being “Well” (i.e., being without a recurrence or progressive UC) 
was larger in the test arm than the conventional arm (90.17% vs 89.52% respectively) over the 
course of two years. This was also the case, if the sensitivity of MA was increased to 70% (i.e., 
probability of being “Well” was 87.27% in the test arm vs. 86.57% in the conventional arm). 
Obviously, changing the costs did not influence the health effect side. 
Figure 10.4 shows that the test arm was equally effective as the conventional arm, if the 
MA had a sensitivity of 60.3% in combination with a specificity of 39.8%, or if the MA had a 
sensitivity of 62.8% in combination with a specificity of 100%, or all linear combinations of 
MA sensitivity and specificity in-between. Table 10.4 shows that, for instance, if the sensitivity 
would increase to 61%, the specificity of MA remains at 73%, and the costs of MA-urine will 
decrease to €70, than the test arm is as effective and cost the same as the conventional arm.
Figure 10.4
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Figure 10.4
Threshold analysis for surveillance strategies. Sensitivity and specificity combinations in the white area indicate that the conventional arm is 
more effective; sensitivity and specificity combinations in the grey area means that the test arm is more effective.
*  = current assumption for MA test (MA sensitivity 58%, MA specificity 73%)
x = if MA-urine test has a sensitivity of 60.5%, a specificity of 47%, and will be free of charge, the test arm will be as effective and cost the 
same as the conventional arm
O = if MA-urine test has a sensitivity of 62.8% and a specificity of 100%, and will cost €130.5, the test arm will be as effective and cost the 
same as the conventional arm
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Discussion
Currently available MA markers are not sensitive enough (sensitivity of 58%) or specific 
(specificity of 73%) to use as a replacement of cystoscopy in the surveillances of bladder 
cancer. The probability of being without recurrence after two years of surveillances was ap-
proximately the same for both surveillance strategies (86.6% conventional arm vs 86.3% test 
arm), but the test arm led to higher costs (€4,104 versus €3,433 per capita). The conventional 
arm hence dominated the test arm (less costs, similar effects). However, the test arm will be as 
effective and cost the same as the conventional arm if the sensitivity of the current available 
MA-markers increases to at least 61%, the specificity of MA remains at 73% and the costs of 
MA-urine test per follow-up moment would decrease from €158 to below €70.
Lotan and Roehrborn12 used a decision tree to evaluate the cost-effectiveness of substitut-
ing cystoscopy by other bladder tumour markers than MA markers. They showed that using 
a urine based tumour marker alternating with cystoscopy is cost-effective for a wide range of 
marker sensitivities, specificities and costs, a 20% to 80% yearly recurrence and a 2% to 40% 
yearly progression rate. Although the sensitivity and specificity of their tumour markers and 
our MA markers were almost the same as in our study (respectively, 50% versus 58%, and 
70% versus 73%), the costs of diagnostic and therapeutic interventions used in both studies 
differed, especially with respect to the costs of the tumour markers. Ignoring the inflation 
rate, the costs of the tumour markers were assumed as $5012, in contrast to €158 for our 
Figure 10.5
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MA urine analysis and €357 for the one-time MA blood analysis. It is plausible that genetic 
analysis (i.e. MA markers) are more expensive than urine sediment diagnosis. However, for 
a fair comparison of costs we should use the same costing method. The costs in our study 
were based on unit prices determined by following the micro-costing method10, while the 
costs in Lotan and Roehrborn12 were according to the listing of the manufacturers. Another 
important difference between both studies is that in our study at stage three, 12 and 24 
months a control cystoscopy took place in addition to MA urine-analysis, which increased 
the costs. 
Our Markov-model did not explicitly account for the burden (i.e. quality of life; e.g. pain, 
infection rate) associated with cystoscopy. Cystoscopy would take place 7.6 times in the 
conventional arm and just 4.3 times in the test arm over the course of two years. However, we 
assumed that this difference is not enough to compensate for the more frequent cystectomy 
or greater risk of dying from cancer. Further, in the test arm at stage three, 12 and 24 months 
MA urine-analysis took place in addition to cystoscopy. Cystoscopy has by definition a high 
sensitivity. Therefore, at these stages the MA-urine-analyses might be superfluous and its 
costs can be saved here; i.e. in practice urologists should use MA as a substitute rather than 
as an adjunct for bladder cancer detection and follow-up. Another point is that MA-blood 
analysis was required to provide reference values for MA-urine analyses. The costs of MA-
blood analysis are made only once, at the start of surveillance. Over the course of e.g. ten 
years instead of two years of surveillance, there will hence be less difference in total costs 
between both arms. 
Our study had some further limitations, primarily related to various assumptions that had 
to be made in the model to make the model manageable. For example, we assumed that 
progression only takes place after recurrence. However, it is conceivable that progression 
occurs directly from the health state “Well”. Based on data from the study, we may assume 
that MA is more sensitive for progression than for recurrence. In all, this would make the 
cost-effectiveness for MA worse. Finally, it is not immediately clear how to exactly translate 
our cost estimates in other countries or clinical practice routines. The costs may vary from 
one area to another in Europe and in the United States, and the panel of tested markers can 
be improved. Further studies in a larger international population in a prospective manner are 
therefore necessary.
Some recommendations can be made. The costs of MA (blood and urine analysis) were 
relatively high compared to the costs of cystoscopy. The large difference in cost is caused 
by material as well as personal costs. Further automation of MA testing might lead to mass 
production and cost reduction. Research is needed to find out how much costs per capita 
will decrease due to automation. According to the model, the current MA-markers were 
not sensitive enough in comparison with cystoscopy. Better MA-markers should be found 
to obtain better cost-effectiveness. Especially, sensitive markers are of interests that do not 
require comparison to a blood sample of the patient for reference values. Noteworthy, based 
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on data from the study it is conceivable that awareness of a positive MA outcome may have 
prompted a higher detection rate of UC recurrences by cystoscopy. Indeed, separate analysis 
of the patients of the MA arm showed an improved cross-sectional sensitivity (70%) of the 
MA test8. Recent developments suggest other DNA-based tests as alternatives, such as de-
tection of FGFR3 mutations (present in the majority of NMI UC) and assays for detection of 
tumour-associated methylation of genes of interest13-17, since these tests are cheaper than 
MA regarding material as well as personnel costs. 
In conclusion, over the course of two years, surveillance in which cystoscopy is partly 
replaced by currently available urinary microsatellite analysis to reduce patient burden can 
only provide a cost-effective alternative to the conventional surveillance if the MA urine test 
would slightly increase its sensitivity and its costs can be reduced.
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Perspectives on management of patients with non-muscle invasive bladder 
cancer 
The medical disciplines involved in the management of patients diagnosed with a low-grade, 
low stage bladder cancer may have a different perspective on how to define an optimal treat-
ment and surveillance strategy. The clinician/urologists’ point of view on the disease may 
differ from that of the pathologist, and both their views will not necessarily coincide with the 
patient’s perspective, or with the societal (public health) perspective. An urologist will require 
an accurate and unequivocal clinical diagnosis, which can be translated directly into the most 
suitable treatment and surveillance regimen. The urologist primarily wants to limit the risk of 
treatment failure as much as possible and secondly he/she wants to prevent over-treatment. 
A pathologist may understand this view but wants to emphasize that the microscopic and 
molecular aspects of bladder cancer may be highly variable. The histological features cover a 
spectrum of diseases rather than distinct entities. This results in a subtler and more nuanced 
separation of bladder cancers, which may not necessarily be of clinical relevance. A patient 
diagnosed with bladder cancer primarily wants to know what it means for his/her future, 
and he/she desires the best possible treatment and the most rigorous surveillance scheme, 
often irrespective of burden, in order to have the best survival options. From the societal 
perspective the interests of the bladder cancer patient have to be balanced against those of 
other health care ‘clients’ based on a cost-effectiveness analysis of treatment modalities and 
surveillance (which also includes quality of life aspects) in order to have a maximum bang 
for the buck. This thesis tries to reflect the above-mentioned perspectives particularly in an 
attempt to define the requirements for an optimal surveillance and treatment strategy for 
these patients. 
Bladder cancer is a common disease with high prevalence as a consequence of its chronicity 
and represents the fifth most expensive cancer to treat, while incurring the highest cost per 
patient of all cancers1. Therefore it is important to obtain comprehensive criteria to define 
optimal management in surveillance and therapeutic options in patients with bladder cancer. 
The rationale for a tight surveillance of patients with low-grade low stage bladder cancer is 
to prevent progression by early interception of recurrences, prior to progressive growth to a 
potentially life-threatening disease. However, it is also acknowledged that such surveillance 
regimens are opinion-based and potentially overshoot or undershoot the optimal regimen 
depending on individual risk. An American study showed that the adherence to clinical 
guidelines on management of bladder cancer is only 60%2. 
The current surveillance regimen in bladder cancer represents several challenges in clini-
cal management, which can ultimately result in the proposal of individualised tailor-made 
schemes using alternating invasive (cystoscopy) and alternative non-invasive methods. A 
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prerequisite for the successful introduction of alternative methods for diagnosis and surveil-
lance is that they must be at least as reliable and feasible in routine clinical practice as the 
current (cystoscopy) practice. It is commonly held that cystoscopy is both a costly as well as a 
burdensome procedure for the patient due to its invasive nature. This thesis addressed these 
two assumptions. 
Alternative surveillance schemes may aim at the reduction of cystoscopy frequency. This 
may be achieved by two mutually non-exclusive strategies: 1) the reliable identification of 
a subset of patients with NMI UC with a low frequency of recurrence and progression using 
clinico-pathologic parameters as well as molecular tissue biomarkers (addressed in Part II of 
the thesis) and 2) establishment of novel urine tests with a sensitivity and specificity that can 
match cystoscopy (Part III). 
A major part of this thesis (Part III-V) covers the results of a randomized clinical trial on the 
cost-effectiveness of follow-up of patients with low-grade non-muscle invasive (NMI) bladder 
cancer (CEFUB trial). The major objective of this trial was to compare a conventional follow-up 
scheme with cystoscopy only to a scheme including the substitution of a number of cystos-
copies by a genetic urine test (i.e. microsatellite analysis or MA to detect genetic alterations) 
on voided urine specimens. The primary endpoint of the trial was to demonstrate more 
recurrences in the intervention arm than in the conventional arm (Part III). Other important 
outcome parameters were the difference in progression to higher stage bladder cancer and 
the identification of upper urinary tract cancers in both trial arms. Further, we studied quality 
of life aspects (Part IV) and costs of the conventional and alternative surveillance scheme 
(Part V). 
How to predict bladder cancer behaviour by tissue biomarkers? 
Can we predict tumour behaviour (recurrence, progression) and identify subsets of patients by 
clinical, pathological and molecular features, which characterise clinically distinct behaviour 
and require specific treatment and surveillance schemes? Studies offering risk-group profil-
ing with nomograms and scoring tables using conventional clinico-pathologic parameters 
have been put forward to offer probability numbers for recurrence and progression to muscle 
invasive (≥pT2) bladder cancer. These different studies may be difficult to compare, because 
the comparability is complicated by the use of different definitions for the common outcome 
parameters “recurrence” and “progression”.
Recurrence and progression
Recurrence may be defined as time to first recurrence, as recurrences in the first year after 
diagnosis, as recurrences after a negative 3-months control cystoscopy or as number of 
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recurrences per year (recurrence rate). Similarly, for the term “progression” a number of 
definitions are in use, although the most common definition is based on “stage” rather than 
“grade” progression. The issue on how to define “progression” arises from the difference in 
clinical and pathological perspective. From the clinical perspective, progression is the result 
of the clinical behaviour of the tumour showing any increase in risk category that can lead 
to an ‘irreversible’ treatment decision like e.g. cystectomy. Until curative therapy is achieved, 
a patient is diagnosed with progressive recurrence if a formerly detected single or multiple 
NMI UC (pTa, pT1, PUNLMP, low-grade carcinoma) develops either into muscle invasive UC (≥ 
pT2, high-grade) or presents with CIS, or the patient becomes a non-responder to intravesical 
therapy or a patient is treated with cystectomy due to disease regardless of the pathological 
diagnosis. We prefer to define pathological progression of bladder cancer as a recurrence 
with any histopathologically higher stage (stage progression) or any higher grade (grade 
progression) as compared to the highest bladder cancer stage/grade in the patient’s history. 
Hence a patient can have a clinical progression without proven pathological progression. 
Prognostic factors
Meta-analyses of conventional clinico-pathologic features
We performed a meta-analysis to identify the most potent prognostic factors for time to first 
recurrence and for pathological stage progression based on data obtained from 14 studies 
of larger bladder cancer patient series (chapter 3) published between 1980 and 2004. Our 
meta-analysis on disease recurrence was based on 11 publications; covering 5,021 patients. 
Data on progression were based on just 4 publications; covering 3,313 patients. The latter 
was caused by differences in definition of progression or unavailability of progression data 
in the other papers. 
Our meta-analysis clearly showed that the prognostic value of conventional clinico-pathologic 
parameters was of limited value in predicting bladder cancer recurrences. Relative risks were 
on average 2. The strongest univariable risk factors for recurrence were a residual bladder 
cancer at the 3-month control cystoscopy (RR 2.2), a history of bladder cancer recurrences 
(RR 1.5) and trigone involvement (RR 1.5). We concluded that it is not possible to reliably 
predict time to recurrence with the conventional characteristics. These findings are largely 
in line with the outcome of another large meta-analysis on a total of 2,596 patients with 
non muscle invasive bladder cancer who participated in a series of randomized phase III 
EORTC studies3. Both studies employed the same definitions of recurrence and progression. 
Main prognosticators for recurrence in the EORTC meta-analysis were a history of prior re-
currences, multifocality and tumour size with hazard ratios in multivariate analysis ranging 
from 1.35-1.56. Since the latter meta-analysis did not include residual tumour at the 3-month 
control cystoscopy as a parameter, this specific feature demonstrated in our meta-analysis 
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could not be further confirmed. The importance of the recurrence pattern, and particularly 
the presence of residual carcinoma at the 3-month control cystoscopy for prediction of future 
recurrences was also emphasized in the earlier study by Fitzpatrick et al4.
For tumour progression our meta-analysis demonstrated that both tumour grade (using 
WHO 1973) and presence of (secondary) carcinoma in situ were strong prognostic factors 
for progression (RR 6.7 and 4.4 respectively), while multiplicity, stage (pTa versus pT1) and 
tumour size had an intermediate effect (RR between 1.7 and 2.2). In the EORTC meta-analysis 
the main prognosticators for progression were presence of carcinoma in situ (HR 3.41), (WHO 
1973) grade (2.67) and pathological stage (pTa versus pT1, HR 2.19). The data indicate that 
particularly patients with a pT1 WHO 1973 grade 3 cancer and with secondary carcinoma in 
situ do poorly. The one and 5-year probability of progression to muscle invasive (pT2) carci-
noma were, however with wide confidence intervals, 29% (CI 10-24%) and 45% (CI 35-55%), 
respectively3. It is clear that additional prognosticators especially regarding pT1G3 UC would 
be of great benefit for clinicians. Treatment decisions in this subset of tumours often have a 
major impact on the patient’s quality of life. 
It should be noted that both meta-analyses discussed above are using the WHO 1973 classi-
fication system of bladder cancers for the grading of these cancers. In an attempt to improve 
the prognostication of recurrences and of progression of bladder cancers the most recent 
WHO 2004 classification of bladder cancers introduced a new grading system of bladder 
tumours with the intent to distinguish more specifically the cancers with a low risk of recur-
rence and low risk of progression from those with a higher risk. 
WHO 1973 and WHO 2004
In chapter 4 we evaluated in tumour tissues derived from 221 patients with NMI UC the 
prognostic value of both the WHO 1973 and 2004 grading system together with the prog-
nostic impact of three tissue biomarkers, CK-20, KI-67 and the FGFR3 gene mutation. We 
showed that both the WHO 1973 and 2004 grading systems contribute independent valuable 
information for prognosis of pathological stage progression in NMI UC. Most importantly, the 
WHO 2004 high-grade NMI UC now represents - by definition - a more heterogeneous group 
than the former WHO 1973 grade 3 NMI UC, and our data imply that its prognostic impact 
may be improved either by adding WHO 1973 grading information (grade 2 versus grade 3) 
or by adding FGFR3 mutation status. The FGFR3 mutation status was able to differentiate 
between those who progress and those who do not both in the total patient series and also 
selectively in the subset of high-grade carcinomas and the subset of pT1 carcinomas. From a 
molecular perspective, the separateness of mutant and wild type FGFR3 bladder cancers was 
demonstrated by clearly distinct expression profiles of these tumours5. Strikingly, in a much 
earlier study Holmang et al showed that the WHO 2004 high-grade cancers, comprising by 
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definition all WHO 1973 grade 3 cancers and a subset of the WHO 1973 grade 2 cancers, can 
be separated in those more prone to progression and those who are not on the basis of DNA 
ploidy status6.
FGFR3 and other biomarkers
Another approach to improve the prognostics of bladder cancer is the identification of mo-
lecular markers, which – preferably independent from conventional prognosticators – would 
help to identify patient at low and at high risk for recurrence and progression.  Similar to 
several studies from our group, one Spanish group also studied the prognostic impact of 
FGFR3 mutation status in a large series of 772 patients with NMI UC. In their large series, 
FGFR3 mutation status was only a risk factor for progression in univariable analysis if all 
patients were considered7. In the subset of their patients with pT1 G3 bladder cancer FGFR3 
mutation analysis was not able to distinguish the progressors from the non-progressors. To 
explain the difference in outcome between the two studies it should be noted that 1) the 
Spanish population comprises a much higher proportion of male patients (7:1) as compared 
to the Dutch and German population (3:1), 2) the lower frequency of mutant FGFR3 detected 
in the Spanish study (50%) as compared to our series (62%), 3) the difference in molecular 
technology used to detect FGFR3 gene mutations, 4) a different definition of “progression” 
utilized in both studies and 5) the difference in frequency of “progression” in the Spanish 
series (6.3%) and Dutch series (9%) and 5) the use of the WHO 1973 grading system in the 
Spanish series and both the WHO 1973 and 2004 grading system in our series. 
Similar to most other studies we did not find any prognostic tissue biomarker to predict 
bladder cancer recurrences. In another large multicenter study on 404 tumours it was also 
not possible to reproduce the prognostic value of a previously reported gene expression 
signature for recurrences8. In contrast, the previously mentioned Spanish study reported that 
the presence of the FGFR3 gene mutation in the subset of patients with a pTaG1 bladder can-
cer would predict a significantly increased risk of recurrence (HR 2.12). A recent case-control 
study on primary papillary urothelial neoplasms of unknown malignant potential (a subset of 
grade 1 WHO 1973 non-invasive bladder cancers) suggested that those without subsequent 
recurrence could be distinguished on the basis of a high expression of the FGFR3 protein 
in combination with a normal CK-20 expression pattern9. Prospective studies are needed to 
verify this potentially interesting finding. An alternative approach to identify biomarkers on 
tissue specimens for recurrence is the analysis of the morphologically normal urothelium in 
patients with (a history of ) bladder cancer. Using this novel approach, Lopez-Beltran et al10 
reported that identification of loss of heterozygosity of DBC1 (deleted in bladder cancer 1 
locus) on chromosome 9 in the normal bladder biopsies of a small series of 49 patients with 
PUN-LMP or low-grade bladder cancer was a strong marker for recurrence, while its presence 
in the tumour was not of prognostic value. 
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pT1 bladder cancer
For the group of pT1 bladder cancers some pathologists have proposed substaging on the 
basis of the depth of tumour invasion relative to the muscularis mucosae and the vascular 
plexus. Although promising, the WHO 2004 classification of bladder tumours decided not to 
include this substaging system. Difficulties encountered in the substaging of pT1 bladder 
cancers according to the depth of invasion are related to the morphologically variable mus-
cularis mucosae and the vascular plexus11 and consequently to the substantial interobserver 
variation in substaging among pathologists12-14. 
In chapter 5 we present a novel approach to the substaging of pT1 bladder cancers based 
on the extent of invasion. Tumours that show invasion of the subepithelial stroma by a single 
focus extending less than a maximum length of 0.5 mm (pT1mic) showed better prognosis 
regarding progression as compared to tumours with multiple invasive foci and/or an ex-
tensively (>0.5mm) infiltrating front (pT1ext). The characteristic that activating FGFR3 gene 
mutations are associated with favourable disease course was again confirmed in this series, 
as FGFR3 gene mutations were commonly observed in pT1mic and rarely in pT1ext, adding 
to the biological significance of this morphological distinction. The findings may also suggest 
that mutant FGFR3 pT1mic and wild type FGFR3 pT1ext do represent separate pathways of 
bladder carcinogenesis associated with a clinically distinct behaviour. To our opinion, this 
simple new sub-staging system for pT1 UC is a very promising tool. Recently, its value could 
be confirmed in a larger series of about 130 pT1 bladder cancers (personal communication: 
Van der Kwast and Van Rhijn; 2008). 
Can we improve surveillance in bladder cancer?
Randomized Clinical Trial
In a final attempt to validate previous smaller studies showing the potential value of mic-
rosatellite analysis (MA) on voided urine samples as a safe alternative for cystoscopy during 
surveillance of patients with low-grade NMI bladder cancer we designed a randomized clini-
cal trial. In one arm the patients were followed by 3-monthly cystoscopy after diagnosis of 
primary or recurrent NMI UC, and in the other (intervention) arm a number of cystoscopies 
was replaced by MA testing on voided urine samples. As target population we selected 
patients with low-grade (WHO 1973 grade 1 and 2), low stage (pTa, pT1) bladder cancer, 
excluding patients with a history high-grade (WHO 1973 grade 3) cancer and with carcinoma 
in situ. The latter patients were not considered good candidates for this trial, since they are by 
definition at high risk for both recurrence and progression, and clinicians would not consider 
it ethically to omit a number of cystoscopies in these patients. 
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Microsatellite Analysis (MA-Test) on voided urine
We reported an overall sensitivity of 58% and a specificity of 73% with a PPV of 20%. These 
figures are lower than the previously reported sensitivity (82%) and specificity (89%)15. An 
explanation is that the latter figures are derived from studies that also included high-grade 
NMI UC patients. A prospective large size multicenter trial like ours is challenging to perform 
because of the technical and logistic difficulties. This was exemplified by the observation that 
about 20% of the urine samples were inadequate for MA because their DNA content was too 
low, probably due to degradation during prolonged storage and transportation. Moreover 
the compliance to an intensive prospective study protocol is subject to the readiness of both 
patients and urologists. 
In a longitudinal analysis of our randomized trial results, the 2-yr risk to develop a recurrence 
reached 83% if MA outcome was persistently positive and 22% when MA was persistently 
negative. Consecutive positive MA results are thus a strong predictor for future recurrences, 
but sensitivity of the test still needs to be improved. Our study indicated that this could 
be achieved by, for example, patient selection and by testing of additional genetic mark-
ers in urine samples. As to patient selection we found that MA misses more recurrences in 
non-smoking patients and in females. Surveillance by MA could be especially valuable for 
smoking patients with an FGFR3 wild type tumour. Besides we noted that the presence of a 
FGFR3 mutation in the tumour at the time of enrolment in the trial was negatively correlated 
with the detection of recurrences using MA. The latter finding can easily be explained, since 
FGFR3 mutant bladder cancers are genetically more stable, with less LOH. For this reason 
an obvious additional genetic marker to be tested on voided urine samples could be the 
FGFR3 mutation itself. As mentioned earlier the FGFR3 gene mutation is common in low stage 
and grade NMI UC (up to 75%) and its high frequency in NMI -UC may provide an additional 
marker. In combination with MA or other assays this biomarker could raise the sensitivity 
of the test to a clinically more acceptable level for the surveillance of patients with NMI UC. 
A preliminary study of our laboratory on a small series of patients reported the enhanced 
sensitivity of a combination of MA and FGFR3 mutation analysis on voided urine samples of 
NMI UC patients16. Van Oers et al reported recently the development of a high-throughput 
method for FGFR3 mutation analysis on both tumour and urine DNA samples17. This easy-to-
use and relatively cheap assay can be used in every laboratory with access to a PCR machine 
and sequencer (T. Zuiverloon, personal communication). The main advantage is that the most 
common mutations in FGFR3 can be detected simultaneously in a single assay. A prospective 
multicenter trial of urinary analysis of FGFR3 combined with MA in the surveillance of patients 
with NMI UC is currently under way (T. Zuiverloon). 
Since the start of the trial two additional papers were published on the application of MA 
on voided urine samples for the surveillance of patients with NMI UC18, 19. The former paper 
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on 47 patients, including 8 high-grade cancers reports a sensitivity of 92% for detection of 
recurrences after a median follow-up of 33 months. Interestingly, they mentioned that 75% 
of the recurrences were detectable between 1 and 9 months by MA prior to the cystoscopic 
detection of the recurrence. In the second paper based on a prospective series of 91 patients 
a sensitivity of about 60% (within the range of the value found in our study) was reported, 
but they noted a higher specificity (93% for recurrences). Again, their higher sensitivity and 
specificity as compared to our study may be the consequence of the inclusion of patients 
with high-grade cancers in their study. Notably, just like in our study (chapter 6), one case of 
high-grade UC remained undetected. In their retrospective analysis they noted an improve-
ment of the sensitivity by combining cytology and MA19. 
Another test, based on the detection of genetic abnormalities in cells shed in urine, using 
fluorescence in situ hybridisation has been marketed for several years, that is the FDA ap-
proved UroVysion FISH test. Although the methodology of this test is different from the MA 
test, it also relies on the detection of genetic changes in voided urine samples. In a very 
recent paper on 250 patients, including patients with a high-grade UC, using UroVysion on 
cytological specimens of voided urine the predictive rather than diagnostic capacity of this 
test was emphasized20. The sensitivity of this test for detection of a recurrence was about 
60%. In this study 3 high-grade, high stage cancers were missed by the FISH test. The same 
authors reported that in 35 of 56 (62.5%) patients with a positive UroVysion test outcome the 
cystoscopy became positive at a later time during a total follow-up period of 29 months. In 
their population of bladder cancer patients 27% would have a positive test outcome without 
a concomitant cystoscopically detectable recurrence. The  findings of our randomized CEFUB 
trial are thus very much in line with 1) the somewhat lower than expected sensitivity of these 
genetic tests (MA and UroVysion-FISH) during follow-up of low-grade low stage bladder 
cancer and 2) the gradually evolving concept that genetic changes either detectable by 
MA test or by FISH analysis often precede the actual cystoscopically detectable recurrence 
several months later. As shown in our trial, the latter results into a very low positive predictive 
value of the MA test (20%). It would suggest that at the time that no detectable bladder 
cancer is present, genetically abnormal cells continue to be shed in the urine, as a very early 
manifestation of a future recurrence. This matches very well with the LOH study on urinary 
bladder tissue biopsies with normal morphology, revealing a good correlation of LOH at the 
DBC1 locus on chromosome 9 and recurrence21. 
Based on the relatively low overall sensitivity (58%) and specificity (73%) found by cross-
sectional analysis in our series (chapter 6) we concluded that urine tests on voided urine 
samples based on the detection of genetic changes (i.e. the MA test, but this holds also 
true for UroVysion FISH) cannot be recommended for implementation in the surveillance of 
patients with non muscle invasive bladder cancer. 
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Diagnostic Review Bias
In our randomized trial we demonstrated a significantly increased number of recurrences 
detected in the intervention (MA) arm as compared to the control (conventional cystoscopy) 
arm. This could have indicated that the intervention was very effective, but this conclusion 
does not add up with the observed low sensitivity, specificity and PPV of the MA test. A po-
tential limitation of our study is that our main analysis was based on the combined data of the 
two trial arms, one of which comprised the unblinding of the urologist for the MA outcome. 
In a separate analysis we found an increased number of recurrences by cystoscopy if informa-
tion of a positive urine test was communicated to the urologist, but not if the result was 
kept blinded. Hence the increased detection rate in the unblinded study arm (‘intervention 
arm’) could not be attributed to a high accuracy of the urine test per se, but to a diagnostic 
review bias (chapter 7). We concluded that communication of a positive urine test outcome 
to the urologist is associated with a substantial diagnostic review bias. This will lead to an 
underestimation of the sensitivity of a urine test when the urologist is blinded for a positive 
test outcome while performing cystoscopy. Indeed, in our CEFUB trial the sensitivity of the 
MA test increased from 29% when the urologist was blinded to 70% if unblinded for the 
MA outcome. As a consequence, the interpretation of the results of any (newly developed) 
point of care urine tests should take this potentially strong bias into account. Obviously, the 
increased detection of recurrences in the intervention arm as a consequence of awareness of 
the positive MA outcome at the time of cystoscopy undermines the notion that cystoscopy 
represents the “gold standard” for surveillance. It clearly shows that the sensitivity of cystos-
copy is operator dependent and recurrences can be missed. Indeed, some studies comparing 
traditional white light cystoscopy with photodynamic blue light cystoscopy also suggested 
that the latter method is more sensitive not only for detection of flat bladder lesions, but 
also for papillary lesions22. To our opinion, these studies even underestimated the lack of 
sensitivity of white light cystoscopy, since their results are based on the comparison of the 
two procedures performed consecutively and it is clear from the above study that this may 
again lead to diagnostic review bias. 
Upper Urinary Tract Tumours
Another objective of the randomized trial was to investigate whether the surveillance by 
MA would increase the number of detected upper urinary tract recurrences. Previous studies 
pointed at this possibility. In the intervention (MA) arm of our trial the number of imaging 
procedures to detect an upper tract UC was larger than in the conventional cystoscopy arm. 
This was a consequence of the protocol requiring a diagnostic work-up of the upper urinary 
tract if two consecutive MA tests were positive while cystoscopy was negative. The increased 
number of upper urinary tract cancers detected in the intervention arm was in line with our 
assumptions. 
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How does surveillance affect patients with NMI UC
The preference of about 90% of patients to opt for cystoscopy, if an alternative test would 
not offer a higher sensitivity than 90%23 can be explained by the relatively low (1.30 on a 
scale from 1-3) overall patient perceived burden of cystoscopy and the absence of physical 
symptoms (fever, haematuria, urinary tract infection) as measured in the CEFUB trial (chapter 
8). These observations are in contrast to the usually held views on the impact of cystoscopy 
on the patients’ quality of life. Most papers advocating the substitution of cystoscopy by a 
urine test refer to the invasive nature of the procedure, causing much discomfort and to the 
higher risk of urinary tract infections. 
The patients with a NMI UC reported a larger proportion (54%) of sexual dysfunction as ever 
been described. The cross-sectional analysis in chapter 9 showed the prevalence of sexual 
function in patients just diagnosed with NMI UC before the start of the intensive surveillance 
scheme. Whether the sexual function is impaired by the diagnosis or by the impact of surveil-
lance remained unanswered and must be assessed in future longitudinal studies. Besides, we 
report the unique finding that a considerable amount of patients is mistakenly afraid to harm 
their partner by sexual contact; the questionnaire series used in chapter 9 however does not 
elaborate on the fear to inflict harm to a partner caused by being a bladder cancer patient 
and with the prospect of intensive surveillance by cystoscopy. This latter question is very 
important and must be answered by extended questionnaires filled out by patients and their 
partners in a longitudinal prospective setting (M. Bekker). 
The Balance of Costs and Effects
The previously mentioned view that it is not feasible to implement the MA test in the routine 
practice of surveillance of patients with NMI UC is further supported by our economic analy-
sis. The latter clearly shows that the inclusion of the MA test leads to a substantial increase in 
expenses (about € 1000.- per capita over a 2-year follow-up period), while the total costs of a 
single cystoscopy in 2007 is € 167.-. It must be considered that even if by automatization and 
other reductions in expenses for the MA urine test the costs of the urine test would be less than 
cystoscopy this would not solve the issue of low sensitivity the test and patient preference for 
a more reliable test. The Medical Services Advisory Committee of the Australian government 
(link: http://www.tripdatabase.com/) issued a report in 2006 regarding the cost-effectiveness 
of the UroVysion FISH test and they concluded that at 5 years, the cost of implementation 
of the UroVysion pathway was Australian $7835, compared to $5959 for the conventional 
practice, while improved health outcome was not shown. Therefore, implementation of the 
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UroVysion FISH test increased the expected cost for patients until first recurrence by $1876 
over current practice. 
Future Perspective
1. Risk stratification
The inclusion of a number of clinico-pathologic variables in an easy tool for clinical decision 
taking helps to stratify patients for an individually tailored approach (Sylvester; www.eortc.
be). Using the data of our prospective trial we anticipate the generation of a nomogram 
including WHO 2004 and FGFR3 mutation status, which could serve as a prognosticator for 
progression. Gene expression profiling studies may help to find additional prognosticators 
for progression. A main drawback is that low-grade UC have a very low progression rate, i.e. 
about 5-10% in 5 years. Thus, data of large numbers of patients are required to identify useful 
biomarkers. The possibility to progress in disease is a phenomenon with a static behaviour, 
which may be captured early in the genomic blueprint of a tumour and can consequently 
be identified early by tumour and patient characteristics. In the low-grade UC tumour group 
recurrent disease is seemingly unrelated to progressive disease. Not because early intercep-
tion has prevented the disease to progress but because progressive disease is not in their 
genomic possibilities; as is recurrent disease an epiphenomenon.
For the prediction of recurrence rate no current marker identified in the tumour sample satis-
fies the requirements. Recurring disease can be considered a dynamic process, which signs 
can be intercepted by a urinary test in the course of the development of the tumour. We 
showed that a positive result of the urinary MA test often antedated, as also proven in studies 
with other urinary tests, a cystoscopically visible tumour lesion as we illustrated in figure 6.3 
in chapter 6. This in contrast to other bladder tumours that were instantly visible at the time 
of the first positive MA-test result. Moreover, in spite of our limited data, these characteristics 
seemed to be patient dependent (data not shown). Maybe some neoplastic proliferations 
remain for some period of time in a subclinical, flat and non-papillary, stage before becoming 
visible for cystoscopic examination. This theory can be supported by the genetic evolutionary 
trees (van Tilborg, Kompier), which show that the primary tumour not always represents the 
first tumour. Future research must focus on the identification of the biological and molecular 
features that determine the velocity of a subclinical, latent urothelial lesion to its visibility. 
Maybe most biomarker studies have even focused on the wrong cells (that is the tumour) 
to find useful tissue biomarkers for prediction of recurrence and instead more focus should 
be on the “morphologically normal” urothelium. The finding of an expression gene signature 
in the normal bladder mucosa in patients consistent with the signature specific for carcinoma 
in situ in patients with high-grade disease may also point into this direction8. 
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2. Future Developments in Genetic Tests and Therapies
Of course future research should be focused on the development of more sensitive and spe-
cific markers than the current ones. A better selection of the polymorphic markers currently 
in use may be of help, but also inclusion of the FGFR3 mutation assays as well as the potential 
of proteomics and methylated DNA assays must be considered. Since recurring disease is a 
dynamic process and our urinary MA test proved to be able to predict recurrent behaviour, 
may be genetic urine tests can help us to identify those patients that need more intensive 
surveillance by cystoscopy and as such they may stratify them in low and high risk of recur-
rence. As to date qualifying urinary markers would be the MA urinary test, UroVysion FISH 
and the promising FGFR3 urinary test. 
To compare two different urinary tests, for example MA and FGFR3 urinary test, a prospective 
randomized clinical trial could be performed in which five patient groups with primary or re-
current NMI UC (PUNLMP, pTa G1/G2 and pTa/pT1 LG tumours; stratified for FGFR3 gene status 
of tumour, stage, grade ’73 and ’04 and hospital) are monitored by five different surveillance 
schemes in which cystoscopy is in any case performed at 3, 12 and 24 months after inclusion; 
1) FGFR3 urinary test followed by cystoscopy in case of positive test result, 2) MA urinary test 
followed by cystoscopy in case of positive test result, 3) FGFR3 combined with MA urinary test 
followed by cystoscopy in case of any positive test result, 4) FGFR3 combined with MA urinary 
test followed by cystoscopy regardless of urinary test result and 5) performing 3-monthly 
FGFR3 urinary test and MA test blinded for urologists next to 3-monthly cystoscopy scheme. 
FGFR3gene status of the recurrent tumour must be determined and patients remain in their 
randomized group after proven recurrent disease. 
From a technical point of view much more effort should be put into effect to the increase 
in the effectiveness of the assays, like automatization and high throughput approaches in 
order to reduce the costs. It is also mandatory to reduce substantially the proportion of 
urine samples inadequate for (DNA) analysis. This could be achieved by improving both the 
logistics and the preservation methodology of the urine samples. Based on the results of our 
study we surmise, however, that the introduction of a urine test in current clinical setting 
replacing a substantial proportion of the cystoscopies is a long-term goal. 
We might consider, however, for the short term future that we should not really focus on the 
reduction of the number of cystoscopies, but rather on the prevention of recurrences by a 
better eradication of abnormal cells and a more effective and more focused therapy. Like we 
showed in our study, others have also demonstrated that a TUR of the bladder contributes 
most to the costs of surveillance (and probably also to patient burden). Therefore it might be 
better to focus our research efforts more to treatment of the disease, may be already before 
a visible tumour is present. A German study recently showed the potential of photodynamic 
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transurethral resections to detect more and earlier lesions. The radical removal of early lesions 
reduced the number of recurrences and therefore proved to be cost-effective24. Knowles has 
generated optimism that therapies targeting the receptor tyrosine kinase of FGFR3 may have 
major application in the treatment of UC25. With improvements in specificity, or the use of 
sequential tests, such approaches may provide a cost-effective means of ‘screening’ for blad-
der cancer in a high-risk population. 
Concluding Remarks
Based on the findings of these studies, it is my opinion that emphasis should be given to re-
search on the development of a combination of tools (e.g. nomograms) to allow a tailor made 
surveillance scheme for individual patients with non-muscle invasive low-grade bladder 
cancer. This includes the determination of the mutation status of the fibroblast growth factor 
3 genes during the pathological work-up of the tumour, the pathological determination of 
the differentiation grade by both the WHO ’73 and ’04 and substaging of the superficially 
invasive UC (pT1). The cystoscopic examination will remain an important ‘confirmer’ but must 
be challenged by technical improvements and new methods (like the promising fluorescence 
labelled cystoscopy). Studies have shown that improved bladder cancer detection during 
surveillance may reduce long-term recurrence rates and costs of treatment26. Bladder tumour 
markers and cystoscopic examination are both valuable in surveillance, they do not perform 
a neck-and-neck race but wage a fight for implementation in an optimal surveillance scheme 
in routine clinical setting. 
Hence, in the near future we should focus predominantly on the identification of NMI UC with 
a significantly higher risk for clinical progression, secondly develop a decision model based 
on these risks for clinical progression and offer these patients an individualized scheme of 
surveillance with a combination of cystoscopic examinations (optimized) and urinary tests 
(tumour and patient specific), finally the focus must lie on the detection and treatment of 
clinical relevant tumours.
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Summary
Urothelial cancer (UC) of the bladder is the fifth most common malignancy in the western 
world. With approximately 357,000 new cases worldwide, tumours of the urinary system 
provide a considerable contribution to the overall human cancer burden. At the time of first 
diagnosis approximately 80% of the patients presents with non-invasive papillary UC (pTa) 
or with superficially invasive UC (pT1). Combined the pTa and pT1 bladder cancers represent 
the non-muscle invasive urothelial carcinomas (NMI UC). Patients with newly diagnosed 
NMI UC will generally undergo local bladder preserving therapy like transurethral resection 
(TUR) and intravesical chemo/immunotherapy. The likelihood that these tumours recur is 
70% in 5 years with its peak incidence in the first year after initial treatment. Up to about 
30% of these recurrent tumours will present with higher histologic grade and about 5-10% 
will progress to muscle infiltrating (pT2) UC. Therefore patients are recommended to adhere 
to regular (urethra)-cystoscopic surveillance (UCS) to detect recurrent tumour at early age. 
(Urethro)-cystoscopy is an endoscopic procedure. Given the prevalence of NMI UC, this 
disease is costly to manage, particularly since both cystoscopy and particularly TUR need to 
be performed repeatedly. Two strategies can be envisioned that may allow the reduction of 
the cystoscopy frequency during bladder cancer surveillance: 1) the reliable identification of 
a subset of patients with NMI UC with a low frequency of recurrence and progression using 
clinic-pathological disease variables (described in Part II), and 2) establishment of novel 
test systems on voided urine samples with a sensitivity and specificity for the detection of 
bladder cancer recurrences that can match cystoscopy (see Part III). It is commonly held that 
these developments are propelled by 1) the burden of cystoscopy as perceived by patients 
(see Part IV) and 2) the potentially lower costs of new techniques as compared to current 
follow-up schemes using cystoscopy (topic of Part V). 
Knowledge of the biologic behaviour of newly diagnosed bladder cancer might enable the 
identification of subgroups of patients to offer a tailor-made surveillance scheme. Part II of 
the thesis describes the prognostic impact of conventional clinic-pathologic markers and a 
few selected novel biomarkers for NMI UC. For decades conventional parameters, being the 
clinical and histological features of the primary tumour, are evaluated in order to provide 
prognostic information to the patient. Chapter 3 covers a meta-analysis of several large stud-
ies quantifying the predictive value of these conventional factors. This meta-analysis demon-
strates that none of the conventional clinic-pathologic parameters are good prognosticators 
for recurrence of bladder cancer, but that both progression and mortality were strongly 
affected by the histopathological tumour grade, as defined by the WHO 1973 bladder cancer 
grading system, and by the presence of carcinoma in situ. One of the most promising novel 
prognosticators of NMI UC is the mutation status of the Fibroblast Growth Factor Receptor 
3 (FGFR3) gene. In UC the presence of this mutation is strongly associated with genetically 
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stable bladder cancer and with low-grade, low stage disease. Chapter 4 analyses the prog-
nostic value of both the grading systems according to the classification of WHO 1973 (G1, G2, 
G3) and 2004 (PUNLMP, low-grade, high-grade) as well as biomarkers FGFR3 mutation status, 
CK20 and Ki-67 in a prospectively collected series of 221 patients with low stage (pTa, pT1) 
bladder cancers. None of the parameters could predict disease recurrence, but the two grading 
systems both contributed valuable independent information for disease progression. For this 
reason, pathologists might consider to report the tumour grade according to both grading 
systems. FGFR3 mutation status was able to discriminate progressors from non-progressors 
in a subset of patients with high-grade UC. The combination of WHO 2004 grading combined 
with FGFR3 status allows a better risk stratification for patients with pTa/pT1 and high-grade 
NMI UC. For this reason we suggest that it may be of clinical value to implement on a routine 
basis the FGFR3 mutation status in pathological reporting of NMI UC. 
Patients with superficially invasive (pT1) papillary UC may run a highly variable disease 
course, creating a challenge for urologists on the choice of optimal treatment of patients 
with this bladder cancer. Several attempts have been made for substaging of UC in order 
to identify the clinical aggressive tumours, but they suffer of poor reproducibility. For this 
reason the current WHO 2004 classification system of bladder tumours does not include 
substaging of pT1 UC. We present a new substaging system in chapter 5, based on an easy 
assessment of the extent of invasion, distinguishing micro-invasive and extensive invasion of 
the subepithelial stroma. Unifocal or micro-invasive (pT1mic) is defined by a single focus of 
carcinoma, invading over a maximum distance of 0.5mm, and extensive pattern of invasion 
(pT1ext) represents either more than one focus of invasion and/or extensive infiltration of the 
subepithelial stroma over 0.5mm). The presence of pT1ext at initial diagnosis proved to be the 
strongest predictor for progression. We tested the diagnostic reproducibility and found 81% 
agreement. Mutant FGFR3 was commonly observed in pT1mic UC (63%) but rarely in pT1ext 
UC (7%), underlining the biological relevance of this simple substaging system. Further studies 
are warranted to validate this substaging system in a separate series of pT1 bladder cancers. 
Worldwide many research groups continue to search for diagnostic tests on voided urine 
samples (urine tests) allowing the detection of bladder cancer recurrences during the 
surveillance of patients with NMI UC. These tests should be at least as accurate, robust and 
cost-effective as cystoscopy, the current gold standard for the detection of recurrent bladder 
cancer in patients with NMI UC. This thesis addresses the important issue of the feasibility and 
cost-effectiveness of surveillance of patients with NMI UC. Part III, IV and V report the out-
comes of a randomized multicenter prospective trial on the feasibility and cost-effectiveness 
of an alternative surveillance strategy in the follow-up of patients with low-grade (WHO 1973 
grade 1 and 2) NMI UC (CEFUB trial) conducted in the region of Rotterdam. 
The CEFUB trial evaluated two surveillance schemes; surveillance by a conventional regi-
men (control arm) and by the follow-up of patients in whom the (conventional white light) 
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cystoscopies at 6, 9, 15, 18 and 21 months of follow-up after the last recurrence were replaced 
by a genetic urine test, i.e. the microsatellite analysis (MA) test, on DNA extracted from 
voided urine samples (test or intervention arm). Primary outcome measure was the number 
of tumour recurrences in the patients randomized to the test arm and the control arm. If 
significantly more tumour recurrences were found in the test arm this might imply that the 
MA test is more sensitive than cystoscopy. Secondary outcome measures were 1) the quality 
of life during follow-up of the patients, including physical complaints as a consequence of 
the diagnostic intervention, 2) comparison of the cost-effectiveness of the two arms of the 
trial and 3) the detection of upper urinary tract carcinomas. 
Patients with primary or recurrent low-grade NMI UC (i.e. TNM 1997 stage pTa, pT1, and 
WHO 1973 grade 1 or 2) were recruited by 10 Dutch hospitals for participation in the random-
ized CEFUB trial (Cost-Effectiveness of Follow-up of Bladder Cancer Trial). All participating 
urologists were informed about the literature on the performance of the MA test for the 
detection of recurrent UC. Patients with a history of carcinoma in situ or WHO 1973 grade 
3 UC were excluded from participation. After transurethral resection (TUR) of a primary or 
recurrent bladder cancer, 448 patients were randomized after signing an informed consent 
form (registration: ClinicalTrials.gov NCT00126958). The patients were stratified for hospital 
(ten hospitals), histopathological diagnosis (grade and stage) and FGFR3 gene mutation 
status (mutation, wild type). Participants were assigned to two trial arms by block randomiza-
tion in order of appearance. Urologists of attendance received Case Record Forms with a 
unique trial number linked to a database in the center of coordination. Study started at the 
first cystoscopy at 3 months after the TUR of inclusion with a follow-up either by 3-monthly 
cystoscopy alone (control arm) or by cystoscopy at 3 months, 12 months and 24 months and 
3-monthly urine tests on voided urine samples (intervention arm). The urine test on voided 
urine samples, i.e. microsatellite analysis (MA), was performed on patients of both the control 
and intervention arm. The laboratory MA tests were done in a central laboratory (Department 
of Pathology, Erasmus MC, Rotterdam) without knowledge of clinical or histological status. 
Urine test results were only communicated (by mail) to the urologist of attendance in the 
test arm, and according to protocol a positive test was followed by a cystoscopy within a few 
weeks. If positive urine test outcome was incongruent with cystoscopy during two subse-
quent follow-up visits the protocol recommended imaging of the upper urinary tract as this 
raised the possibility of UC in the ureter or in the pelvicalyceal part. The primary outcome of 
the study was tumour recurrence, defined as the presence of a histopathologically confirmed 
UC detected by a cystoscopy during the follow-up. 
Part III comprises chapter 6 and 7 and describes the results of the randomized trial (CEFUB). 
In chapter 6 we describe the feasibility and clinical utility of Microsatellite Analysis (MA) on 
voided urine samples in the setting of the CEFUB trial, comprising 14 outpatient clinics (in 10 
hospitals), for the detection or prediction of NMI UC bladder cancer recurrences. Although the 
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vast majority of urine samples (81%) were of sufficient quality to allow MA testing, transporta-
tion times longer than 48 hours to the central laboratory adversely affected the proportion of 
samples giving satisfactorily results. Thus, adequate logistics are required prior to implemen-
tation of MA testing in a routine setting. Sensitivity and specificity of the MA urine test for 
detection of a recurrence at the time of the subsequent cystoscopy within a few weeks after 
the urine test (cross sectional analysis) was 58% and 73%, respectively. The positive predictive 
value of MA was only 20% in cross-sectional analysis. However in longitudinal analysis, the 
2-year risk to develop a recurrence reached 83% if in a patient the MA outcome at consecutive 
urine tests was persistently positive and 22% when persistently negative. Moreover we found 
a higher detection rate for recurrences of the MA-test in male-smoking patients, that is a high 
number of false negative moments in females and non-smokers. Tumours of the pyelo-caliceal 
system and ureter were also preceded by a positive MA test. We concluded that consecutive 
positive MA results are a strong predictor for future recurrences. However, the main finding 
of our study is the relatively low cross-sectional sensitivity and specificity, so MA testing on 
voided urine samples is not sufficiently accurate to recommend its implementation in routine 
clinical practice. In spite of the limited accuracy of the MA test for detection of bladder cancer 
recurrences, the number of recurrences detected in the intervention arm exceeded that of the 
control arm (primary outcome parameter of the CEFUB-trial). During a median follow-up time 
of 34 months, 257 recurrences were detected in the intervention arm, compared to 205 in the 
control arm (log rank p=.008). We suggest that this can be explained by the unblinding of the 
urologist for the MA outcome in the intervention arm, while in the control arm the attending 
urologist was not informed about the outcome of the urine test. We considered in chapter 
7 the possibility that the awareness of a positive MA outcome may have prompted a higher 
detection rate of UC recurrences by cystoscopy. This phenomenon is also known as diagnostic 
review bias. Indeed, separate analysis of the patients of the intervention arm showed a much 
higher cross-sectional sensitivity (70%) of the MA test compared to that of the control arm 
(29%). Further, there was no difference in detection of recurrences between the two trial arms 
when urine test results were negative. We conclude that communication of a positive urine 
test outcome to the urologist is associated with a substantial diagnostic review bias. Our find-
ings imply that cystoscopy may not be as reliable as generally thought, detracting from its role 
as the gold standard.  As a consequence, the interpretation of the results of (newly developed, 
possibly point-of-care) urine tests should take this potentially strong bias into account. 
Part IV focuses on the perspective of the bladder cancer patients by evaluating the outcome 
of questionnaire studies addressing the effects of surveillance by cystoscopy and urine test-
ing on the perception of their quality of life. The study was a part of the randomized CEFUB 
trial. Chapter 8 contains the analysis of the burden of cystoscopy as perceived by patients 
under regular surveillance for NMI UC during the different stages of the cystoscopic examina-
tion and in the subsequent week. The overall burden of cystoscopy was mild, i.e. a score of 1.3 
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on a scale from 1-3, mainly as the consequence of pain and discomfort, particularly during 
the introduction of the scope. The burden of MA appeared fully attributable to the waiting 
time for the test result. Not surprisingly, the average overall burden was significantly higher 
after cystoscopy than after a urine test as surveillance test. Notably, physical symptoms like 
urinary tract infections, fever and haematuria were very rare in our NMI UC patient group, 
in contrast to previous findings. Therefore, it is not surprising that patients will adhere to 
cystoscopic surveillance as long as cystoscopy is considered the gold standard. In chapter 
9 we describe the prevalence of sexual dysfunction in our patients under surveillance with 
NMI UC and evaluated the risk factors. Patients were asked to fill in questionnaires, four 
weeks after diagnosis. The prevalence of sexual dysfunction in patients with NMI UC is high 
(54%) compared to an age and gender matched healthy population (20-45%). Diagnosis of 
NMI UC can be considered as a diagnosis of a chronic disease; therefore long-term sexual 
performance of these patients and partners would be likely to benefit from proper sexual 
information in the outpatient clinic. However, whether the sexual function is impaired by the 
diagnosis or by the impact of surveillance remained unanswered. 
Part V concerns the societal perspective of the effects of alternative surveillance schemes in 
patients with bladder cancer as studied in during our randomized CEFUB trial. In chapter 10 
we determined how to achieve cost-effectiveness in the surveillance of NMI UC by replacing 
a proportion of cystoscopies for MA testing on voided urine samples during surveillance 
of patients under surveillance for NMI UC. The costs and effects (probability of being in a 
specific health state) were compared for the two trial arms. Various sensitivity analyses were 
performed to determine the MA sensitivity, MA specificity, and costs of MA urine for which 
the test arm was as cost-effective as the conventional arm. The test arm led to higher costs 
(€4,104 versus €3,433 per capita). The test arm would be as effective as the conventional arm 
if the sensitivity of the currently available MA-markers increased at least to 63% and would 
cost the same if the costs of MA-urine decreased from €158 to at most €130.50.
It is our opinion that the research on the development of a combination of tools (e.g. no-
mograms) should be emphasized to achieve a better risk stratification and to allow a tailor 
made surveillance scheme for individual patients with NMI low-grade UC. The determination 
of the mutation status of the FGFR3 gene in the tumour during the pathological work-up 
of the tumour may become routine and its outcome may be included such a nomogram. 
Urine testing improvements should both become focused on a better selection of molecular 
markers, future urine tests may also include the detection of FGFR3 mutant DNA and much 
emphasis needs to be put in the reduction of the costs of an alternative urine test. Although 
the cystoscopic examination will remain important but technical improvements and new 
visualization methods may allow a better detection of recurrences. 
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Samenvatting
Kanker van de urinewegen wordt per jaar bij ongeveer 4550 mensen in Nederland geconsta-
teerd. De urineblaas, de plasbuis, urineleiders en het nierbekken zijn bekleed met urotheel 
en tumoren kunnen op al deze plaatsen ontstaan. Verreweg de meeste urotheelceltumoren 
worden echter in de blaas gevonden (90%). Blaascarcinoom is een vorm van kanker die 4 keer 
vaker bij mannen dan bij vrouwen voorkomt. De belangrijkste risicofactor voor blaaskanker 
is roken. Het risico om blaaskanker te krijgen is bij rokers 2-6x groter dan bij niet rokers. 
Waarschijnlijk is dit de reden dat meer mannen dan vrouwen blaaskanker krijgen. De tumo-
ren worden meestal ontdekt doordat de patiënt bemerkt dat hij/zij bloed bij de urine heeft 
en hiermee naar de huisarts gaat. De huisarts zal in het algemeen eerst onderzoeken of de 
bloeding door een ontsteking komt. Is dit niet het geval, dan wordt de patiënt doorverwezen 
naar een uroloog. Deze onderzoekt de blaas met een cystoscoop (camera) die via de plasbuis 
wordt ingebracht.  
In 95% van de blaastumoren betreft het een carcinoom (kanker) van de urotheelcellen. Het 
urotheelcelcarcinoom vertegenwoordigt een breed spectrum aan pathologische diagnoses, 
van oppervlakkig groeiend en goed-gedifferentieerd (Ta G1) tot carcinoma in situ (CIS) en 
spierinvasief, slecht-gedifferentieerd (T2-4 G3). Blaastumoren worden ingedeeld in stadia af-
hankelijk van de mate waarin ze doorgegroeid zijn in het urotheel of de andere weefsellagen 
van de blaas. Een Ta tumor is een poliepachtige (wratachtige) tumor die zijn basis heeft in de 
urotheellaag. Carcinoma in situ (CIS) is een vlakke laesie die alleen in de urotheellaag groeit. 
In de stadia T1-T4 zijn de tumoren verder doorgegroeid in de blaaswand. Ta en CIS worden 
de niet invasieve tumoren genoemd. Ta, T1 en carcinoma in situ (CIS) worden samen de niet-
spierinvasieve tumoren genoemd. Stadia T2-T4 zijn spier-invasief en het is mogelijk dat er 
dan uitzaaiingen zijn in lymfeklieren of elders. Als de tumor zich nog in de blaas bevindt 
zal behandeling van spierinvasieve tumoren bestaan uit het weghalen van de hele blaas 
(cystectomie), radicaal met aanliggende organen (prostaat en uterus) en met omringende 
lymfeklieren. De 5 jaars overleving voor patiënten met T2 tumoren die behandeld zijn met 
een radicale cystectomie is 45%, dit is lager voor de stadia T3 en T4. 
De niet-spierinvasieve tumoren vormen de meerderheid van de voor het eerst gediagnosti-
seerde blaaskankers (80%). De behandeling van deze vorm van blaaskanker bestaat uit het 
weghalen van de tumor door middel van een transurethrale resectie (TUR), dat wil zeggen 
dat via de plasbuis de tumor uit de blaas wordt weggesneden. De 5 jaars overleving van de 
oppervlakkige tumoren is zeer goed (90%). Een nadeel is echter dat ze vaak terugkomen 
(recidiveren). In 70% van de patiënten ontwikkelt zich opnieuw een tumor binnen 5 jaar en 
in 10% van de gevallen kunnen deze uitgroeien tot een spierinvasieve tumor. De recidieven 
ontwikkelen zich overal in de blaas, zelfs in de hogere urinewegen en in veel patiënten worden 
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er uiteindelijk meerdere recidieftumoren gevonden. Vanwege het hoge risico op recidivering 
en de kans op progressie tot een levensbedreigend spierinvasieve blaaskanker bij patiënten 
met de diagnose niet-spierinvasief urotheelcelcarcinoom (pTa/pT1) is een frequente follow-
up noodzakelijk. Tot op heden geldt de cystoscopie als gouden standaard voor het opsporen 
van recidieven. In het eerste jaar na diagnose zullen patiënten 3-maandelijks worden gecon-
troleerd, na uitblijven van recidief kan de frequentie van controle eventueel afnemen naar 
4-maandelijks, halfjaarlijks of zelfs jaarlijks. Nieuwe methoden waarbij met fluorescerende 
stoffen wordt gewerkt in combinatie met een andere belichting hebben aangetoond dat 
bij deze techniek meer vlakke blaastumoren, zoals met name het carcinoma in situ worden 
ontdekt. Vanzelfsprekend is cystoscopie niet in staat om recidieven in de hogere urinewegen 
(urineleiders, nierbekken) te detecteren. 
Er worden met regelmaat studies gedaan om te zoeken naar andere mogelijkheden van 
follow-up bij patiënten met oppervlakkig blaascarcinoom. Belangrijke redenen om naar 
alternatieve methoden voor cystoscopie te zoeken zijn 1) de aanname dat patiënten het 
onderzoek ook daadwerkelijk als zeer belastend ervaren én 2) de verwachting dat alterna-
tieve (urine)testen goedkoper zullen zijn dan de cystoscopie. Deze alternatieve methodes 
dienen echter even sensitief en specifiek te zijn als cystoscopie. Er zijn twee manieren om 
het huidige intensieve follow-up schema van scopiën minder belastend voor de patient te 
maken:1) door patiënten groepen te ontdekken die een minder frequente follow-up nodig 
hebben omdat de tumor als minder agressief kan worden gekarakteriseerd of 2) door een 
nieuwe test te vinden die afwisselend met de cystoscopy een minder intensief en belastend 
follow-up schema kan bezorgen. Zulke nieuwe urinetesten maken gebruik van de spontane 
urine van de patient, waarin zich tumor cellen of specifieke moleculen bevinden, die duiden 
op de aanwezigheid van een blaaskanker recidief. 
In deel II van dit proefschrift worden karakteristieken van patiënten en tumoren aangetoond 
die gekoppeld zijn aan een gunstig of minder gunstig verloop van het tumorproces. In 
hoofdstuk 3 worden alle vanouds bekende klinische en pathologische factoren met een 
voorspellende waarde (predictor) die tussen 1983-2004 in grote prospectieve studies zijn 
beschreven geanalyseerd. Uit deze meta-analyse blijkt dat het niet mogelijk is om met deze 
factoren de tijd tot het volgende recidief te voorspellen, maar de kans op progressie van de 
tumor kan hiermee wel redelijk voorspeld worden. In hoofdstuk 4 worden naast de bekende 
pathologische voorspellers ook een aantal moleculaire markers onderzocht, zoals het optre-
den van een mutatie in het fibroblast groeifactor receptor 3 (FGFR3) gen. 
Het FGFR3-gen behoort tot een van membraan gebonden celreceptoren, welke na binding 
aan fibroblast groei factor een signaal afgeeft aan de cel. Een mutatie van dit gen is de meest 
voorkomende kiemcelafwijking bij de mens, verantwoordelijk voor meer dan 7 erfelijke ske-
letafwijkingen, leidend tot dwerggroei. Het gen is gelokaliseerd op chromosoom 4  en wordt 
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door de mutatie geactiveerd. Ook in blaaskanker treedt frequent een activerende mutatie in 
het FGFR3-gen op. Mutaties in het FGFR3 gen worden gevonden in ongeveer de helft van 
alle urotheelceltumoren, met de hoogste frequentie in Ta tumoren (ongeveer 75%) verge-
leken met de invasieve pT2-T4 tumoren (20%) of CIS (0%). Er zijn 11 verschillende mutaties 
gevonden in 3 delen van het gen. In ons laboratorium hebben we een test ontworpen die 
alle mutaties in een keer kan aantonen. Deze test kan zowel uitgevoerd worden op het DNA 
afkomstig van de in paraffine ingebedde tumor als op DNA geëxtraheerd uit urine. De sterke 
associatie tussen FGFR3-mutatie en laaggradige tumoren suggereert het bestaan van een 
subgroep van patiënten met beter verloop van de niet-spier invasieve blaastumoren. Dit zou 
kunnen betekenen dat deze groep patiënten in hun follow-up minder vaak een cystoscopie 
of zelfs TUR behoeven te ondergaan. In hoofdstuk 4, 5 en 6 van ditproefschrift laten we zien 
dat de FGFR3 mutatie een prognostische gustige groep van blaaskankers identificeerd bin-
nen de groep van hooggradige blaaskankers, zoals gekarkateriseerd door het meest recente 
graderingssysteem (WHO 2004). Ook lieten we zien dat het mogelijk is om het beloop van 
de klinisch problematische groep van pT1 blaaskankers beter te voorstellen door toepassing 
van een nieuw systeem van substageren. 
Het is al langer bekend dat tumorcellen in urine te vinden zijn. In 1864 werden voor het eerst 
neoplastische urotheelcellen in urine herkend. Pas halverwege de vorige eeuw beschreven 
Papanicolaou en Marschall het gebruik van cytologie voor de diagnose van urotheelcelcarci-
noom. Tumorcellen kunnen door de patholoog worden onderscheiden van normale cellen die 
zich eveneens in urine bevinden (cytologie). Sinds die tijd wordt cytologie in combinatie met 
cystoscopie in veel centra gebruikt als screeningsmethode voor blaascarcinoom. Cytologie 
is echter weinig gevoelig voor detectie van laaggradige niet-spierinvasieve blaascarcinomen 
(30-60% sensitiviteit). Aangezien de meeste blaaskanker recidieven laaggradig zullen zijn, 
heeft cytologie maar een beperkte waarde bij de surveillance van patienten met een laag-
gradige niet-spierinvasieve blaaskanker. Het zijn de hooggradige, de meer invasieve carcino-
men en carcinoma in situ, die wel door middel van cytologie gediagnosticeerd worden. De 
zoektocht naar het ontwikkelen van nauwkeurige, snelle en prognostische methoden voor 
follow-up en naar methoden voor vroege detectie van blaascarcinoom hebben geleid tot de 
ontdekking van verschillende veelbelovende blaastumormarkers.
Een aantal van deze potentieel diagnostische markers zijn gebaseerd op tumor-geassocieerde 
antigenen, zoals de Blaas Tumor Antigen-test en Immunocyt, op een verhoogde productie van 
vasculaire endotheliale groei factoren, of op veranderingen in celmorfologie, de cytoskelet 
markers. Ondanks grote vooruitgang in de ontwikkeling van deze markers voor detectie van 
blaastumoren zijn ze nog niet  nauwkeurig genoeg om eventueel de cystoscopie te vervan-
gen. Een nieuwe benadering die van het laatste decennium dateert is om tumorgebonden 
DNA veranderingen te gebruiken. 
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Het humaan genoom wordt gevormd door 23 chromosomenparen, waarbij elk paar be-
staat uit een kopie van een maternaal en van een paternaal chromosoom. Het DNA in de 
chromosomen wordt gevormd door een opeenvolging van 4 verschillende basen (Adenine, 
Thymine, Cytosine, en Guanine). De volgorde van deze basen codeert voor de belangrijke 
genetische informatie van een organisme. Een microsatelliet is een herhaling van een sim-
pele base-volgorde van 2, 3 of 4 basen in het DNA. De totale lengte kan variëren tussen 15 
en 20 herhalingen van diezelfde base-combinatie, bijvoorbeeld een (CA)n-repeat. Ze komen 
overal in het genoom voor, in allerlei lengtes en combinaties. Door de hoge mate van variatie 
tussen deze microsatellieten bestaan er van mens tot mens grote verschillen in het DNA. Voor 
kankeronderzoek is deze variatie van groot belang. 
Microsatellieten zijn relatief instabiel en dit resulteert in verschillen in het aantal CA 
herhalingen waardoor de lengte van de microsatelliet varieert. Als de microsatelliet in 
lengte verschilt op de maternale en paternale kopieën van een chromosoom (heterozygotie) 
kunnen we dit lengteverschil aantonen. Is een van de twee chromosomen in de kankercel 
verloren gegaan, dan spreken we van verlies van heterozygotie, of LOH. Voor het urineonder-
zoek gebruiken we meerdere microsatelliet markers op verschillende chromosomen om de 
gevoeligheid te vergroten. LOH-analyse is een methode die gebruik maakt van de mogelijk-
heid om een microsatellietsequentie in het DNA te herkennen. Deze DNA veranderingen zijn 
met de huidige technologieën relatief gemakkelijk zichtbaar te maken. Bovendien zijn deze 
veranderingen aanwezig in de oppervlakkige blaastumoren, die niet met cytologie kunnen 
worden gedetecteerd doordat de cellen er normaal uitzien. In dit proefschrift wordt deze 
analyse getest en MA-test (Microsatellite Analyse Test) genoemd. 
In een grootschalig onderzoek gefinancierd door ZONMW hebben we in samenwerking 
met 10 regionale ziekenhuizen de gevoeligheid van de MA test voor het opsporen van een 
blaaskanker recidief onderzocht op 815 urine monsters van patiënten die gevolgd werden 
in verband met een eerder verwijderde oppervlakkige blaastumor (hoofdstuk 6). In deze 
gerandomiseerde trial werden patienten met een laaggradige niet-spierinvasieve blaaskan-
ker ingedeeld in twee groepen, te weten patienten die vervolgd werden op de gebruikelijke 
manier (cystoscopie) elke drie maanden na de diagnose (controle arm) en patienten bij wie 
een deel van de cystoscopieen werden vervangen door de MA test (test arm). Indien in de 
test arm evenveel recidieven zouden worden opgespoord als in de controle arm, bij gelijk-
blivende aantallen patienten met progressie zou de trial een voorkeur voor het alternatieve 
surveillance schema aangeven. Overigens werd in de controle arm ook een MA test uitge-
voerd ten tijde van de cystoscopie, maar de uitslag daarvan werd niet meegedeeld aan de 
uroloog of patient.
We waren in staat om in de deelnemers aan de CEFUB trial bij wie urine test en correspon-
derende cystoscopie resultaten bekend waren 49 van de 84 recidieven aan te tonen (sen-
sitiviteit 58%). Deze sensitiviteit was lager dan op basis van eerdere studies te verwachten 
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was. Uit deze cross-sectionele analyse (vergelijken van de diagnostische testen op hetzelfde 
tijdstip) bleek ook, dat er een groot aantal “vals positieven” was. Dat wil zeggen dat de MA 
test positief was en er op dat moment met cystoscopie geen tumoren werd gevonden. De 
positief voorspellende waarde  (PPV) van de MA test was derhalve slechts 20%. Dit suggereert 
dat de test niet gevoelig is en vaak ten onrechte positief uitvalt. Hier kunnen we echter een 
aantal kanttekeningen bij plaatsen. De MA test bleek vaak eerder dan de cystoscopie recidief 
tumoren te kunnen detecteren. Vervolgden we de patiënten namelijk na een positieve MA 
test en een negatieve cystoscopie dan bleken ze enige tijd later toch een recidief tumor te 
hebben ontwikkeld. In de longitudinale analyse zien we dat de PPV van 20 naar meer dan 
80% klimt als de urines positief blijven. De MA test heeft dus toch wel een voorspellende 
waarde en ook is ze in staat om blaaskanker in de hogere urinewegen op te sporen. Toch 
moeten we concluderen dat de test op dit moment niet goed genoeg is om aan te bevelen 
als een nieuwe routine test voor de surveillance van patienten met een laaggradige niet-
spierinvasieve blaaskanker. Ondanks de lage PPV van de MA test bleek het aantal recidieven 
in de test arm van de trial duidelijk meer te zijn dan in de controle arm (cystoscopie follow-up 
alleen). Dit zou kunnen leiden tot de conclusie dat de urinetest toch een goed alternatief zou 
zijn. Echter, in de trial opzet was de uroloog in de test arm op de hoogte van de uitslag van de 
MA test voor het uitvoeren van de scopie, terwijl de uroloog van de patienten in de controle 
arm dit niet wist. Het is dus voorstelbaar dat de wetenschap van de uitslag van een positief 
urinetest van invloed kan zijn op de cystoscopische beoordeling van de blaas. In hoofdstuk 
7 wordt dit verder onderzocht en bevestigd. Voorkennis van de uitslag van een positive 
urinetest bleek een hogere detectie van recidieven op te leveren, en dit verschijnsel heet een 
diagnostische review bias. In het geval van een negatieve uitslag van de urine test was dit 
niet het geval. Dit leidt tot het onderschatten van de sensitiviteit van een urinetest als een 
uroloog is geblindeerd voor de resultaten. Deze bevinding is erg belangrijk in toekomstige 
onderzoeken van diagnostische urinetesten. 
Verder vonden we dat de microsatelliet test gevoeliger was bij mannelijke patiënten en 
bij patiënten die geen FGFR3 mutatie in hun tumor hadden en/of rookten (hoofdstuk 6). Dit 
komt vermoedelijk doordat deze tumoren in het algemeen andere DNA afwijkingen hebben 
die juist met de MA test kunnen worden aangetoond. De meeste tumoren die werden gemist 
met de MA test waren kleine laaggradige Ta tumoren, maar ook 1 T1 graad 3 tumor. Daaren-
tegen werden 4 tumoren van de urineleiders met de MA test gedetecteerd die niet zichtbaar 
zijn bij cystoscopie. De conclusies uit deze studies zijn dat meerdere positieve MA testen een 
sterke voorspeller zijn van een recidief blaastumor maar dat de gevoeligheid nog verbeterd 
kan worden bijvoorbeeld door selectie van patiënten en door combinatie met andere mar-
kers zoals FGFR3. Verder moesten we constateren dat een aantal markers niet goed werkte 
en dat we waarschijnlijk ook effectievere markers kunnen selecteren door bijvoorbeeld meer 
markers te kiezen uit gebieden van het genoom die in blaastumoren vaak verloren gaan. Dit 
zal in de nabije toekomst verder worden onderzocht. De MA test kan het niet goed doen als 
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er veel normale cellen in de urine zitten. Een beperking zal bovendien altijd zijn dat er niet 
in ieder urinemonster tumorcellen zitten. Een belangrijke bevinding is wel dat de MA-test 
tumoren in de hogere urinewegen kan aantonen die niet gezien worden met cystoscopie. 
Voor detectie van deze tumoren zijn andere, kostbare  beeldvormende  technieken zoals een 
CT scan nodig. Verder is het belangrijk dat de MA-test een voorspellende waarde heeft; een 
positieve test wordt vaak op enige termijn gevolgd door de ontdekking van een recidief.
Scopiëren is een endoscopische invasieve methode waarvan we denken dat het voor patiën-
ten erg vervelend is. In hoofdstuk 8 zien we dat een cystoscopie door de patiënt in geringe 
mate als onaangenaam wordt ervaren en er een kleine kans is op urineweginfecties en pijn 
bij het plassen in de dagen na de cystoscopie. Wel hebben blaaskanker patienten meer last 
van sexuele dysfunctie in vergelijking met andere patiënten populaties (hoofdstuk 9), maar 
het is niet duidelijk of dit veroorzaakt wordt door de cystoscopie of door de surveillance op 
zich.
In part V worden de effecten vergeleken met de kosten. Het kosten-vraagstuk is in de ge-
zondheidszorg natuurlijk erg belangrijk. In hoofdstuk 10 berekenen we daarom de kosten 
effectiviteit van de follow-up als de cystoscopien gedeeltelijk worden vervangen door de 
MA test. De controle arm is de groep patiënten die gecontroleerd wordt door middel van 
cystoscopie en in de test arm worden patiënten afwisselend gecontroleerd middels scopie 
en MA test (zoals eerder beschreven). De kosten en effecten (de kans om in een bepaalde 
gezondheids toestand te zijn) worden in beide armen met elkaar vergeleken. Vervolgens 
zijn er verschillende sensitiviteits analyses uitgevoerd om te bepalen bij welke sensitiviteit, 
specificiteit en prijs de beide armen aan elkaar gelijk zijn. De test arm was duurder dan de 
controle arm (€ 4104,= versus € 3433,= per capita). De test arm is berekend even effectief te 
zijn als de controle arm als de sensitiviteit minimaal 63% is en de kosten van een MA test zou 
dalen van € 158,= naar hoogstens € 130,50.
Naar aanleiding van het onderzoek beschreven in part III is duidelijk geworden dat er nog 
veel winst behaald kan worden uit de ontwikkeling van urine testen en de verbetering van 
de cystoscopie techniek. We moeten de nadruk leggen op de ontwikkeling van combinaties 
van methoden (nomogrammen) om tot een follow-up-op-maat te komen. De bepaling van 
de FGFR3 mutatie status van de tumor hoort bij de standaard work-up van de tumor door 
de patholoog. Uit preliminary results blijkt dat de combinatie van de FGFR3 en MA testen in 
staat is om in 75% van de gevallen een gelijktijdig recidief aan te tonen. De vraag is of deze 
sensitiviteit nog omhoog kan. De DNA testen zijn dus in staat om recidieftumoren eerder te 
ontdekken dan routine cystoscopie, maar de testen ontdekken niet alle tumoren en missen 
soms zelfs belangrijke tumoren. Ondanks het feit dat één derde van de patiënten de cys-
toscopie als een belastend onderzoek ervaart, kiest de meerderheid van de patiënten voor 
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de methode waarvan zij denken dat die de meeste zekerheid geeft. Wellicht is het de beste 
strategie om ons allereerst a) te richten op het herkennen van de groepen patiënten binnen 
de niet-spierinvasieve blaaskanker patiënten met een duidelijk hoger risico voor progressie 
en b) op basis van dit risicoprofiel een beslismodel te ontwikkelen waarbij gebruik wordt 
gemaakt van een follow-up schema waarin urinetesten en cystoscopiën (beide in geopti-
maliseerde vorm) gecombineerd worden, waardoor c) de hoogste relevante detectiegraad 
wordt bereikt. Tenslotte duidt ons onderzoek op het belang van 1) het bepalen van de FGFR3 
mutatie status en 2) het substageren van de groep van oppervlakkig invasief groeiende (pT1) 
blaaskankers een belangrijke rol kan spelen bij het bepalen van het risico op progressie.  
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De schijnwerpers dansen door de zaal, een zaal vol mensen. Zo op het eerste gezicht lijken 
er meer mannen dan vrouwen aanwezig te zijn, en opvallend veel rokers eigenlijk. Vandaag 
mag dat blijkbaar. Er wordt heel hard geapplaudiseerd! Vanaf het balkon boven de ingang 
heb ik goed zicht op het feestelijke gebeuren. De zaal is rond, een warm koepelvormig licht 
plafond ademt lente-avond. Het is winter. In de ruimte rondom de vloer zijn, met een vrolijke 
diversiteit in hoogte en vorm, balkonnetjes gebouwd met sierlijke ballustrades. Een aantal 
wenteltrappen biedt toegang tot de verschillende balkonnen. Tegenover de ingang, aan de 
andere kant van de zaal, valt een prachtig mooie verhoging op met aan weerszijden een 
aantal treden om het podium te bereiken. Boven het podium hangt een gigantisch wit laken 
waarop in rood de letters ‘C’, ‘E’, ‘F’, ‘U’ en ‘B’ en moeilijker leesbaar iets van ‘tiralalalaa’.
Er heerst een frivole, uitgelaten stemming. De schijnwerpers richten hun lichten op het 
podium waar even daarvoor is gestart met een officieel programma. Precies 484 mensen ko-
men om de beurt op van links, ontvangen met een officieel gebaar en woord een glanzende 
CEFUB-sjerp en verlaten uitgelaten het podium van rechts onder luid geklap en gejoel. De 
wat schuchter ingezette polonaise zie je langzaam veranderen in een waar feestgedruis. Vol 
overgave wordt er gefloten, geklapt, ‘Bravo’ of ‘Caramba’ geroepen. Het applaus voor de 484 
mensen vanuit de zaal is oorverdovend!
En dan klinken er ontkurkende geluiden. De schijnwerpers bewegen precies op het afgespro-
ken moment gecoordineerd naar een balkon links van de ingang. De aanwezigen in de zaal 
zien nog net de verraste gezichten op het balkon nat worden van de bruisende champagne. 
Kurken vliegen door de lucht en confetti plakt aan warme wangen. Een jazz-combo speelt op 
het podium. De hele zaal proost, laat zich meeslepen door de muziek en kijkt naar het balkon 
waar de sjerpen uitgedeeld worden. Af en toe wordt er van herkenning, enthousiast, een 
naam uitgeroepen. Albert Schweitzer doet vol overtuiging de twist met aan weerszijde Jen-
neke Vis en Toine Zeegers. De enige echte Erasmus trekt, zoals altijd iets gebogen staande, 
zijn pij op en slaat onze Sint Franciscus zeer hartelijk op de schouder en roept iets uit over 
wij monikken en bruggen bouwen. De lof der efficiëntie, doortastendheid en schijnbare 
logistieke eenvoud gaan vervolgens uit naar Stefan Haensel en Egbert Boevé, boegbeelden 
van rust en klasse in de Haven. Clara en Amphia doen samen een moeilijke versie van de 
klompendans en maken daarbij zoveel mogelijk lawaai. Reinier de Graaff laat zijn follikels 
weer eens rammelen in een spetterend duet met dj maestro JFAT Bogdanovicz en als je goed 
kijkt zie je hier en daar enkele tranen van ontroering, prachtig. De zaal geniet en stemt vol-
mondig in als er vervolgens een naamsverandering van Ikazia naar I-Kats-ia en van Vlietland 
naar Lie-land wordt voorgesteld. Verdiend! Het LUMC kijkt stilzwijgend toe en geniet terwijl 
Caroline de Jong-Mom haar prachtige rode schoentjes precies op de maat van het combo 
laat dansen. Een groot applaus zwelt op en als de jazzy klanken dan weer door de zwoele zaal 
klinken lijkt de schijnwerper te zoeken.
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In het midden van dit hele spektakel tussen al die mensen en druppels deinen 3 opvallende 
gestalten, vrolijk lachend kijken ze geamuseerd om zich heen en dansen alle drie op geheel 
eigen wijze, erg grappig. Af en toe zwaaien ze, roepen ze wat in elkaars oor en lachen. Mensen 
komen op ze af en maken een praatje. 
De eerste gestalte waar het licht opvalt, is een schijnbaar coordinatieloos bewegende lange 
tengere gestalte, die in één hand een fles Eiswein vasthoudt en met de andere drukgebarend 
een verhaal kracht bijzet. Als je goed luistert hoor je hem giechelen en de ene grap na de 
andere vertellen. Het is Theo, professor Theodorus H van der Kwast, patholoog in Toronto. 
“Thééééooooohooooo!” klinkt het ineens hard en ongepast door de zaal. Ik schrik want ik 
ben het zelf die zo roept! Oei, denk ik nog, wat nu! Ineens is het stil, zelfs het combootje zet 
onbedoeld een decrescendo in. Ik sta nog steeds op dat balkon te kijken, verschrikt nu, en zie 
hoe alle blikken zich langzaam vol verwachting op dat balkonnetje boven de ingang richten. 
En zie ook hoe de ingehuurde cabaretier verbaasd en zenuwachtig door zijn papieren bla-
dert. Maar de ballustrade biedt geen enkele vorm van beschutting. “Hééé Theeéoo,” herhaal 
ik voorzichtig iets zachter, en nog zachter voeg ik daar “jij hier!?” aan toe. Theo is mijn held, 
mijn inspirator, mijn wetenschappelijk voorbeeld. Op Theo kun je bouwen en vertrouwen, 
Theo is bescheiden en helpt oprecht, Theo denkt verder en breder dan alleen zichzelf. Theo 
rent af en toe vol onschuld als een olifant door een porseleinkast, en dat vind ik ontzettend 
grappig! Theo werkt harder en denkt sneller dan het licht. Met Theo kun je paralelle gesprek-
ken voeren, ongelofelijk lachen en heel veel grappen per minuut maken. Theo staat voor zijn 
liefde voor Veena en zijn zonen, Theo is verloren zonder Veena. Theo is Theo, uniek in zijn 
soort. Zonder Theo zou de CEFUB trial nooit zo succesvol zijn afgerond. Wat nu? Wat moet ik 
zeggen? Voordat de eerste ‘s-‘ tot SSSPEECH kan uitgroeien roep ik wanhopig met een tikje 
dramatiek: “Theo, jij was de drijvende kracht achter de CEFUB-trial, zonder jou was het geheel 
niet gebundeld geweest! Bedankt....(en iets harder en dramatischer) bédankt!!!” Het applaus 
zwelt weer aan en ik denk, professionaliteit, je moet professioneel blijven, dit is professioneel. 
Niet te emotioneel allemaal, straks gewoon even naar Theo toelopen en hem eens stevig 
bedanken. 
Net naast de lichtbundel staat een man hard te klappen en te lachen. Af en toe lijkt hij 
wat te mompelen als “ja, dat is inderdaad zo, ja inderdaad...mmm..., als we de kansen op 
deze manier berekenen maakt dat een significant verschil, hoewel dat er misschien niet toe 
doet, precies, moet ik eens uitrekenen, ja leuk, moet een vrij simpel sommetje zijn eigenlijk..
mmmja.....” Het is Ewout, professor Ewout W Steyerberg, klinisch besliskundige aan het Eras-
mus MC. Het licht van de schijnwerper draait nu zijn kant op en Ewout staat iets verlegen 
maar prachtig midden in de bundel. Het staat hem goed, licht, de lichtbundels lijken zijn 
gedachten te reflecteren. Nee niet weerkaatsen echt reflecteren. Golven van berekeningen 
en mogelijkheden worden teruggebeamd. Ewout heeft ook zoveel betekend voor de trial 
en voor mijn persoonlijke ontwikkeling, met herwonnen zelfvertrouwen roep ik zo hard als 
ik kan: “Applaus, applaus voor Eéééwout...!” Ontelbare besprekingen, eerst op de 20ste met 
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prachtig uitzicht later op de 2de met prachtig uitzicht. Altijd gezellig en altijd met iets lekkers, 
uren bomen, schematiseren, rekenen en discussieren om pas echt naar elkaar te luisteren als 
we allebei murw geluld waren. Het was een waar genoegen. Iedereen begrijpt wat er bedoelt 
wordt en stampende voeten, lucht-tong-en-tand-technieken worden aangewend om het 
heersende gevoel kracht bij te zetten. En het applaus is oorverdovend.
Weer lijkt de schijnwerper zijn licht te willen verplaatsen, naar iemand die vlak naast Ewout 
staat, het is een vrouw. De vrouw kijkt en observeert kritisch, lijkt het, met haar rechter wijs-
vinger draait zij zachtjes rondjes rondom haar lippen en met de andere hand houdt zij gedis-
tingeerd een glas van de beste Bordeaux vast. Ze geniet van de aandacht, van de wijnen, het 
overheerlijke Franse en Italiaanse eten, ze geniet van de resultaten en gelooft krachtig in haar 
produkt. Haar produkt, de urine analyse, de ‘simpele’ methode om mutaties aan te tonen. Het 
is Ellen, Professor Ellen C Zwarthoff, biochemica. En ik roep aanzwellend “...én...Elluhuhuhn!...” 
Inmiddels staat ook Ellen in het volle licht en het applaus zet zich voort. De drie musketiers 
grijpen elkaar bij de gesjerpte schouders en dansen heel stijlvol de Griekse zirtaki....
Ik besluit me in het donker van het balkon terug te trekken om ongestoord goed naar de 
andere kant van de zaal te kunnen kijken. Er is zoveel leuks te zien.
In de gezellig grote ruimte bevinden zich 3 grote wenteltrappen die in verbinding staan met 
de hogere gelegen balkon-delen. Een wat kleinere gestalte daalt één van de wenteltrap-
pen af, duidelijk een man, heel zijn houding straalt kracht, autoriteit en plezier uit. Het is 
overduidelijk Jaap, dé Jaap, professor Jaap Zwartendijk, uroloog in het LUMC, Leiden. Een 
leermeester pur sang. Wentel, de bocht om. Een grijns verlicht zijn gezicht. Iedereen weet dat 
deze man met een stoere goedheid en een onverschrokken beheerst moreel zijn gelederen 
genadeloos temt en opvoedt in rechtvaardigheid. Dat is nou Jaap, hij weet alles en is overal. 
Op dat moment grijnst hij naar me en trekt zijn linker wenkbrauw hoog, heel hoog op terwijl 
de rechter wenkbrauw laag blijft. De sjerp past trouwens goed bij zijn lintje. Ik wil zwaaien en 
“joehoeoe” roepen en “.....zolang het maar klinisch relevant en niet te duur is, hè Jaap!” maar 
hij draait de wentel weer door. Ik zie hem richting de ronde tafels die voor het podium staan 
lopen. Daar zit ik ook professor Schröder, uroloog, herr Fritz, dat laatste zou ik trouwens nooit 
tegen hem durven zeggen, maar ik vind hem zo bijzonder. Met rood strikje en geknepen 
ogen zit hij samen met Chris Bangma, professor Chris Bangma, aan een tafeltje vlak naast 
het podium, ze lachen heel ontspannen. Een slanke vrouw met halflang zwart haar zweeft 
sierlijk langs, och, het is die lieve, pittige mevrouw Bonnema. Ik herinner me de gezellige 
etentjes en bijeenkomsten met de prostaatgroep. Helaas spraken we natuurlijk veel te veel 
over prostaatscreening, à la, niet erg Ingrid kwam ervoor terug uit Zwolle. Oh kijk Winand & 
Wil, Wil & Winand zijn er ook, dan is het daar zeker gezellig. Professor M Hunink en professor 
W Oosterhuis zie ik daar ook zitten. Professor B Kiemeney schuift aan en er lijkt zich een 
geanimeerd gesprek te ontwikkelen. 
Acknowledgement / Dankwoord 259
Ondertussen deint de dansvloer op de ritmische golven van het combo bandje, dat zich 
inmiddels versterkt ziet met een aantal musici. Met een Bas-gitarist die de lead ondersteund 
door vol overgave de hendel op zijn gitaar heen en weer te bewegen (lijkt trouwens erg op 
Bas van Rhijn, och ... het ís Bas van Rhijn), met dé Theo van der Poel die met zijn mondharmo-
nica heel knap een bridge maakt naar het nummer ‘money, money, money’ en daarnaast ook 
nog een verrassend soepele moonwalk uit de kast trekt. Op de banjo zet Marie-Louise Essink 
Bot een harmonische septiem in. Twee achtergrondzangeressen worden aangekondigd als 
de typical ladies of ‘100 swings a minute’ Carrie en de enige echte Ingrid van Woerkoóóóm. 
De zaal barst uit zijn voegen als beide dames knippend met de vingers en draaiend met de 
heupen een kraakhelder ‘ahoe’ ten gehore brengen. Een daverende drumriff van niemand 
minder dan Irene Lurkin dwingt de zaal weer tot beweging. En dan in een volle octaaf hoger, 
in een perfecte harmonie, zingen Marion Verhoef, Fatima en Mina het kippenvel op ieders 
armen, wat een warme stemmen.... ondertussen worden er steeds mensen het podium 
opgeroepen en door de bekende cabaratier met pakkende woorden en een CEFUB-sjerp 
gehuldigd. ZON-MW heeft dat gratis weten te regelen.
In de verte zie ik in een loungehoek onder een balkonnetje een gehuldigd groepje gebogen 
staan over een laag tafeltje. Nieuwsgierig ga ik even kijken. Het zijn Merel, Kirstin, Yvette en 
Twan. Ze spelen een analytisch spel. Het ziet er razend moeilijk uit maar ze schijnen exact 
te weten wat ze moeten doen. Om hun heen staan Angela, Marcel, Magda, Tahlita, Martijn 
en Marjolein. Af en toe mogen deze omstanders ook wat roepen of joelen. Bij verlies van 
een potje moet je blijkbaar een hoeveelheid grote glazen epjes met een gelige vloeistof 
opdrinken. Dat gaat dan gepaard met een afgrijzend ge-oe door de rest van de groep en 
de omstanders, een teken voor Irene-Lurkin-achter-drums om prompt een drumsalvo af te 
vuren. Deze club is ontzettend belangrijk geweest voor de CEFUB-trial. 
Rondom de favorite punch-bar waarop bier, zoete-witte-wijn opties en hot chicken wings 
staan een aantal rare lui volledig uit hun dak te gaan. De één nog gekker dan de ander. Een 
man met snor komt naar me toe en ik schrik. Omdat ik hem niet meteen herken wrijft hij 
door zijn krullen en steekt een sjakkie op! Vervolgens doet hij zijn snor omhoog en bromt 
vanuit de grillige diepten van zijn rokerige longen: “...It is I, Alèx!..” Hé Aaaaaahl roepen 2 
stemmen in koor vlak achter me, het zijn dé Moniqueskes. Twee blonde Brabantse moeders 
met veel jolijt in de kop. Ik geniet, daar komt ook Brutus aandansen. Met een uitgestreken 
gezicht, waarop een veel te grote zware zwarte zonnebril, swingt hij vol overgave recht op 
het chicken wings rek af. Alex ziet dat en geeft hem een klein corrigerend duwtje richting 
de punch.....en gromt “dat spul is toch niet te zuipen.” Ik wil graag blijven maar dan zie ik een 
aantal dames lachend discussieren. Het zijn Hilde, Esther, Lucie, Joke, Fatma en Renske. Lieve 
mensen die me dierbaar zijn in vriendschap en wetenschap en prachtige resultaten hebben 
beschreven. Mijn aandacht wordt getrokken naar een lawaaierig balkon en ik sla Lucie en 
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Fatma nog met een harde klop op de schouders en knijp nog even lekker in hun wangen....
zet ‘m op lieve ladies!
Op een hoog balkon staan een aantal mensen op geheel eigen en subtiele wijze met hun 
wijsvinger en met scopes in de lucht te priemen en te zwaaien. Volle bak op dat balkon. Je 
ziet kalende, blonde, kale, extreem blonde, gekrulde en hele kort gestylde koppies, ontzet-
tend gebruinde en iets blekere gezichten, groene en blauwe kapjes, met en zonder bril en 
er klinkt een enorm gekakel. De wijn en de lach vloeien rijkelijk, de kaas ruikt lekker. Wat een 
gezellige groep. Daar Henk en Milou, een veelbelovende energieke combinatie. Dat zijn nou 
de urologie collega’s van het LUMC en het Haga en oh Ruben staat er ook (natuurlijk met 
twee wijsvingers) te priemen en te shaken ....joehoeoe... wat een gezelligheid! 
Als ik heel ver voorover leun en over de rand van de ballustrade hang kan ik door de ingang 
van de zaal de grote entrée hal inkijken en de foyer zien. Aan de bar in de foyer van het 
gebouw staat een groep mensen luid te lachen, kinderen dansen er omheen en spelen 
verstoppertje. Dat was lang geleden dat ik die zo met zijn allen heb zien staan. Suus, Reinout 
en Lars, Ivo, Milou, Sas, Rem en Lotte, Olivier, Merel, Iris, Eric en Benthe, Mickel, en nog een 
heel klein wezentje, Manon, Martijn en Julius, Joyce & Martijn, Auk, Tone en Finn, Ollie, Alain 
en Max, Tessa, Lionel en Coco, Simone, Deau en Joep, Guus, Jack, Jor en Mees, Fiep, Floor, Ilse, 
Peter en Klaas, Adriaan, Koen, Caroline en Lucas, Liesbeth, Herman, Walter, Severine en Jort, 
Olivier, Nicky, Hans en Ivy, Fenn. Tot snel! En ik leun nog verder naar voren om alle anderen 
te kunnen zien en te roepen dat het te lang geleden is en dat het me spijt dat het zo lang 
geleden is en dat ik slecht bereikbaar was enzo.
Maar dan word ik ineens aan mijn benen naar beneden getrokken. Het is de familie Hornstra. 
Ze hebben mijn benen weer op de grond gezet. ‘Dat was gevaarlijk hoor,’ zegt Anniek lief 
en Floris doet meteen op de grond voor wat er had kunnen gebeuren als ze me niet had-
den vastgepakt en roept hard lachend ‘farligt!’ Peet en Niels! Ik vlieg ze om de hals, wat ben 
ik blij om ze weer te zien. Belangeloos en menselijk, het gewoonste en meest wonderlijke, 
eerlijk en altijd geduldig, echte vrienden zijn het. Ook Jennie, Jeroen, Valentijn en Julius staan 
vlak naast me en kijken mee de zaal in. Valentijn en Julius hebben, liggend op hun buik, 
hun hoofden over de rand gehangen en kijken wie er het verst kan spugen. Valentijn biedt, 
genereus als hij is, Lulies nog een verzwaard spuugje aan, maar hij heeft er al één en rochelt 
een beste de menigte in. Jeroen ziet het en grijpt in. En kleine mama Jennie groeit, mijn Sjaan 
is zichtbaar trots op haar drie mannen. Met een volledig ontwikkelt mediteraan gevoel van 
moederschap en ware vriendschap danst zij door het leven. Wat een plezier om mee door het 
leven te dansen, onvergelijkbaar en onvergetelijk. Valentijn volgt ondertussen een spoor van 
stro, met in zijn kielzog een wankele Julius, dat leidt naar een hoogst eigenaardig tafereel. 
Daar staat een shetlander met een pluizig mupje midden op haar kop, een fors konijn zo te 
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zien. Ze snorkt tegen een IJslander aan waarop een heel klein pittig meisje haar flesje drinkt. 
Bízar! En het lijkt ook nog allemaal met elkaar te communiceren. Wat blijkt: Viktor zit op de 
kop van Heidi en fluistert haar in het oor dat ze aan Blökk moet vragen of hij bij Britt mag 
zitten, omdat hij Britt zo lief vindt. De vader van Britt staat er naast, Niels! Met een hele grote 
glimlach houdt hij haar met één hand vast. Maar dat betekent maar één ding, mijn Roomie 
is in de buurt, Roooomiiie! Waar is ze? Niels wijst met zijn vrije hand en een nog grotere 
glimlach naar de onderkant van het paard. Als ik dan tussen het stro mijn lieve Roomie zie, 
wisselen we toch snel even de meest fantastische grappen uit. Ze knielt achter de uiers van 
Blökk, stro in haar haar en in haar mond. Roomie!?! Wat...wat doe je daar? Terwijl ze onder 
Blökk vandaan kruipt, houdt ze haar handen heel voorzichtig als een kommetje. Ze straalt. Ik 
lach. Ze krabbelt moeilijk op, ik lach en geef haar een zacht duwtje, ze sluit haar handen en 
lacht. Mysterieus loopt ze naar Britt, geeft Niels een kus en stopt iets bij Britt in haar zakjes, 
mijn hart glimlacht. Britt straalt. Linetta en Niels geven licht. Het liefst zou ik het hoofd van 
Roomie tussen mijn handen nemen om te vertellen hoe mooi en bijzonder ze is, maar ik weet 
het even niet goed uit te drukken, het wonder van een oprechte vriendschap die ooit begon 
in Be-332 en alleen maar groeit. 
Rondom de paarden staat de familie Lubbers te kletsen en te lachen met elkaar en ieder-
een. Janne Sophie en Florian houden de paarden aan een touw, Manon en Herman vertellen 
de kinderen over ‘Viktor en de Ooievaar’, Pauline loopt rond met een dienblad vol heerlijke 
hapjes (hoe doet ze dat toch?) terwijl Jan Harman een strootje uit het haar van Linetta plukt 
en, aan wie het maar horen wil, vertelt over de ontwikkeling van zijn laatste project, ‘stro 
en kastanjes, heel 2009’. En daartussen staan lieve Leo en Margareth te genieten van het 
samenzijn, de open haard brandt en het knetterend haardvuur voelt als thuis.
Broertjes! Suusjes! Ook hier! Lieve Sjoerd & Suus & Maurits, Sytze & kleine Suus & lief klein 
mensje in de buik van kleine Suus. Hier, ooit, daar, nu, toen, aan tafel, ontbijt, diner of late-
night snack, in een kroeg met of zonder dak, aan de telefoon of op het veld, overal is thuis 
met jullie. Proooost, zeggen we heel hard en ik kijk even trots naar Roos en Ton, naar míjn 
lieve moeder en vader, zij zitten zoals altijd in een hele comfortabele chaise longue op mijn 
linker schouder. We steken de duimen omhoog en ik voel de kracht en de warmte diep in 
mijn ziel en mijn hart maakt een huppeltje.
Dan voel ik op mijn rechter schouder een hand heel even liefdevol een zacht kneepje geven. 
Die sterke hand, zo bekend en betrouwbaar. Mijn gezicht gloeit als ik me omdraai en recht in 
zijn warme ogen kijk. Mijn grote liefde. Op zijn rechter arm draagt hij ons klein lief mannetje. 
Het kleine wezentje lacht, en lacht de liefste en warmste glimlach van de wereld....kom we 
gaan! Op naar een nieuw avontuur....samen!
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